<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Oral antifungal medication for toenail onychomycosis - Kreijkamp‐Kaspers, S - 2017 | Cochrane Library</title> <meta content="Oral antifungal medication for toenail onychomycosis - Kreijkamp‐Kaspers, S - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010031.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Oral antifungal medication for toenail onychomycosis - Kreijkamp‐Kaspers, S - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010031.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010031.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Oral antifungal medication for toenail onychomycosis" name="citation_title"/> <meta content="Sanne Kreijkamp‐Kaspers" name="citation_author"/> <meta content="The University of Queensland" name="citation_author_institution"/> <meta content="s.kreijkampkaspers@uq.edu.au" name="citation_author_email"/> <meta content="Kate Hawke" name="citation_author"/> <meta content="The University of Queensland" name="citation_author_institution"/> <meta content="Linda Guo" name="citation_author"/> <meta content="The University of Queensland" name="citation_author_institution"/> <meta content="George Kerin" name="citation_author"/> <meta content="The University of Queensland" name="citation_author_institution"/> <meta content="Sally EM Bell‐Syer" name="citation_author"/> <meta content="Cochrane" name="citation_author_institution"/> <meta content="Parker Magin" name="citation_author"/> <meta content="The University of Newcastle" name="citation_author_institution"/> <meta content="Sophie V Bell‐Syer" name="citation_author"/> <meta content="Severn Deanery" name="citation_author_institution"/> <meta content="Mieke L van Driel" name="citation_author"/> <meta content="The University of Queensland" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="7" name="citation_issue"/> <meta content="10.1002/14651858.CD010031.pub2" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/07/14" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010031.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010031.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010031.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Administration, Oral; Antifungal Agents [administration &amp; dosage, adverse effects, *therapeutic use]; Azoles [administration &amp; dosage, adverse effects, *therapeutic use]; Foot Dermatoses [*drug therapy]; Griseofulvin [administration &amp; dosage, adverse effects, *therapeutic use]; Naphthalenes [administration &amp; dosage, adverse effects, *therapeutic use]; Onychomycosis [*drug therapy]; Randomized Controlled Trials as Topic; Recurrence; Secondary Prevention; Terbinafine" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010031.pub2&amp;doi=10.1002/14651858.CD010031.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010031.pub2&amp;doi=10.1002/14651858.CD010031.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010031.pub2&amp;doi=10.1002/14651858.CD010031.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010031.pub2&amp;doi=10.1002/14651858.CD010031.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010031.pub2&amp;doi=10.1002/14651858.CD010031.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010031.pub2&amp;doi=10.1002/14651858.CD010031.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010031.pub2&amp;doi=10.1002/14651858.CD010031.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010031.pub2&amp;doi=10.1002/14651858.CD010031.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010031.pub2&amp;doi=10.1002/14651858.CD010031.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010031.pub2&amp;doi=10.1002/14651858.CD010031.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010031.pub2&amp;doi=10.1002/14651858.CD010031.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010031.pub2&amp;doi=10.1002/14651858.CD010031.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010031.pub2&amp;doi=10.1002/14651858.CD010031.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010031.pub2&amp;doi=10.1002/14651858.CD010031.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010031.pub2&amp;doi=10.1002/14651858.CD010031.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010031.pub2&amp;doi=10.1002/14651858.CD010031.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010031.pub2&amp;doi=10.1002/14651858.CD010031.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010031.pub2&amp;doi=10.1002/14651858.CD010031.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010031.pub2&amp;doi=10.1002/14651858.CD010031.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010031.pub2&amp;doi=10.1002/14651858.CD010031.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010031.pub2&amp;doi=10.1002/14651858.CD010031.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010031.pub2&amp;doi=10.1002/14651858.CD010031.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010031.pub2&amp;doi=10.1002/14651858.CD010031.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="4nUWI3Cc";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010031\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010031\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010031\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010031\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ru","th","ms","hr","fr","pl","zh_HANS","fa","zh_HANT"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD010031.pub2",title:"Oral antifungal medication for toenail onychomycosis",firstPublishedDate:"Jul 14, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Skin Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=4nUWI3Cc&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010031.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010031.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010031.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010031.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010031.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010031.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010031.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010031.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010031.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010031.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>49935 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010031.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010031.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010031.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010031.pub2/full#CD010031-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010031.pub2/full#CD010031-sec-0162"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010031.pub2/full#CD010031-sec-0043"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010031.pub2/full#CD010031-sec-0044"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010031.pub2/full#CD010031-sec-0055"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010031.pub2/full#CD010031-sec-0056"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010031.pub2/full#CD010031-sec-0083"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010031.pub2/full#CD010031-sec-0145"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010031.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010031.pub2/appendices#CD010031-sec-0167"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010031.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010031.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/table_n/CD010031StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/table_n/CD010031StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010031.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010031.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010031.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010031.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010031.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010031.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Oral antifungal medication for toenail onychomycosis</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010031.pub2/information#CD010031-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Sanne Kreijkamp‐Kaspers</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010031.pub2/information#CD010031-cr-0003">Kate Hawke</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010031.pub2/information#CD010031-cr-0004">Linda Guo</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010031.pub2/information#CD010031-cr-0005">George Kerin</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010031.pub2/information#CD010031-cr-0006">Sally EM Bell‐Syer</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010031.pub2/information#CD010031-cr-0007">Parker Magin</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010031.pub2/information#CD010031-cr-0008">Sophie V Bell‐Syer</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010031.pub2/information#CD010031-cr-0009">Mieke L van Driel</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/information/en#CD010031-sec-0177">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 14 July 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010031.pub2">https://doi.org/10.1002/14651858.CD010031.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010031-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010031-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010031-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010031-abs-0016">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010031-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/th#CD010031-abs-0002">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010031-abs-0014">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010031-abs-0001" lang="en"> <section id="CD010031-sec-0001"> <h3 class="title" id="CD010031-sec-0001">Background</h3> <p>Fungal infection of the toenails, also called onychomycosis, is a common problem that causes damage to the nail's structure and physical appearance. For those severely affected, it can interfere with normal daily activities. Treatment is taken orally or applied topically; however, traditionally topical treatments have low success rates due to the nail's physical properties. Oral treatments also appear to have shorter treatment times and better cure rates. Our review will assist those needing to make an evidence‐based choice for treatment. </p> </section> <section id="CD010031-sec-0002"> <h3 class="title" id="CD010031-sec-0002">Objectives</h3> <p>To assess the effects of oral antifungal treatments for toenail onychomycosis.</p> </section> <section id="CD010031-sec-0003"> <h3 class="title" id="CD010031-sec-0003">Search methods</h3> <p>We searched the following databases up to October 2016: the Cochrane Skin Group Specialised Register, CENTRAL, MEDLINE, Embase, and LILACS. We also searched five trials registers and checked the reference lists of included and excluded studies for further references to relevant randomised controlled trials (RCTs). We sought to identify unpublished and ongoing trials by correspondence with authors and by contacting relevant pharmaceutical companies. </p> </section> <section id="CD010031-sec-0004"> <h3 class="title" id="CD010031-sec-0004">Selection criteria</h3> <p>RCTs comparing oral antifungal treatment to placebo or another oral antifungal treatment in participants with toenail onychomycosis, confirmed by one or more positive cultures, direct microscopy of fungal elements, or histological examination of the nail. </p> </section> <section id="CD010031-sec-0005"> <h3 class="title" id="CD010031-sec-0005">Data collection and analysis</h3> <p>We used standard methodological procedures expected by Cochrane.</p> </section> <section id="CD010031-sec-0006"> <h3 class="title" id="CD010031-sec-0006">Main results</h3> <p>We included 48 studies involving 10,200 participants. Half the studies took place in more than one centre and were conducted in outpatient dermatology settings. The participants mainly had subungual fungal infection of the toenails. Study duration ranged from 4 months to 2 years. </p> <p>We assessed one study as being at low risk of bias in all domains and 18 studies as being at high risk of bias in at least one domain. The most common high‐risk domain was 'blinding of personnel and participants'. </p> <p>We found high‐quality evidence that terbinafine is more effective than placebo for achieving clinical cure (risk ratio (RR) 6.00, 95% confidence interval (CI) 3.96 to 9.08, 8 studies, 1006 participants) and mycological cure (RR 4.53, 95% CI 2.47 to 8.33, 8 studies, 1006 participants). Adverse events amongst terbinafine‐treated participants included gastrointestinal symptoms, infections, and headache, but there was probably no significant difference in their risk between the groups (RR 1.13, 95% CI 0.87 to 1.47, 4 studies, 399 participants, moderate‐quality evidence). </p> <p>There was high‐quality evidence that azoles were more effective than placebo for achieving clinical cure (RR 22.18, 95% CI 12.63 to 38.95, 9 studies, 3440 participants) and mycological cure (RR 5.86, 95% CI 3.23 to 10.62, 9 studies, 3440 participants). There were slightly more adverse events in the azole group (the most common being headache, flu‐like symptoms, and nausea), but the difference was probably not significant (RR 1.04, 95% CI 0.97 to 1.12; 9 studies, 3441 participants, moderate‐quality evidence). </p> <p>Terbinafine and azoles may lower the recurrence rate when compared, individually, to placebo (RR 0.05, 95% CI 0.01 to 0.38, 1 study, 35 participants; RR 0.55, 95% CI 0.29 to 1.07, 1 study, 26 participants, respectively; both low‐quality evidence). </p> <p>There is moderate‐quality evidence that terbinafine was probably more effective than azoles for achieving clinical cure (RR 0.82, 95% CI 0.72 to 0.95, 15 studies, 2168 participants) and mycological cure (RR 0.77, 95% CI 0.68 to 0.88, 17 studies, 2544 participants). There was probably no difference in the risk of adverse events (RR 1.00, 95% CI 0.86 to 1.17; 9 studies, 1762 participants, moderate‐quality evidence) between the two groups, and there may be no difference in recurrence rate (RR 1.11, 95% CI 0.68 to 1.79, 5 studies, 282 participants, low‐quality evidence). Common adverse events in both groups included headache, viral infection, and nausea. </p> <p>Moderate‐quality evidence shows that azoles and griseofulvin probably had similar efficacy for achieving clinical cure (RR 0.94, 95% CI 0.45 to 1.96, 5 studies, 222 participants) and mycological cure (RR 0.87, 95% CI 0.50 to 1.51, 5 studies, 222 participants). However, the risk of adverse events was probably higher in the griseofulvin group (RR 2.41, 95% CI 1.56 to 3.73, 2 studies, 143 participants, moderate‐quality evidence), with the most common being gastrointestinal disturbance and allergic reaction (in griseofulvin‐treated participants) along with nausea and vomiting (in azole‐treated participants). Very low‐quality evidence means we are uncertain about this comparison's impact on recurrence rate (RR 4.00, 0.26 to 61.76, 1 study, 7 participants). </p> <p>There is low‐quality evidence that terbinafine may be more effective than griseofulvin in terms of clinical cure (RR 0.32, 95% CI 0.14 to 0.72, 4 studies, 270 participants) and mycological cure (RR 0.64, 95% CI 0.46 to 0.90, 5 studies, 465 participants), and griseofulvin was associated with a higher risk of adverse events, although this was based on low‐quality evidence (RR 2.09, 95% CI 1.15 to 3.82, 2 studies, 100 participants). Common adverse events included headache and stomach problems (in griseofulvin‐treated participants) as well as taste loss and nausea (in terbinafine‐treated participants). No studies addressed recurrence rate for this comparison. </p> <p>No study addressed quality of life.</p> </section> <section id="CD010031-sec-0007"> <h3 class="title" id="CD010031-sec-0007">Authors' conclusions</h3> <p>We found high‐quality evidence that compared to placebo, terbinafine and azoles are effective treatments for the mycological and clinical cure of onychomycosis, with moderate‐quality evidence of excess harm. However, terbinafine probably leads to better cure rates than azoles with the same risk of adverse events (moderate‐quality evidence). </p> <p>Azole and griseofulvin were shown to probably have a similar effect on cure, but more adverse events appeared to occur with the latter (moderate‐quality evidence). Terbinafine may improve cure and be associated with fewer adverse effects when compared to griseofulvin (low‐quality evidence). </p> <p>Only four comparisons assessed recurrence rate: low‐quality evidence found that terbinafine or azoles may lower the recurrence rate when compared to placebo, but there may be no difference between them. </p> <p>Only a limited number of studies reported adverse events, and the severity of the events was not taken into account. </p> <p>Overall, the quality of the evidence varied widely from high to very low depending on the outcome and comparison. The main reasons to downgrade evidence were limitations in study design, such as unclear allocation concealment and randomisation as well as lack of blinding. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010031-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010031-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD010031-abs-0006">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD010031-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010031-abs-0017">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010031-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD010031-abs-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD010031-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD010031-abs-0012">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD010031-abs-0007">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD010031-abs-0008">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010031-abs-0015">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD010031-abs-0018">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010031-abs-0005" lang="en"> <h3>What is the best medication for a fungal infection of the toenail?</h3> <p><b>Review question</b> </p> <p>We aimed to find out which medications, taken by mouth for at least six weeks, are the most effective at curing fungal infection of the toenail, a condition that is known as onychomycosis, in people of any age. We compared these medications to each other or placebo (an inactive drug or treatment). </p> <p><b>Background</b> </p> <p>Fungal infection of the toenails is a common condition, which has a low risk of complications and associated health risks. However, for those severely affected, it might affect normal daily activities. </p> <p>Medication taken by mouth appears to cure the condition more quickly and effectively than topical treatment. There are three main antifungal medications: griseofulvin, different medications in the azole group (itraconazole, fluconazole, albaconazole, posaconazole, ravuconazole), and terbinafine. </p> <p>We wanted to assess the following two main outcomes.</p> <p>1. Does the nail look normal after treatment (clinical cure)?<br/> 2. Is the nail free from fungus at a microscopic level (mycological cure)? </p> <p><b>Study characteristics</b> </p> <p>We identified 48 studies with 10,200 participants of both sexes. The average age of the participants across studies ranged from 36 to 68; most studies included participants aged 18 and over. Our included studies compared the three main groups of medication against each other or to placebo. Most studies took place in outpatient dermatology settings in the USA and Europe. The participants mainly had fungal infection under the toenails. A small number of studies included a specific group of participants, such as those with diabetes. All but one study looked at fungal infections caused by dermatophyte, which are fungi that digest keratin. Study duration ranged from 4 months to 2 years, with most lasting 12 to 15 months. </p> <p><b>Key results</b> </p> <p>The evidence is current to October 2016.</p> <p>We found high‐quality evidence that compared with placebo, both terbinafine and azoles are more effective for achieving a normal‐looking nail and curing the toenail infection (i.e. looking at the microscopic level to see if the fungus is gone). Terbinafine or azoles may also prevent the infection reoccurring more than placebo (low‐quality evidence). There was probably no significant difference in the risk of adverse events reported when comparing either azoles or terbinafine with placebo (moderate‐quality evidence). The most common adverse events amongst terbinafine‐treated and azole‐treated participants included stomach problems and headache. </p> <p>We found that compared to azoles, terbinafine was probably more effective in curing the nails in terms of appearance and infection (moderate‐quality evidence). The risk of side effects was probably the same for both treatments (moderate‐quality evidence), and the most common adverse events in both groups were headache, viral infection, and rash. There may be no difference in recurrence rate (low‐quality evidence). </p> <p>A third type of treatment, griseofulvin, was probably as effective as the azole medications in curing the nails in terms of appearance and infection (moderate‐quality evidence), but it may be less effective than terbinafine when assessing the same outcomes (low‐quality evidence). Griseofulvin caused more side effects than the other two treatments, although the quality of the evidence was moderate (compared to azole) to low (compared to terbinafine). The most common adverse events in both groups included stomach problems and feeling sick. We are uncertain about the effect of griseofulvin compared to azoles on the rate of recurrence, and studies comparing terbinafine and griseofulvin did not assess this outcome. </p> <p><b>Quality of the evidence</b> </p> <p>The evidence for the primary outcomes of cure (in terms of appearance and infection) was high to moderate quality except for the comparisons of griseofulvin versus terbinafine (low quality) and combination terbinafine plus azole versus terbinafine alone (very low quality). The evidence quality for side effects was mainly moderate, but two comparisons had low evidence for this outcome. Not all comparisons measured recurrence rate, and the available evidence was based on low‐ to very low‐quality evidence. No studies reported on participants' quality of life. Many studies had problems in the study design: it was often unclear how they decided which participants would receive which treatment or ensured that participants weren't aware of the treatment allocation. Many studies also did not use a placebo. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010031-sec-0162" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010031-sec-0162"></div> <h3 class="title" id="CD010031-sec-0163">Implications for practice</h3> <section id="CD010031-sec-0163"> <p>There is high‐quality evidence to support the conclusion that oral azole and terbinafine treatments are more effective for achieving mycological cure and clinical cure for onychomycosis compared to placebo. When compared directly, terbinafine is probably more effective than azoles and likely not associated with excess adverse events (both moderate‐quality evidence). </p> <p>For adverse events overall, the quality of the evidence was moderate to low; only a limited number of studies reported adverse events, and the severity of the events was not taken into account, which limits the direct application to clinical practice. </p> <p>Low‐certainty evidence showed griseofulvin to be less effective than terbinafine in terms of both mycological and clinical cure, while griseofulvin and azole probably had similar efficacy (moderate‐quality evidence). Griseofulvin was associated with more adverse reactions than azoles (moderate‐quality) and terbinafine (low‐quality). </p> <p>The evidence in this review applies for treatments of least 12 weeks in duration, as all included studies had the typical treatment duration of at least 12 weeks. </p> <p>In terms of limitations of the current evidence, reporting of the secondary outcomes was limited. None of the included studies assessed quality of life, and only a few studies reported recurrence rate, mainly leading to non‐significant results. Also, most studies included participants with <i>T rubrum</i> and <i>T mentagrophytes</i> , so the results might not be applicable to onychomycosis caused by non‐dermatophyte moulds and <i>Candida</i>. </p> </section> <h3 class="title" id="CD010031-sec-0164">Implications for research</h3> <section id="CD010031-sec-0164"> <p>This review found a large evidence base for the efficacy and effectiveness of the different oral treatments for onychomycosis. The quality of the evidence was high when comparing terbinafine or azole with placebo for the primary outcomes; however, the direct comparison for terbinafine and azole was only of moderate quality, mostly due to limitations in the study designs such as the lack of blinding. This could be consolidated with further well‐designed, double‐blind randomised controlled trials with enough follow‐up, possibly up to 12 months, to fully judge the effect of treatment. Furthermore, none of the included studies addressed the impact on quality of life. Further research could concentrate on the effect of treatment on quality of life as well as the adverse events associated with these treatments, including the severity of the adverse events associated with oral azoles and oral terbinafine, to further strengthen our confidence when prescribing these medications. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD010031-sec-0043" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD010031-sec-0043"></div> <div class="table" id="CD010031-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Azole compared to terbinafine for toenail onychomycosis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Azole compared to terbinafine for toenail onychomycosis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population</b> : participants with confirmed toenail onychomycosis<br/> <b>Setting</b> : outpatients clinics<br/> <b>Intervention</b> : azole<br/> <b>Comparison</b>: terbinafine </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with terbinafine</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with azole</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Clinical cure</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.82<br/> (0.72 to 0.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2168<br/> (15 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>575 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>471 per 1000<br/> (414 to 546) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mycological cure</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.77<br/> (0.68 to 0.88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2544<br/> (17 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>682 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>525 per 1000<br/> (464 to 600) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.00<br/> (0.86 to 1.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1762<br/> (9 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>346 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>346 per 1000<br/> (298 to 405) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence rate</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.11<br/> (0.68 to 1.79) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>282<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>333 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>370 per 1000<br/> (227 to 597) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>None of the studies addressed quality of life.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI</b> : confidence interval; <b>RCT</b> : randomised controlled trial; <b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality</b> : we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality</b> : our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality</b>: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one level for risk of bias because of large number of unblinded studies, lack of description of randomisation process and allocation concealment for most studies.<br/> <sup>b</sup>Downgraded by one level for risk of bias (large number of unblinded studies, lack of description of randomisation process and allocation concealment for most studies).<br/> <sup>c</sup>Downgraded by two levels for risk of bias (large number of unblinded studies, lack of description of randomisation process and allocation concealment for most studies) and imprecision (small numbers of participants in this comparison). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010031-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Terbinafine compared to placebo for toenail onychomycosis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Terbinafine compared to placebo for toenail onychomycosis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population</b> : patients with confirmed toenail onychomycosis<br/> <b>Setting</b> : outpatient clinics<br/> <b>Intervention</b> : terbinafine<br/> <b>Comparison</b>: placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with terbinafine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Clinical cure</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 6.00<br/> (3.96 to 9.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1006<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> High<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>62 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>370 per 1000<br/> (244 to 560) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mycological cure</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 4.53<br/> (2.47 to 8.33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1006<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> High<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>167 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>755 per 1000<br/> (412 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.13<br/> (0.87 to 1.47) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>399<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>429 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>484 per 1000<br/> (373 to 630) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recurrence rate</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>667 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>33 per 1000</p> <p>(7 to 253)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.05</p> <p>(0.01 to 0.38)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not addressed by any of the trials</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI</b> : confidence interval; <b>RCT</b> : randomised controlled trial; <b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality</b> : we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality</b> : our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality</b>: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Large number of unblinded studies and studies with poor description of blinding and randomisation but large effect estimate; therefore, this outcome was not downgraded for risk of bias as the quality of evidence was considered to be high because of the large effect observed.<br/> <sup>b</sup>Downgraded by one level due to risk of bias (randomisation and blinding was poorly described in most studies).<br/> <sup>c</sup>Downgraded by two levels due to poor description of randomisation and blinding as well as due to selective follow‐up and only single study with small number of participants. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010031-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Azole compared to placebo for toenail onychomycosis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Azole compared to placebo for toenail onychomycosis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population</b> : participants with confirmed toenail onychomycosis<br/> <b>Setting</b> : outpatient clinics<br/> <b>Intervention</b> : azole<br/> <b>Comparison</b>: placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with azole</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Clinical cure</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 22.18</p> <p>(12.63 to 38.95)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3440<br/> (9 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> High<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>14 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>309 per 1000</p> <p>(176 to 543)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mycological cure</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 5.86<br/> (3.23 to 10.62) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3440<br/> (9 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> High<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>74 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>431 per 1000<br/> (237 to 781) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.04<br/> (0.97 to 1.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3441<br/> (9 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>537 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>559 per 1000<br/> (521 to 602) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence rate</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.55</p> <p>(0.29 to 1.07)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>26</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1000 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>550 per 1000</p> <p>(290 to 1000)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>None of the studies addressed quality of life.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI</b> : confidence interval; <b>RCT</b> : randomised controlled trial; <b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality</b> : we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality</b> : our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality</b>: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Large number of unblinded studies and studies with poor description of blinding and randomisation, but large effect estimate; therefore, this outcome was not downgraded for risk of bias as the quality of evidence was considered to be high because of the large effect observed.<br/> <sup>b</sup>Downgraded by one level because of risk of bias (high number of unblinded studies and studies with poor description of blinding and randomisation).<br/> <sup>c</sup>Downgraded by two levels due to poor description of randomisation and blinding as well as selective follow‐up and only single study with small number of participants. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010031-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Griseofulvin compared to azole for toenail onychomycosis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Griseofulvin compared to azole for toenail onychomycosis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population</b> : participants with confirmed toenail onychomycosis<br/> <b>Setting</b> : outpatient clinics<br/> <b>Intervention</b> : griseofulvin<br/> <b>Comparison</b>: azole </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with azole</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with griseofulvin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Clinical cure</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.94<br/> (0.45 to 1.96) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>222<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>144 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>136 per 1000<br/> (65 to 283) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mycological cure</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.87<br/> (0.50 to 1.51) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>222<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>186 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>161 per 1000<br/> (93 to 280) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.41<br/> (1.56 to 3.73) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>143<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>276 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>665 per 1000<br/> (430 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence rate</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 4.00<br/> (0.26 to 61.76) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>7<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>None of the studies addressed quality of life.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI</b> : confidence interval; <b>RCT</b> : randomised controlled trial; <b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality</b> : we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality</b> : our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality</b>: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one level due to risk of bias (about half of the studies were not blinded).<br/> <sup>b</sup>Downgraded by one level due to risk of bias (two unblinded studies; neither participants nor outcome assessors were blinded).<br/> <sup>c</sup>Downgraded by three levels due to risk of bias (single study; neither participants nor outcome assessors were blinded) and imprecision (two levels due to single study, low number of participants and wide confidence intervals). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010031-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Griseofulvin compared to terbinafine for toenail onychomycosis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Griseofulvin compared to terbinafine for toenail onychomycosis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population</b> : participants with confirmed toenail onychomycosis<br/> <b>Setting</b> : outpatient clinics<br/> <b>Intervention</b> : griseofulvin<br/> <b>Comparison</b>: terbinafine </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with terbinafine</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Griseofulvin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Clinical cure</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.32<br/> (0.14 to 0.72) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>270<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>561 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>179 per 1000<br/> (78 to 404) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mycological cure</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.64<br/> (0.46 to 0.90) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>465<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>716 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>458 per 1000<br/> (329 to 645) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.09<br/> (1.15 to 3.82) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>100<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>160 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>334 per 1000<br/> (184 to 611) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recurrence rate</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No studies addressed recurrence rate.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No studies addressed quality of life.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI</b> : confidence interval; <b>RCT</b> : randomised controlled trial; <b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality</b> : we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality</b> : our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality</b>: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by two levels due to risk of bias (two studies not blinded; other studies at unclear risk for blinding of participant and outcome assessor).<br/> <sup>b</sup>Downgraded by two levels due to risk of bias (two levels: one unblinded study; one study at unclear risk of bias for blinding or participants and outcome assessor). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010031-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Combination terbinafine plus azole compared to terbinafine monotherapy for toenail onychomycosis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Combination terbinafine plus azole compared to terbinafine monotherapy for toenail onychomycosis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population</b> : participants with confirmed toenail onychomycosis<br/> <b>Setting</b> : outpatient clinics<br/> <b>Intervention</b> : combination terbinafine plus azole<br/> <b>Comparison</b>: terbinafine monotherapy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with terbinafine monotherapy</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with combination terbinafine plus azole</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Clinical cure</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.41</p> <p>(1.01 to 1.97)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>176<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>368 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>519 per 1000</p> <p>(732 to 726)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mycological cure</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.41</p> <p>(1.08 to 1.83)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>176<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>474 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>668 per 1000<br/> (512 to 867) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.64<br/> (0.34 to 1.21) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>176<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>232 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>148 per 1000<br/> (79 to 280) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recurrence rate</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No studies addressed recurrence rate.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No studies addressed quality of life.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI</b> : confidence interval; <b>RCT</b> : randomised controlled trial; <b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality</b> : we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality</b> : our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality</b>: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by three levels due to risk of bias (two levels: single non‐blinded study) and imprecision (single study).<br/> <sup>b</sup>Downgraded by two levels due to risk of bias (single non‐blinded study) and imprecision (single study) </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010031-sec-0044" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD010031-sec-0044"></div> <p>Please see <a href="./appendices#CD010031-sec-0168">Appendix 1</a> for a glossary of the medical terms used throughout the text. </p> <section id="CD010031-sec-0045"> <h3 class="title" id="CD010031-sec-0045">Description of the condition</h3> <p>Fungal infection is a common problem that can affect both the skin and nails of the foot. Fungal infection of the nail is also known as 'onychomycosis' or 'tinea unguium'. Onychomycosis is a chronic disorder affecting the structure of the nail (<a href="http://archie.cochrane.org/sections/documents/view?version=32E48C8F82E26AA200C5294D3E09DF70%26format=REVMAN#REF-Baran-1999" target="_blank">Baran 1999</a>). While distressing (<a href="./references#CD010031-bbs2-0085" title="DrakeLA , PatrickDL , FleckmanP , AndrJ , BaranR , HanekeE , et al. The impact of onychomycosis on quality of life: development of an international onychomycosis‐specific questionnaire to measure patient quality of life. Journal of the American Academy of Dermatology1999;41(2 Pt 1):189‐96. [PUBMED: 10426887] ">Drake 1999</a>), for most people the condition has a low risk of complications or associated health risks (<a href="./references#CD010031-bbs2-0088" title="Dermatology Expert Group, Skin Infections Expert Group. Therapeutic Guidelines: Dermatology. Version 3. Melbourne: Therapeutic Guidelines Limited, 2009. [ISBN: 9780980476439] ">ETG Dermatology 2009</a>). Exceptions are those with peripheral vascular disease and the immunosuppressed, where complications associated with the infection are more common (<a href="./references#CD010031-bbs2-0098" title="GuptaAK , KonnikovN , MacDonaldP , RichP , RodgerNW , EdmondsMW , et al. Prevalence and epidemiology of toenail onychomycosis in diabetic subjects: a multicentre survey. British Journal of Dermatology1998;139(4):665‐71. [PUBMED: 9892911] ">Gupta 1998</a>). A particular and common example of both of these circumstances is diabetes. Onychomycosis is common in people with diabetes (<a href="./references#CD010031-bbs2-0098" title="GuptaAK , KonnikovN , MacDonaldP , RichP , RodgerNW , EdmondsMW , et al. Prevalence and epidemiology of toenail onychomycosis in diabetic subjects: a multicentre survey. British Journal of Dermatology1998;139(4):665‐71. [PUBMED: 9892911] ">Gupta 1998</a>), and complications of onychomycosis in people with diabetes can be limb‐threatening (<a href="./references#CD010031-bbs2-0079" title="CathcartS , CantrellW , ElewskiB . Onychomycosis and diabetes. Journal of the European Academy of Dermatology and Venereology: JEADV2009;23(10):1119‐22. [PUBMED: 19309423] ">Cathcart 2009</a>). </p> <p>There are several clinical forms of onychomycosis, and <a href="./references#CD010031-bbs2-0101" title="HayRJ , BaranR . Onychomycosis: a proposed revision of the clinical classification. Journal of the American Academy of Dermatology2011; Vol. 65, issue 6:1219‐27. [PUBMED: 21501889] ">Hay 2011</a> has proposed a new classification based on current understanding of the underlying pathophysiology. </p> <p> <ol id="CD010031-list-0001"> <li> <p>Distal lateral subungual onychomycosis (DLSO) – this is the most common form of onychomycosis, where the fungus invades from the distal or lateral undersurface of the nail plate. Clinical features include hyperkeratosis and a range of dyschromias (discolouration) including melanonychia (brown or black pigmentation of the nail), onycholysis (detachment of the nail from the nail bed), and streaking (coloured bands) of the nail. Streaking appears in other forms of onychomycosis but is most common in DLSO. </p> </li> <li> <p>Superficial onychomycosis (SO) – this is where the nail plate itself can be white or black and present with a wide range of dyschromias. The nail surface is infected, whereas the rest of the nail plate, the nail bed, and the matrix remain unaltered. It can present as superficial patches or striae (groove‐like marks on the nail). </p> </li> <li> <p>Endonyx onychomycosis (EO) – the nail plate is invaded through direct penetration of the fungal hyphae in the distal nail plate. It presents as lamellar (or length‐wise) splitting of the nail and discolouration in the nail plate without nail bed invasion. </p> </li> <li> <p>Proximal subungual onychomycosis (PSO) – this classically originates from the proximal nail and nailfold, slowly extending distally. This form of onychomycosis is difficult to treat successfully. </p> </li> <li> <p>Mixed pattern onychomycosis (MPO) ‐ different patterns of nail plate invasion often appear in the same person, sometimes even in the same nail. Proximal subungual onychomycosis and SO regularly occur together as well as DLSO with SO. </p> </li> <li> <p>Total dystrophic onychomycosis (TDO) – this presents at the end stage of different forms of nail plate invasion, and it is caused by different organisms. The nail is completely damaged and crumbles away, while the nailbed is thickened and ridged. </p> </li> </ol> </p> <p>Onychomycosis can present as a secondary complication of other conditions, such as psoriasis or trauma to the nail (<a href="./references#CD010031-bbs2-0087" title="ElewskiBE , TostiA . Risk Factors and Comorbidities for Onychomycosis: Implications for Treatment with Topical Therapy. Journal of Clinical and Aesthetic Dermatology2015;8(11):38‐42. [PUBMED: 26705439] ">Elewski 2015</a>). </p> <p>Please refer to <a href="./references#CD010031-bbs2-0082" title="DeBerkerD . Nail anatomy. Clinics in Dermatology2013;31(5):509‐15. [PUBMED: 24079579] ">De Berker 2013</a> or <a href="./references#CD010031-bbs2-0090" title="FleckmanP , AllanC . Surgical anatomy of the nail unit. Dermatologic Surgery2001;27(3):257‐60. [PUBMED: 11277893] ">Fleckman 2001</a> for information on normal nail anatomy. </p> <section id="CD010031-sec-0046"> <h4 class="title">Prevalence</h4> <p>The prevalence of onychomycosis is estimated to be 2% to 14% (<a href="./references#CD010031-bbs2-0092" title="GhannoumMA , HajjehRA , ScherR , KonnikovN , GuptaAK , SummerbellR , et al. A large‐scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. Journal of the American Academy of Dermatology2000;43(4):641‐8. [PUBMED: 11004620] ">Ghannoum 2000</a>; <a href="./references#CD010031-bbs2-0114" title="WatanabeS , HaradaT , HirumaM , IozumiK , KatohT , MochizukiT , et al. Epidemiological survey of foot diseases in Japan: results of 30,000 foot checks by dermatologists. Journal of Dermatology2010;37(5):397‐406. [PUBMED: 20536644] ">Watanabe 2010</a>). Approximately a third of people with diabetes have onychomycosis (<a href="./references#CD010031-bbs2-0079" title="CathcartS , CantrellW , ElewskiB . Onychomycosis and diabetes. Journal of the European Academy of Dermatology and Venereology: JEADV2009;23(10):1119‐22. [PUBMED: 19309423] ">Cathcart 2009</a>). </p> </section> <section id="CD010031-sec-0047"> <h4 class="title">Infecting organism</h4> <p>Onychomycosis can be caused by dermatophytes (fungi that digest keratin), yeasts (microscopic fungi) and non‐dermatophyte moulds (fungi) (<a href="./references#CD010031-bbs2-0077" title="BombaceF , IoveneMR , GaldieroM , MartoraF , NicolettiGF , D'AndreaM , et al. Non‐dermatophytic onychomycosis diagnostic criteria: an unresolved question. Mycoses2016;59(9):558‐65. [PUBMED: 27061613] ">Bombace 2016</a>). Most cases of onychomycosis are caused by dermatophytes, which are classified in three genera: <i>Trichophyton</i> ,<i>Microsporum</i> , and <i>Epidermophyton</i> (<a href="http://archie.cochrane.org/sections/documents/view?version=32E48C8F82E26AA200C5294D3E09DF70%26format=REVMAN#REF-Weitzman-1995" target="_blank">Weitzman 1995</a>). In onychomycosis, <i>Trichophyton rubrum</i> and <i>Trichophyton mentagrophytes</i> are the most common pathogens (<a href="http://archie.cochrane.org/sections/documents/view?version=32E48C8F82E26AA200C5294D3E09DF70%26format=REVMAN#REF-Weitzman-1995" target="_blank">Weitzman 1995</a>). The <i>Candida</i> genus is the most common yeast involved in onychomycosis, and the non‐dermatophyte moulds include <i>Scopulariopsis brevicaulis</i> , <i>Aspergillus</i> , and <i>Fusarium</i> spp as well as others (<a href="./references#CD010031-bbs2-0077" title="BombaceF , IoveneMR , GaldieroM , MartoraF , NicolettiGF , D'AndreaM , et al. Non‐dermatophytic onychomycosis diagnostic criteria: an unresolved question. Mycoses2016;59(9):558‐65. [PUBMED: 27061613] ">Bombace 2016</a>). The causative organisms vary by type of infection. DLSO can be caused by a wide variety of fungi; the most commonly encountered species in this form are dermatophytes, but<i>Candida albican</i> s (yeasts) and <i>Fusarium</i> spp (non‐dermatophyte moulds) are not uncommon. The most common cause of SO is the dermatophyte <i>T mentagrophytes</i> or<i>T rubrum</i> , but it can also be caused by <i>Fusarium</i> or <i>Acremonium</i> , while a wide array of fungi can cause PSO, including <i>T rubrum</i> , <i>Fusarium</i> , <i>Candida</i> , and <i>Aspergillus</i> (<a href="http://archie.cochrane.org/sections/documents/view?version=32E48C8F82E26AA200C5294D3E09DF70%26format=REVMAN#REF-Weitzman-1995" target="_blank">Weitzman 1995</a>). In EO, the nail plate is most commonly invaded by <i>Trichophyton soudanense</i> or <i>Trichophyton violaceum</i> (<a href="./references#CD010031-bbs2-0101" title="HayRJ , BaranR . Onychomycosis: a proposed revision of the clinical classification. Journal of the American Academy of Dermatology2011; Vol. 65, issue 6:1219‐27. [PUBMED: 21501889] ">Hay 2011</a>). </p> </section> <section id="CD010031-sec-0048"> <h4 class="title">Diagnosis of the fungal infection</h4> <p>Onychomycosis is the most prevalent nail disease, accounting for approximately 50% of all onychopathies (<a href="./references#CD010031-bbs2-0116" title="WolffK , LowellAG , KatzSI , GilchrestBA , PallerAS , LeffellDJ . Fitzpatrick's Dermatology in General Medicine. 7. McGraw‐Hill Professional, 2007. [ISBN: 0071466908] ">Wolff 2007</a>). An accurate diagnosis is important, and it is desirable to confirm the presence of fungi by culture or of hyphae (branching filamentous structures) by microscopy (<a href="./references#CD010031-bbs2-0088" title="Dermatology Expert Group, Skin Infections Expert Group. Therapeutic Guidelines: Dermatology. Version 3. Melbourne: Therapeutic Guidelines Limited, 2009. [ISBN: 9780980476439] ">ETG Dermatology 2009</a>), as some dermatological conditions can produce changes to the nail and skin that mimic fungal infection (e.g. trauma or psoriasis) (<a href="http://archie.cochrane.org/sections/documents/view?version=32E48C8F82E26AA200C5294D3E09DF70%26format=REVMAN#REF-Andre-1987" target="_blank">Andre 1987</a>), and the causative fungus will inform treatment (<a href="./references#CD010031-bbs2-0081" title="DeBerkerD . Clinical practice. Fungal nail disease. New England Journal of Medicine2009;360(20):2108‐16. [PUBMED: 19439745] ">De Berker 2009</a>). At present, clinicians rely on clinical examination and a combination of direct microscopic (potassium hydroxide (KOH)) examination and fungal culture to establish a diagnosis (<a href="./references#CD010031-bbs2-0109" title="ScherRK , TavakkolA , SigurgeirssonB , HayRJ , JosephWS , TostiA , et al. Onychomycosis: diagnosis and definition of cure. Journal of the American Academy of Dermatology2007;56(6):939‐44. [PUBMED: 17307276] ">Scher 2007</a>). </p> <p>If both microscopy and culture are performed, one of the two will be positive in approximately 80% of cases of onychomycosis (<a href="./references#CD010031-bbs2-0088" title="Dermatology Expert Group, Skin Infections Expert Group. Therapeutic Guidelines: Dermatology. Version 3. Melbourne: Therapeutic Guidelines Limited, 2009. [ISBN: 9780980476439] ">ETG Dermatology 2009</a>; <a href="./references#CD010031-bbs2-0099" title="GuptaAK , SimpsonFC . Diagnosing onychomycosis. Clinics in dermatology2013;31(5):540‐3. [PUBMED: 24079582] ">Gupta 2013</a>; <a href="./references#CD010031-bbs2-0115" title="WeinbergJM , KoestenblattEK , TutroneWD , TishlerHR , NajarianL . Comparison of diagnostic methods in the evaluation of onychomycosis. Journal of the American Academy of Dermatology2003;49(2):193‐7. [PUBMED: 12894064] ">Weinberg 2003</a>). However, a direct microscopy assessment is negative in up 20% of cases, while culture may yield a false negative result in up to 40% of cases that are positive for microscopy (<a href="./references#CD010031-bbs2-0078" title="Brillowska‐DabrowskaA , SaunteDM , ArendrupMC . Five‐hour diagnosis of dermatophyte nail infections with specific detection of Trichophyton rubrum. Journal of Clinical Microbiology2007;45(4):1200‐4. [PUBMED: 17267633] ">Brillowska‐Dabrowska 2007</a>). The results of the culture will vary with the methods used as well as the method of collecting the nail sample, and some studies have reported even lower diagnostic accuracy (<a href="./references#CD010031-bbs2-0112" title="ShenoyMM , TeerthanathS , KarnakerVK , GirishaBS , Krishna PrasadMS , PintoJ . Comparison of potassium hydroxide mount and mycological culture with histopathologic examination using periodic acid‐Schiff staining of the nail clippings in the diagnosis of onychomycosis. Indian journal of dermatology, venereology and leprology2008;74(3):226‐9. [PUBMED: 18583788] ">Shenoy 2008</a>; <a href="./references#CD010031-bbs2-0115" title="WeinbergJM , KoestenblattEK , TutroneWD , TishlerHR , NajarianL . Comparison of diagnostic methods in the evaluation of onychomycosis. Journal of the American Academy of Dermatology2003;49(2):193‐7. [PUBMED: 12894064] ">Weinberg 2003</a>). Nail infections caused by non‐dermatophytes such as <i>Scopulariopsis</i> and<i>Scystalidium</i> may require repeated microscopy or culture, as non‐dermatophytes can be both contaminants as well as causative organisms (<a href="./references#CD010031-bbs2-0077" title="BombaceF , IoveneMR , GaldieroM , MartoraF , NicolettiGF , D'AndreaM , et al. Non‐dermatophytic onychomycosis diagnostic criteria: an unresolved question. Mycoses2016;59(9):558‐65. [PUBMED: 27061613] ">Bombace 2016</a>). More recently, studies have suggested that at least two positive tests (microscopy, culture, histological sample, etc.) are required to confirm diagnoses (<a href="./references#CD010031-bbs2-0099" title="GuptaAK , SimpsonFC . Diagnosing onychomycosis. Clinics in dermatology2013;31(5):540‐3. [PUBMED: 24079582] ">Gupta 2013</a>). Also, it is time consuming to conduct cultures due to the slow growth of the fungus (<a href="./references#CD010031-bbs2-0078" title="Brillowska‐DabrowskaA , SaunteDM , ArendrupMC . Five‐hour diagnosis of dermatophyte nail infections with specific detection of Trichophyton rubrum. Journal of Clinical Microbiology2007;45(4):1200‐4. [PUBMED: 17267633] ">Brillowska‐Dabrowska 2007</a>). If direct microscopic examination by potassium hydroxide preparation and fungal culture are negative, histological examination of the nail plate may be advisable (<a href="./references#CD010031-bbs2-0078" title="Brillowska‐DabrowskaA , SaunteDM , ArendrupMC . Five‐hour diagnosis of dermatophyte nail infections with specific detection of Trichophyton rubrum. Journal of Clinical Microbiology2007;45(4):1200‐4. [PUBMED: 17267633] ">Brillowska‐Dabrowska 2007</a>). More recently, polymerase chain reaction techniques have been developed to aid the diagnosis and identification of the causative agent (<a href="./references#CD010031-bbs2-0113" title="VerrierJ , ProninaM , PeterC , BontemsO , FrattiM , SalaminK , et al. Identification of infectious agents in onychomycoses by Polymerase Chain Reaction‐Terminal Restriction Fragment Length Polymorphism. Journal of Clinical Microbiology2012;50(3):553‐61. [PUBMED: 22170903] ">Verrier 2012</a>); this might become more important in the future. </p> </section> <section id="CD010031-sec-0049"> <h4 class="title">Quality of life</h4> <p>Although onychomycosis is not a life‐threatening condition, it can alter many important nail functions and have adverse effects on the person's quality of life. The impact is greater on psychosocial functioning than on physical functioning (<a href="./references#CD010031-bbs2-0111" title="ShawJW , JoishVN , CoonsSJ . Onychomycosis: health‐related quality of life considerations. PharmacoEconomics2002;20(1):23‐36. [PUBMED: 11817990] ">Shaw 2002</a>). Whilst it is dismissed by many as a purely cosmetic problem, relegated to causing no more distress to the person than a crinkly nail (<a href="http://archie.cochrane.org/sections/documents/view?version=32E48C8F82E26AA200C5294D3E09DF70%26format=REVMAN#REF-Stone-2000" target="_blank">Stone 2000</a>), to those severely affected, it can interfere with normal daily activities, such as walking and standing. It can cause shoes to fit poorly and may affect the productivity of those whose work requires them to stand all day (<a href="./references#CD010031-bbs2-0084" title="DrakeLA , ScherRK , SmithEB , FaichGA , SmithSL , HongJJ , et al. Effect of onychomycosis on quality of life. Journal of the American Academy of Dermatology1998;38(5 Pt 1):702‐4. [PUBMED: 9591814] ">Drake 1998</a>). In those with diabetes mellitus, onychomycosis has been linked to more severe complications, such as foot ulcers and cellulitis (<a href="./references#CD010031-bbs2-0106" title="MayserP , FreundV , BudihardjaD . Toenail onychomycosis in diabetic patients: issues and management. American Journal of Clinical Dermatology2009;10(4):211‐20. [PUBMED: 19489654] ">Mayser 2009</a>). </p> </section> </section> <section id="CD010031-sec-0050"> <h3 class="title" id="CD010031-sec-0050">Description of the intervention</h3> <section id="CD010031-sec-0051"> <h4 class="title">Drug therapy and its history</h4> <p>Prior to 1958, when griseofulvin was introduced as the first significant oral antifungal agent (<a href="./references#CD010031-bbs2-0096" title="GuptaAK , SauderDN , ShearNH . Antifungal agents: an overview. Part I. Journal of the American Academy of Dermatology1994;30(5 Pt 1):677‐98; quiz 698‐700. [PUBMED: 8176006] ">Gupta 1994</a>), only topical drugs existed for fungal infection (<a href="./references#CD010031-bbs2-0081" title="DeBerkerD . Clinical practice. Fungal nail disease. New England Journal of Medicine2009;360(20):2108‐16. [PUBMED: 19439745] ">De Berker 2009</a>). While the use of topical treatments may avoid the risk of adverse effects associated with systemic treatments, the response rate is poor, especially with multiple nail involvement or with involvement of more than the distal two‐thirds of the nail plate (i.e. thick nails) (<a href="./references#CD010031-bbs2-0095" title="GroverC , KhuranaA . An update on treatment of onychomycosis. Mycoses2012;55(6):541‐51. [PUBMED: 22540995] ">Grover 2012</a>), although the more recently developed topical treatments tavaborole and efinaconazole have shown promising results (<a href="./references#CD010031-bbs2-0107" title="PoulakosM , GraceY , MachinJD , DorvalE . Efinaconazole and tavaborole: emerging antifungal alternatives for the topical treatment of onychomycosis. Journal of Pharmacy Practice 2016 Feb 11 [Epub ahead of print]. [DOI: 10.1177/0897190016630904; PUBMED: 26873506] ">Poulakos 2016</a>). </p> <p>Griseofulvin is produced by various species of <i>Penicillium</i> and is effective against dermatophyte infection but not against <i>C albicans</i> (yeasts) (<a href="http://archie.cochrane.org/sections/documents/view?version=32E48C8F82E26AA200C5294D3E09DF70%26format=REVMAN#REF-Blank-1959" target="_blank">Blank 1959</a>). In 1944, benzimidazole was the first azole discovered to have antifungal activity, and 1969 saw the introduction of clotrimazole and miconazole, followed by econazole in 1974 and ketoconazole in 1977 (<a href="./references#CD010031-bbs2-0096" title="GuptaAK , SauderDN , ShearNH . Antifungal agents: an overview. Part I. Journal of the American Academy of Dermatology1994;30(5 Pt 1):677‐98; quiz 698‐700. [PUBMED: 8176006] ">Gupta 1994</a>). No oral form of miconazole nitrate or econazole was ever marketed, as they are poorly absorbed from the gastrointestinal tract (<a href="./references#CD010031-bbs2-0096" title="GuptaAK , SauderDN , ShearNH . Antifungal agents: an overview. Part I. Journal of the American Academy of Dermatology1994;30(5 Pt 1):677‐98; quiz 698‐700. [PUBMED: 8176006] ">Gupta 1994</a>). Although clotrimazole is a broad‐spectrum azole, it is not used when oral treatment is required because orally or parenterally (intravenously) administered clotrimazole induces an enzyme reaction that results in the accelerated degradation of the drug with loss of antifungal activity (<a href="./references#CD010031-bbs2-0096" title="GuptaAK , SauderDN , ShearNH . Antifungal agents: an overview. Part I. Journal of the American Academy of Dermatology1994;30(5 Pt 1):677‐98; quiz 698‐700. [PUBMED: 8176006] ">Gupta 1994</a>). Ketoconazole has been available since 1977, but it is associated with hepatotoxicity (<a href="http://archie.cochrane.org/sections/documents/view?version=32E48C8F82E26AA200C5294D3E09DF70%26format=REVMAN#REF-Jones-1982" target="_blank">Jones 1982</a>). Although this appears to be a rare adverse effect, it has significantly reduced its popularity as an oral antifungal agent (<a href="http://archie.cochrane.org/sections/documents/view?version=32E48C8F82E26AA200C5294D3E09DF70%26format=REVMAN#REF-Jones-1982" target="_blank">Jones 1982</a>). </p> <p>The development of azoles continued with the introduction of itraconazole and fluconazole in the 1980s (<a href="./references#CD010031-bbs2-0097" title="GuptaAK , SauderDN , ShearNH . Antifungal agents: an overview. Part II. Journal of the American Academy of Dermatology1994;30(6):911‐33; quiz 934‐6. [PUBMED: 7619094] ">Gupta 1994a</a>). The absorption of itraconazole is rapid and can be maximised if taken with food. Fluconazole was discovered in 1982 and can be given intravenously as well as in oral form. Fluconazole is indicated for candidiasis as well as fungal skin infection; it has been used in the past to treat fungal nail infections and is still used for this indication in some countries. The allylamine group of antifungal drugs is the most recent development, with naftifine becoming the first commercially available allylamine in 1985 (but only in topical form) (<a href="./references#CD010031-bbs2-0097" title="GuptaAK , SauderDN , ShearNH . Antifungal agents: an overview. Part II. Journal of the American Academy of Dermatology1994;30(6):911‐33; quiz 934‐6. [PUBMED: 7619094] ">Gupta 1994a</a>). The next significant event was the introduction of oral terbinafine; terbinafine is an allylamine with a broad spectrum of antifungal activity. Its mechanism of action is fungicidal (i.e. it kills fungi directly), as opposed to fungistatic agents such as azoles, which simply halt new fungal growth (<a href="./references#CD010031-bbs2-0097" title="GuptaAK , SauderDN , ShearNH . Antifungal agents: an overview. Part II. Journal of the American Academy of Dermatology1994;30(6):911‐33; quiz 934‐6. [PUBMED: 7619094] ">Gupta 1994a</a>). Because terbinafine is currently the only allylamine for oral treatment, we use the term 'terbinafine' rather than 'allylamines' throughout the review. </p> <p>Currently, terbinafine (continuous dosing) and itraconazole (pulse dosing one week per month) are the mainstays of oral treatments for onychomycosis (<a href="./references#CD010031-bbs2-0081" title="DeBerkerD . Clinical practice. Fungal nail disease. New England Journal of Medicine2009;360(20):2108‐16. [PUBMED: 19439745] ">De Berker 2009</a>). The cure rates reported are around 50%, although they vary widely (<a href="./references#CD010031-bbs2-0081" title="DeBerkerD . Clinical practice. Fungal nail disease. New England Journal of Medicine2009;360(20):2108‐16. [PUBMED: 19439745] ">De Berker 2009</a>). The elderly and those with nondermatophyte infections are less likely to respond to treatment (<a href="./references#CD010031-bbs2-0081" title="DeBerkerD . Clinical practice. Fungal nail disease. New England Journal of Medicine2009;360(20):2108‐16. [PUBMED: 19439745] ">De Berker 2009</a>). </p> </section> <section id="CD010031-sec-0052"> <h4 class="title">Side effects</h4> <p>The most common side effects of oral antifungal agents include headaches, gastrointestinal side effects, and rashes (<a href="./references#CD010031-bbs2-0081" title="DeBerkerD . Clinical practice. Fungal nail disease. New England Journal of Medicine2009;360(20):2108‐16. [PUBMED: 19439745] ">De Berker 2009</a>). Severe adverse reactions, including fatal hepatotoxicity, are seen in fewer than 1% of cases (<a href="./references#CD010031-bbs2-0094" title="GreenblattHK , GreenblattDJ . Liver injury associated with ketoconazole: review of the published evidence. Journal of Clinical Pharmacology2014;54(12):1321‐9. [PUBMED: 25216238] ">Greenblatt 2014</a>; <a href="./references#CD010031-bbs2-0105" title="KaoWY , SuCW , HuangYS , ChouYC , ChenYC , ChungWH , et al. Risk of oral antifungal agent‐induced liver injury in Taiwanese. British Journal of Clinical Pharmacology2014;77(1):180‐9. [PUBMED: 23750489] ">Kao 2014</a>; <a href="./references#CD010031-bbs2-0117" title="YanJ , WangX , ChenS . Systematic review of severe acute liver injury caused by terbinafine. International Journal of Clinical Pharmacy2014;36(4):679‐83. [PUBMED: 24986266] ">Yan 2014</a>). Drug interactions can cause serious problems during oral treatment therapy, and the azole drugs can inhibit hepatic drug metabolism (<a href="http://archie.cochrane.org/sections/documents/view?version=32E48C8F82E26AA200C5294D3E09DF70%26format=REVMAN#REF-Back-1992" target="_blank">Back 1992</a>). Women who are pregnant or may become pregnant should not use oral antifungals. Ketoconazole, fluconazole, and terbinafine may be excreted in breast milk; therefore, it is not advisable to breastfeed whilst being treated (<a href="./references#CD010031-bbs2-0088" title="Dermatology Expert Group, Skin Infections Expert Group. Therapeutic Guidelines: Dermatology. Version 3. Melbourne: Therapeutic Guidelines Limited, 2009. [ISBN: 9780980476439] ">ETG Dermatology 2009</a>). </p> </section> </section> <section id="CD010031-sec-0053"> <h3 class="title" id="CD010031-sec-0053">How the intervention might work</h3> <p>The antifungal agents either halt the growth of the fungus (fungistatic) or actually kill the fungus (fungicidal) (<a href="./references#CD010031-bbs2-0096" title="GuptaAK , SauderDN , ShearNH . Antifungal agents: an overview. Part I. Journal of the American Academy of Dermatology1994;30(5 Pt 1):677‐98; quiz 698‐700. [PUBMED: 8176006] ">Gupta 1994</a>). The azoles (e.g. ketoconazole) impair the synthesis of ergosterol in fungal cell membranes, which leads to the breakdown of the cell, while griseofulvin disrupts the cell microtubule function (<a href="./references#CD010031-bbs2-0096" title="GuptaAK , SauderDN , ShearNH . Antifungal agents: an overview. Part I. Journal of the American Academy of Dermatology1994;30(5 Pt 1):677‐98; quiz 698‐700. [PUBMED: 8176006] ">Gupta 1994</a>). Both are fungistatic, while terbinafine, which is fungicidal, interacts with ergosterol synthesis at an earlier stage, causing cell death (<a href="./references#CD010031-bbs2-0097" title="GuptaAK , SauderDN , ShearNH . Antifungal agents: an overview. Part II. Journal of the American Academy of Dermatology1994;30(6):911‐33; quiz 934‐6. [PUBMED: 7619094] ">Gupta 1994a</a>). Different dosing regimens have been used, both continuous daily dosing as well as pulse dosing (e.g. 1 week of treatment followed by 3 weeks with no treatment, with a minimum treatment duration of 12 weeks) (<a href="./references#CD010031-bbs2-0100" title="GuptaAK , DaigleD , PaquetM . Therapies for Onychomycosis A Systematic Review and Network Meta‐analysis of Mycological Cure. Journal of the American Podiatric Medical Association2015;105(4):357‐66. [PUBMED: 25032982] ">Gupta 2015</a>). Given that the condition is caused by infestation of the nail by different fungi, most commonly <i>Trichophytum</i>, antifungal agents should eliminate the cause of the nail changes, namely the fungal infection, and allow for the return of the normal nail (<a href="./references#CD010031-bbs2-0100" title="GuptaAK , DaigleD , PaquetM . Therapies for Onychomycosis A Systematic Review and Network Meta‐analysis of Mycological Cure. Journal of the American Podiatric Medical Association2015;105(4):357‐66. [PUBMED: 25032982] ">Gupta 2015</a>). </p> </section> <section id="CD010031-sec-0054"> <h3 class="title" id="CD010031-sec-0054">Why it is important to do this review</h3> <p>Onychomycosis is a common complaint. It can be treated either orally or with topical agents. Topical treatments have traditionally been more readily available as over‐the‐counter preparations, and they are the first‐line treatment for fungal skin conditions (<a href="./references#CD010031-bbs2-0086" title="El‐GoharyM , vanZuurenEJ , FedorowiczZ , BurgessH , DoneyL , StuartB , et al. Topical antifungal treatments for tinea cruris and tinea corporis. Cochrane Database of Systematic Reviews2014, Issue 8. [DOI: 10.1002/14651858.CD009992.pub2] ">El‐Gohary 2014</a>). However, topical treatments have very low success rates due to the physical properties of the nail (<a href="./references#CD010031-bbs2-0080" title="CrawfordF , HollisS . Topical treatments for fungal infections of the skin and nails of the foot. Cochrane Database of Systematic Reviews2007, Issue 3. [DOI: 10.1002/14651858.CD001434.pub2] ">Crawford 2007</a>; <a href="./references#CD010031-bbs2-0093" title="GhannoumM , IshamN . Fungal nail infections (onychomycosis): a never‐ending story?. PLoS Pathogens2014;10(6):e1004105. [PUBMED: 24901242] ">Ghannoum 2014</a>), even if the more recently developed topical treatments tavaborole and efinaconazole have shown more promising results (<a href="./references#CD010031-bbs2-0107" title="PoulakosM , GraceY , MachinJD , DorvalE . Efinaconazole and tavaborole: emerging antifungal alternatives for the topical treatment of onychomycosis. Journal of Pharmacy Practice 2016 Feb 11 [Epub ahead of print]. [DOI: 10.1177/0897190016630904; PUBMED: 26873506] ">Poulakos 2016</a>). Oral treatments are more commonly prescribed for onychomycosis, and they appear to have the benefit of shorter treatment times and better cure rates than topical preparations (<a href="./references#CD010031-bbs2-0100" title="GuptaAK , DaigleD , PaquetM . Therapies for Onychomycosis A Systematic Review and Network Meta‐analysis of Mycological Cure. Journal of the American Podiatric Medical Association2015;105(4):357‐66. [PUBMED: 25032982] ">Gupta 2015</a>). There have been several published reviews and overviews of oral treatments, but no recent systematic review of the evidence has been produced (<a href="http://archie.cochrane.org/sections/documents/view?version=32E48C8F82E26AA200C5294D3E09DF70%26format=REVMAN#REF-Bandolier-1996" target="_blank">Bandolier 1996</a>; <a href="http://archie.cochrane.org/sections/documents/view?version=32E48C8F82E26AA200C5294D3E09DF70%26format=REVMAN#REF-Crawford-2002" target="_blank">Crawford 2002</a>; <a href="http://archie.cochrane.org/sections/documents/view?version=32E48C8F82E26AA200C5294D3E09DF70%26format=REVMAN#REF-Epstein-1998" target="_blank">Epstein 1998</a>; <a href="http://archie.cochrane.org/sections/documents/view?version=32E48C8F82E26AA200C5294D3E09DF70%26format=REVMAN#REF-Trepanier-1998" target="_blank">Trepanier 1998</a>). A systematic review of the evidence for oral treatments for toenail onychomycosis will assist clinicians and people with the condition in making an evidence‐based choice for treatment. </p> <p>The plans for this review were published as a protocol 'Oral antifungal medication for toenail onychomycosis' (<a href="./references#CD010031-bbs2-0118" title="Kreijkamp‐KaspersS , Bell‐Syer SallyEM , MaginP , Bell‐Syer SophieV , vanDriel MiekeL . Oral antifungal medication for toenail onychomycosis. Cochrane Database of Systematic Reviews2012, Issue 8. [DOI: 10.1002/14651858.CD010031] ">Kreijkamp‐Kaspers 2012</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010031-sec-0055" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010031-sec-0055"></div> <p>To assess the effects of oral antifungal treatments for toenail onychomycosis.</p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010031-sec-0056" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010031-sec-0056"></div> <section id="CD010031-sec-0057"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010031-sec-0058"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials (RCTs) with a parallel group design. We also included cross‐over trials. </p> </section> <section id="CD010031-sec-0059"> <h4 class="title">Types of participants</h4> <p>Participants of all ages with toenail onychomycosis confirmed by at least one positive culture or confirmed fungal elements on direct microscopy or histological examination of the nail. </p> </section> <section id="CD010031-sec-0060"> <h4 class="title">Types of interventions</h4> <p>We considered all oral antifungal interventions for treating toenail onychomycosis with treatment durations from a minimum of six weeks. Comparisons were as follows. </p> <p> <ul id="CD010031-list-0002"> <li> <p>Oral active treatment versus another oral active treatment (we did not consider dose‐finding studies of the same drug unless they also contained a placebo group). </p> </li> <li> <p>Oral active treatment versus placebo.</p> </li> </ul> </p> </section> <section id="CD010031-sec-0061"> <h4 class="title">Types of outcome measures</h4> <section id="CD010031-sec-0062"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD010031-list-0003"> <li> <p>Clinical cure, i.e. the proportion of participants that on clinical examination are 'cured'. We followed the definition of 'clinical cure' as given by the authors of the included studies. The timeframes for clinical cure may vary by study and might be as long as 6 to 24 months post‐treatment. </p> </li> <li> <p>Mycological cure demonstrated by negative results on microscopy, no growth of dermatophyte in culture, or both. This outcome is distinct from the disease‐free nail in that it does not require the demonstration of the normal‐appearing nail and requires shorter participant follow‐up. </p> </li> </ol> </p> <p>When studies recorded measurements at multiple time points during the intervention, we consider the measurement at the predefined endpoint of the study as our primary outcome. </p> </section> <section id="CD010031-sec-0063"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD010031-list-0004"> <li> <p>Quality of life</p> </li> <li> <p>Adverse events</p> </li> <li> <p>Recurrence rate</p> </li> </ol> </p> </section> </section> </section> <section id="CD010031-sec-0064"> <h3 class="title">Search methods for identification of studies</h3> <p>We aimed to identify all relevant randomised controlled trials (RCTs) regardless of language or publication status (published, unpublished, in press, or in progress). </p> <section id="CD010031-sec-0065"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases up to 12 October 2016.</p> <p> <ul id="CD010031-list-0005"> <li> <p>The Cochrane Skin Group Specialised Register using the search strategy in <a href="./appendices#CD010031-sec-0169">Appendix 2.</a> </p> </li> <li> <p>The Cochrane Central Register of Controlled Trials (CENTRAL; 2015, Issue 10) in the Cochrane Library using the strategy in <a href="./appendices#CD010031-sec-0170">Appendix 3.</a> </p> </li> <li> <p>MEDLINE via Ovid (from 1946) using the strategy in <a href="./appendices#CD010031-sec-0171">Appendix 4.</a> </p> </li> <li> <p>Embase via Ovid (from 1974) using the strategy in <a href="./appendices#CD010031-sec-0172">Appendix 5.</a> </p> </li> <li> <p>LILACS (Latin American and Caribbean Health Science Information database from 1982) using the strategy in <a href="./appendices#CD010031-sec-0173">Appendix 6</a>. </p> </li> </ul> </p> <section id="CD010031-sec-0066"> <h5 class="title">Trials registers</h5> <p>We searched the following trials registers on 22 May 2016. See <a href="./appendices#CD010031-sec-0174">Appendix 7</a> for search strategies. </p> <p> <ul id="CD010031-list-0006"> <li> <p>The ISRCTN registry (<a href="http://www.isrctn.com" target="_blank">www.isrctn.com</a>). </p> </li> <li> <p>ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>). </p> </li> <li> <p>The Australian New Zealand Clinical Trials Registry (<a href="http://www.anzctr.org.au" target="_blank">www.anzctr.org.au</a>). </p> </li> <li> <p>The World Health Organization International Clinical Trials Registry Platform (ICTRP) (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>). </p> </li> <li> <p>The EU Clinical Trials Register (<a href="https://www.clinicaltrialsregister.eu/" target="_blank">www.clinicaltrialsregister.eu</a>). </p> </li> </ul> </p> </section> </section> <section id="CD010031-sec-0067"> <h4 class="title">Searching other resources</h4> <section id="CD010031-sec-0068"> <h5 class="title">References from published studies</h5> <p>We checked the bibliographies of included and excluded studies for further references to relevant trials. </p> </section> <section id="CD010031-sec-0069"> <h5 class="title">Unpublished literature</h5> <p>We sought to identify unpublished and ongoing trials by correspondence with authors and by contacting the pharmaceutical companies that produce relevant products. We contacted the following drug companies. </p> <p> <ul id="CD010031-list-0007"> <li> <p>AstraZeneca.</p> </li> <li> <p>GlaxoSmithKline.</p> </li> <li> <p>Janssen‐Cilag Ltd.</p> </li> <li> <p>Pfizer Ltd.</p> </li> <li> <p>Novartis (Sandoz, the generic pharmaceuticals division of Novartis).</p> </li> </ul> </p> <p>We did not identify further companies producing other products identified from trials.</p> </section> <section id="CD010031-sec-0070"> <h5 class="title">Adverse effects</h5> <p>We did not perform a separate search for adverse effects of the target interventions. However, we examined data on adverse effects from the included studies we identified. </p> </section> </section> </section> <section id="CD010031-sec-0071"> <h3 class="title" id="CD010031-sec-0071">Data collection and analysis</h3> <p>We included six 'Summary of findings' tables for six comparisons, which included all of our primary and secondary outcomes. We also used the GRADE approach to assess the quality of all outcomes using the following five domains: risk of bias, inconsistency, imprecision, indirectness, and publication bias. Quality of evidence could be either high, moderate, low, or very low (<a href="./references#CD010031-bbs2-0103" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>; <a href="./references#CD010031-bbs2-0110" title="SchünemannH , BrożekJ , GuyattG , OxmanA , editors. The GRADE Working Group. GRADE handbook for grading quality of evidence and strength of recommendations. www.guidelinedevelopment.org/handbook2013. ">Schünemann 2013</a>). </p> <section id="CD010031-sec-0072"> <h4 class="title">Selection of studies</h4> <p>Two review authors (SKK and KH) independently checked titles and abstracts identified from the searches. We set aside studies where it was clear that they were not relevant; we retrieved, for further independent assessment, the full text of those citations for which it was not possible to make a decision. Two review authors independently decided which trials met the inclusion criteria and resolved any disagreements by discussion or referral to a third review author (MvD). We detailed excluded studies and reasons for exclusion in the 'Characteristics of excluded studies' tables in the review. </p> </section> <section id="CD010031-sec-0073"> <h4 class="title">Data extraction and management</h4> <p>Four review authors (SKK, LG, GK, KH) independently extracted data using a data extraction form. We resolved discrepancies by discussion or through consultation with a third review author (MvD). We requested missing data from trial authors where relevant. One review author (SKK) checked and entered all data. The review authors were not blinded to the names of study authors, journals, or institutions. </p> </section> <section id="CD010031-sec-0074"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (SKK and LG, GK or KH) independently assessed each included study using the Cochrane Collaboration's tool for assessing risk of bias, described in Chapter 8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010031-bbs2-0103" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). This tool addresses six specific domains, namely sequence generation, allocation concealment, blinding, incomplete outcome data, selective outcome reporting, and other issues (e.g. extreme baseline imbalance). We assessed blinding and completeness of outcome data for each outcome separately. We completed a 'Risk of bias' table for each eligible study. We discussed any disagreement amongst all review authors to achieve a consensus. </p> <p>We reported the 'Risk of bias' assessment using a 'Risk of bias' summary figure, which presents all of the judgements for every study. This may guide readers to the weight they should give to results of each study. </p> </section> <section id="CD010031-sec-0075"> <h4 class="title">Measures of treatment effect</h4> <p>We entered data into Cochrane Review Manager 5 (RevMan 5) software for data analysis (<a href="./references#CD010031-bbs2-0108" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). We reported estimates for dichotomous outcomes as risk ratios (RRs) with 95% confidence intervals (CI). </p> </section> <section id="CD010031-sec-0076"> <h4 class="title">Unit of analysis issues</h4> <p>In RCTs the unit of analysis was the individual participant, not the individual nail(s) affected. If we had identified cross‐over RCTs, we would have only extracted and analysed data from the first period due to the likely carry‐over effect from the first treatment episode in the cross‐over period. In the case of multiple treatment trials, we created pair‐wise comparisons as set out in Chapter 16.3.1 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="https://archie.cochrane.org/sections/documents/view?document=21240113052813388078110520145656%26format=REVMAN#REF-Higgins-2011" target="_blank">Higgins 2011</a>). </p> </section> <section id="CD010031-sec-0077"> <h4 class="title">Dealing with missing data</h4> <p>Where possible, we extracted data to allow an intention‐to‐treat (ITT) analysis including all randomised participants according to the groups to which they were originally assigned. We calculated the percentage lost to follow‐up in each group and reported this information. When there was a discrepancy in the number randomised and the number analysed in each treatment group, we attempted to obtain missing data or further information from trial authors when needed. We did not make any assumptions about loss to follow‐up for dichotomous or continuous data, and we analysed results for those who completed the trial. </p> </section> <section id="CD010031-sec-0078"> <h4 class="title">Assessment of heterogeneity</h4> <p>We examined heterogeneity in a two‐step process. First, we assessed clinical heterogeneity (e.g. age, severity of disease, different populations). Second, we examined statistical heterogeneity using the I² statistic (<a href="./references#CD010031-bbs2-0102" title="HigginsJPT , Thompson , SG , Deeks , JJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7417):557‐60. ">Higgins 2003</a>). Values of I² statistic under 25% indicate a low level of heterogeneity and would justify use of a fixed‐effect model for meta‐analysis. I² values between 25% and 75% are considered moderate, while values higher than 75% indicate high levels of heterogeneity. We used a random‐effects model for all analyses, as in the absence of heterogeneity the estimates would be similar to a fixed‐effect analysis. We did not pool studies if important 'face value' heterogeneity or substantial statistical heterogeneity were present. We used the I² statistic as a guide in the interpretation of the evidence, not as an absolute measure to make major decisions (<a href="./references#CD010031-bbs2-0104" title="IoannidisJP , PatsopoulosNA , EvangelouE . Uncertainty in heterogeneity estimates in meta‐analyses. BMJ2007;335(7626):914‐6. ">Ioannidis 2007</a>). </p> </section> <section id="CD010031-sec-0079"> <h4 class="title">Assessment of reporting biases</h4> <p>When we identified more than 10 RCTs in a single comparison, we drew funnel plots to test for reporting bias as discussed in chapter 10.4 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010031-bbs2-0103" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> </section> <section id="CD010031-sec-0080"> <h4 class="title">Data synthesis</h4> <p>We pooled data using a random‐effects model.</p> </section> <section id="CD010031-sec-0081"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Methods of synthesising the studies depended on quality, design, and heterogeneity. We explored both clinical and statistical heterogeneity as described above. We first investigated 'face value' heterogeneity (which includes participants' age and severity of the condition). If there were no obvious clinical reasons for important heterogeneity that may impact on the outcome of pooling, we proceeded to assessing statistical heterogeneity. In the presence of statistical heterogeneity, we explored the cause of this by means of a sensitivity analysis (removing or adding studies one by one in order to identify the source of heterogeneity). </p> <p>The studies did not allow for the planned subgroups analyses, which were based on the following. </p> <p> <ol id="CD010031-list-0008"> <li> <p>Subtype of onychomycosis.</p> </li> <li> <p>Participants with underlying health conditions, such as diabetes mellitus, peripheral vascular disease, and immunosuppression. </p> </li> </ol> </p> <p>We did perform subgroup analysis based on the duration of follow‐up as a toenail will need at least 12 months to grow out completely (<a href="./references#CD010031-bbs2-0091" title="GeyerAS , OnumahN , UyttendaeleH , ScherRK . Modulation of linear nail growth to treat diseases of the nail. Journal of the American Academy of Dermatology2004;50(2):229‐34. [PUBMED: 14726877] ">Geyer 2004</a>). </p> </section> <section id="CD010031-sec-0082"> <h4 class="title">Sensitivity analysis</h4> <p>We included all eligible trials in the initial analysis and carried out sensitivity analyses to evaluate the effect of trials at risk of bias. This was done by excluding trials most susceptible to bias based on the 'Risk of bias' assessment: those with inadequate allocation concealment; high levels of postrandomisation losses or exclusions; and uncertain or unblinded outcome assessments. By the same method, we also assessed the impact of heterogeneity on the overall estimate. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010031-sec-0083" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010031-sec-0083"></div> <section id="CD010031-sec-0084"> <h3 class="title">Description of studies</h3> <section id="CD010031-sec-0085"> <h4 class="title">Results of the search</h4> <p>The primary database searches described in <a href="#CD010031-sec-0065">Electronic searches</a> yielded 444 records, and we identified an additional 136 records through the trial registry searches; after removing duplicates, there were a total of 534 unique records, none of which pertained to ongoing trials. </p> <p>We excluded 439 records based on titles and/or abstracts, leaving 95 full‐text records. We excluded 27 (see <a href="./references#CD010031-sec-0184" title="">Characteristics of excluded studies</a>), leaving 68 included papers reporting on 48 studies and involving 10,200 participants (see <a href="./references#CD010031-sec-0183" title="">Characteristics of included studies</a>). </p> <p>Five studies did not contribute to the pooled analyses. One excluded and replaced participants that did not show response to treatment and did not account for these participants in analysis (<a href="./references#CD010031-bbs2-0003" title="ArenasR , FernandezG , DominguezL . Onychomycosis treated with itraconazole or griseofulvin alone with and without a topical antimycotic or keratolytic agent. International Journal of Dermatology1991;30(8):586‐9. [PUBMED: 1657803] ">Arenas 1991</a>). <a href="./references#CD010031-bbs2-0025" title="HayRJ , ClaytonYM , GriffithsWA , DowdPM . A comparative double blind study of ketoconazole and griseofulvin in dermatophytosis. British Journal of Dermatology1985;112(6):691‐6. [PUBMED: 3890924] ">Hay 1985</a> included a wide range of dermatophyte infections and conducted analyses based on number of toenails rather than affected participants. Furthermore, three studies included both fingernail and toenail onychomycosis but did not separate the fingernail and toenail data (<a href="./references#CD010031-bbs2-0001" title="Al RubaieSM . Double blind comparison between terbinafine &amp; griseofulvin in the treatment of fingernail and toe nail onychomycosis. Australasian Journal of Dermatology1997;38(Suppl 2):289. [CENTRAL: CN‐00499326] ">Al Rubaie 1997</a>; <a href="./references#CD010031-bbs2-0037" title="MishraM , PandaPL . A comparative study of efficacy of oral itraconazole and terbinafine pulse therapy in the treatment of onychomycosis. Annales de Dermatologie et de Venereologie2002;129:IC1753. [CENTRAL: CN‐00454549] ">Mishra 2002</a>; <a href="./references#CD010031-bbs2-0038" title="PiepponenT , BlomqvistK , BrandtH , HavuV , HollmenA , KohtamakiK , et al. Efficacy and safety of itraconazole in the long‐term treatment of onychomycosis. Journal of Antimicrobial Chemotherapy1992;29(2):195‐205. [PUBMED: 1324238] ">Piepponen 1992</a>). We have contacted the authors to obtain further data and will include them in the quantitative analyses when data become available. </p> <p>We did not identify any cross‐over trials.</p> <p>We included 43 studies in the pooled data analyses. Please see <a href="#CD010031-fig-0001">Figure 1</a> for our study flow diagram. </p> <div class="figure" id="CD010031-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD010031-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_n/nCD010031-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD010031-sec-0086"> <h4 class="title">Included studies</h4> <p>The pooled analyses included 43 studies with 9730 participants (see the <a href="./references#CD010031-sec-0183" title="">Characteristics of included studies</a> section). </p> <section id="CD010031-sec-0087"> <h5 class="title">Trial settings</h5> <p>All studies were RCTs, and 16 had a placebo arm. Twenty‐six were published in 2000 or earlier. Authors described more than half (24 studies) as multicentre, and most were conducted in outpatient dermatology settings in Western countries: 17 studies had at least one trial site in the USA, and 16 studies had a European trial site. </p> </section> <section id="CD010031-sec-0088"> <h5 class="title">Participants</h5> <p>Sample size varied from 20 to 1381 participants (median 120). The average age of the participants across studies ranged from 36 to 68 years, and most studies included participants aged 18 and over, with only three studies accepting participants aged 14 to 16 years (<a href="./references#CD010031-bbs2-0033" title="LaPlacaM , StinchiC , VenturoN , MorelliR , TostiA . Terbinafine vs griseofulvin in the treatment of dermatophyte onychomycosis [Terbinafina vs griseofulvina nella terapia delle onicomicosi da dermatofiti]. Giornale Italiano di Dermatologia e Venereologia1994;129(4):19‐22. [EMBASE: 1994255170] ">La Placa 1994</a>; <a href="./references#CD010031-bbs2-0036" title="MaddinS , QuiringJ , BulgerL . Randomised, placebo‐controlled, phase 3 study of itraconazole for the treatment of onychomycosis. Journal of Drugs in Dermatology2013;12(7):758‐763. [PUBMED: 23884486] ">Maddin 2013</a>; <a href="./references#CD010031-bbs2-0043" title="SvejgaardE . Oral ketoconazole as an alternative to griseofulvin in recalcitrant dermatophyte infections and onychomycosis. Acta Dermato‐venereologica1985;65(2):143‐9. [PUBMED: 2408417] ">Svejgaard 1985</a>). All studies included participants of both sexes. Most were open to general dermatology outpatients with subungual onychomycosis of the toenail, but a small number of studies included only a specific patient group such as people with diabetes in <a href="./references#CD010031-bbs2-0022" title="GuptaA , GoverM . Pulse itraconazole versus continuous terbinafine for the treatment of dermatophyte toenail onychomycosis in patients with diabetes mellitus. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB151. [CENTRAL: CN‐00602562] GuptaAK , GoverMD , LyndeCW . Pulse itraconazole vs. continuous terbinafine for the treatment of dermatophyte toenail onychomycosis in patients with diabetes mellitus. Journal of the European Academy of Dermatology and Venereology : JEADV2006;20(10):1188‐93. [PUBMED: 17062029] ">Gupta 2006</a> or black participants (term used by study authors) in <a href="./references#CD010031-bbs2-0006" title="BillsteinS , KianifardF , JusticeA . Terbinafine vs. placebo for onychomycosis in black patients. International Journal of Dermatology1999;38(5):377‐379. [PUBMED: 10369551] ">Billstein 1999</a>. One study looked specifically at non‐dermatophyte nail infections (<a href="./references#CD010031-bbs2-0039" title="RanawakaRR , NagahawatteA , GunasekaraTA , WeerakoonHS , deSilvaSH . Randomized, double‐blind, comparative study on efficacy and safety of itraconazole pulse therapy and terbinafine pulse therapy on nondermatophyte mold onychomycosis: A study with 90 patients. The Journal of dermatological treatment2016;27(4):364‐72. [PUBMED: 26651495] ">Ranawaka 2016</a>). </p> </section> <section id="CD010031-sec-0089"> <h5 class="title">Interventions</h5> <p>Trials evaluated several oral antifungal interventions, including terbinafine, azoles (itraconazole, fluconazole, albaconazole, posaconazole, ravuconazole) and griseofulvin in continuous or intermittent pulse therapy. Eight studies compared terbinafine monotherapy with placebo (<a href="./references#CD010031-bbs2-0006" title="BillsteinS , KianifardF , JusticeA . Terbinafine vs. placebo for onychomycosis in black patients. International Journal of Dermatology1999;38(5):377‐379. [PUBMED: 10369551] ">Billstein 1999</a>; <a href="./references#CD010031-bbs2-0011" title="DrakeLA , ShearNH , ArletteJP , CloutierR , DanbyFW , ElewskiBE , et al. Oral terbinafine in the treatment of toenail onychomycosis: North American multicenter trial. Journal of the American Academy of Dermatology1997;37(5 Pt 1):740‐5. [PUBMED: 9366820] ">Drake 1997</a>; <a href="./references#CD010031-bbs2-0013" title="ElewskiBE , ElCharifM , CooperKD , GhannoumM , BirnbaumJE . Reactivity to trichophytin antigen in patients with onychomycosis: effect of terbinafine. Journal of the American Academy of Dermatology2002;46(3):371‐5. [PUBMED: 11862171] ">Elewski 2002</a>; <a href="./references#CD010031-bbs2-0014" title="ElewskiB , PollakR , AshtonS , RichP , SchlessingerJ , TavakkolA . A randomized, placebo‐ and active‐controlled, parallel‐group, multicentre, investigator‐blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis. British Journal of Dermatology2012;166(2):389‐98. [PUBMED: 21967490] ElewskiB , TavakkolA , PollakR , AshtonS . A randomized, placebo‐ and active‐controlled, parallel‐group, multicenter,investigator‐blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis. Journal of American Academy of Dermatology2010;62(3 Suppl 1):AB76. [EMBASE: 70142781] ">Elewski 2012</a>; <a href="./references#CD010031-bbs2-0016" title="GoodfieldMJ . Short‐duration therapy with terbinafine for dermatophyte onychomycosis: a multicentre trial. British Journal of Dermatology1992;126(Suppl 39):33‐5. [PUBMED: 1531926] GoodfieldMJ , AndrewL , EvansEG . Short term treatment of dermatophyte onychomycosis with terbinafine. BMJ1992;304(6835):1151‐4. [PUBMED: 1392793] ">Goodfield 1992</a>; <a href="./references#CD010031-bbs2-0034" title="LebwohlMG , DanielCR , LeydenJ , MormonM , ShavinJS , TschenE , et al. Efficacy and safety of terbinafine for nondermatophyte and mixed nondermatophyte and dermatophyte toenail onychomycosis. International Journal of Dermatology2001;40(5):358‐60. [PUBMED: 11555003] ">Lebwohl 2001</a>; <a href="./references#CD010031-bbs2-0044" title="BrandrupF , LarsenPO . Long‐term follow‐up of toe‐nail onychomycosis treated with terbinafine. Acta Dermato‐venereologica1997;77(3):238. [PUBMED: 9188883] SvejgaardEL , BrandrupF , KragballeK , LarsenPO , VeienNK , HolstM , et al. Oral terbinafine in toenail dermatophytosis. A double‐blind, placebo‐controlled multicenter study with 12 months' follow‐up. Acta Dermato‐venereologica1997;77(1):66‐9. [PUBMED: 9059684] ">Svejgaard 1997</a>; <a href="./references#CD010031-bbs2-0047" title="EllisDH , WatsonAB , MarleyJE , WilliamsTG . Non‐dermatophytes in onychomycosis of the toenails. British Journal of Dermatology1997;136(4):490‐3. [PUBMED: 9155945] WatsonA , MarleyJ , EllisD , WilliamsT . Terbinafine in onychomycosis of the toenail: a novel treatment protocol. Journal of the American Academy of Dermatology1995;33(5 Pt 1):775‐9. [PUBMED: 7593777] ">Watson 1995</a>), and nine studies compared azole monotherapy with placebo (<a href="./references#CD010031-bbs2-0012" title="ElewskiBE , ScherRK , AlyR , DanielR3rd , JonesHE , OdomRB , et al. Double‐blind, randomized comparison of itraconazole capsules vs. placebo in the treatment of toenail onychomycosis. Cutis1997;59(4):217‐20. [PUBMED: 9104548] OdomR , DanielCR , AlyR . A double‐blind, randomized comparison of itraconazole capsules and placebo in the treatment of onychomycosis of the toenail. Journal of the American Academy of Dermatology1996;35(1):110‐1. [PUBMED: 8682945] ">Elewski 1997</a>; <a href="./references#CD010031-bbs2-0013" title="ElewskiBE , ElCharifM , CooperKD , GhannoumM , BirnbaumJE . Reactivity to trichophytin antigen in patients with onychomycosis: effect of terbinafine. Journal of the American Academy of Dermatology2002;46(3):371‐5. [PUBMED: 11862171] ">Elewski 2002</a>; <a href="./references#CD010031-bbs2-0017" title="GuptaAK , MaddinS , ArletteJ , GirouxJ‐M , ShearNH . Itraconazole pulse therapy is effective in dermatophyte onychomycosis of the toenail: a double‐blind placebo‐controlled study. Journal of Dermatological Treatment2000;11(1):33‐7. [EMBASE: 2000114935] ">Gupta 2000</a>; <a href="./references#CD010031-bbs2-0021" title="GuptaAK , LeonardiC , StoltzRR , PiercePF , ConettaB . A phase I/II randomized, double‐blind, placebo‐controlled, dose‐ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis. Journal of the European Academy of Dermatology and Venereology : JEADV2005;19(4):437‐43. [PUBMED: 15987289] ">Gupta 2005</a>; <a href="./references#CD010031-bbs2-0028" title="JonesHE , ZaiasN . Double‐blind, randomized comparison of itraconazole capsules and placebo in onychomycosis of toenail. International Journal of Dermatology1996;35(8):589‐90. [PUBMED: 8854164] ">Jones 1996</a>; <a href="./references#CD010031-bbs2-0035" title="LingMR , SwinyerLJ , JarrattMT , FaloL , MonroeEW , TharpM , et al. Once‐weekly fluconazole (450 mg) for 4, 6, or 9 months of treatment for distal subungual onychomycosis of the toenail. Journal of the American Academy of Dermatology1998;38(6 Pt 2):S95‐102. [PUBMED: 9631991] ">Ling 1998</a>; <a href="./references#CD010031-bbs2-0036" title="MaddinS , QuiringJ , BulgerL . Randomised, placebo‐controlled, phase 3 study of itraconazole for the treatment of onychomycosis. Journal of Drugs in Dermatology2013;12(7):758‐763. [PUBMED: 23884486] ">Maddin 2013</a>; <a href="./references#CD010031-bbs2-0040" title="ElewskiBE . US experience with fluconazole in nail infections. Journal of the European Academy of Dermatology and Venereology1998;11(Suppl 2):S106. [CENTRAL: CN‐00478523; DOI: 10.1111/j.1468‐3083.1998.tb00994.x] RichP , ScherRK , BrenemanD , SavinRC , FeingoldDS , KonnikovN , et al. Pharmacokinetics of three doses of once‐weekly fluconazole (150, 300, and 450 mg) in distal subungual onychomycosis of the toenail. Journal of the American Academy of Dermatology1998;38(6 Pt 2):S103‐9. [PUBMED: 9631992] ScherRK , BrenemanD , RichP , SavinRC , FeingoldDS , KonnikovN , et al. Once‐weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail. Journal of the American Academy of Dermatology1998;38(6 Pt 2):S77‐86. [PUBMED: 9631989] ">Scher 1998</a>; <a href="./references#CD010031-bbs2-0042" title="SigurgeirssonB , vanRossemK , MalahiasS , RaterinkK . A phase II, randomized, double‐blind, placebo‐controlled, parallel group, dose‐ranging study to investigate the efficacy and safety of 4 dose regimens of oral albaconazole in patients with distal subungual onychomycosis. Journal of the American Academy of Dermatology2013;69(3):416‐25. [PUBMED: 23706639] ">Sigurgeirsson 2013</a>). Seventeen studies compared terbinafine monotherapy with azole monotherapy (<a href="./references#CD010031-bbs2-0002" title="ArcaE , TastanHB , AkarA , KurumluZ , GurAR . An open, randomized, comparative study of oral fluconazole, itraconazole and terbinafine therapy in onychomycosis. Journal of Dermatological Treatment2002;13(1):3‐9. [PUBMED: 12006131] ">Arca 2002</a>; <a href="./references#CD010031-bbs2-0007" title="BrautigamM . Terbinafine versus itraconazole: a controlled clinical comparison in onychomycosis of the toenails. Journal of the American Academy of Dermatology1998;38(5 Pt 3):S53‐6. [PUBMED: 9594938] BrautigamM , NoltingS , SchopfRE , WeidingerG . German randomized double‐blind multicentre comparison of terbinafine and itraconazole for the treatment of toenail tinea infection. British Journal of Dermatology1996;134(Suppl 46):18‐21. [PUBMED: 8763463] BrautigamM , NoltingS , SchopfRE , WeidingerG . Randomised double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection. Seventh Lamisil German Onychomycosis Study Group. BMJ1995;311(7010):919‐22. [PUBMED: 7580551] BrautigamM , WeidingerG , NoltingS . Successful treatment of toenail mycosis with terbinafine and itraconazole gives long term benefits. BMJ1998;317(7165):1084. [PUBMED: 9774312] ">Brautigam 1995</a>; <a href="./references#CD010031-bbs2-0009" title="DeBackerM , DeVroeyC , LesaffreE , ScheysI , DeKeyserP . Twelve weeks of continuous oral therapy for toenail onychomycosis caused by dermatophytes: a double‐blind comparative trial of terbinafine 250 mg/day versus itraconazole 200 mg/day. Journal of the American Academy of Dermatology1998;38(5 Pt 3):S57‐63. [PUBMED: 9594939] DeCuyperC , HindryckxPH . Long‐term outcomes in the treatment of toenail onychomycosis. British Journal of Dermatology1999;141(Suppl 56):15‐20. [PUBMED: 10730909] ">De Backer 1998</a>; <a href="./references#CD010031-bbs2-0010" title="DegreefH , delPalacioA , MygindS , GinterG , Pinto SoaresA , Zuluaga de CadenaA . Randomized double‐blind comparison of short‐term itraconazole and terbinafine therapy for toenail onychomycosis. Acta Dermato‐Venereologica1999;79(3):221‐3. [PUBMED: 10384922] ">Degreef 1999</a>; <a href="./references#CD010031-bbs2-0014" title="ElewskiB , PollakR , AshtonS , RichP , SchlessingerJ , TavakkolA . A randomized, placebo‐ and active‐controlled, parallel‐group, multicentre, investigator‐blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis. British Journal of Dermatology2012;166(2):389‐98. [PUBMED: 21967490] ElewskiB , TavakkolA , PollakR , AshtonS . A randomized, placebo‐ and active‐controlled, parallel‐group, multicenter,investigator‐blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis. Journal of American Academy of Dermatology2010;62(3 Suppl 1):AB76. [EMBASE: 70142781] ">Elewski 2012</a>; <a href="./references#CD010031-bbs2-0018" title="GuptaAK , KonnikovN , LyndeCW . Single‐blind, randomized, prospective study on terbinafine and itraconazole for treatment of dermatophyte toenail onychomycosis in the elderly. Journal of the American Academy of Dermatology2001;44(3):479‐84. [PUBMED: 11209118] ">Gupta 2001a</a>; <a href="./references#CD010031-bbs2-0019" title="GuptaAK , Gregurek‐NovakT . Efficacy of itraconazole, terbinafine, fluconazole, griseofulvin and ketoconazole in the treatment of Scopulariopsis brevicaulis causing onychomycosis of the toes. Dermatology2001;202(3):235‐8. [PUBMED: 11385230] ">Gupta 2001b</a>; <a href="./references#CD010031-bbs2-0022" title="GuptaA , GoverM . Pulse itraconazole versus continuous terbinafine for the treatment of dermatophyte toenail onychomycosis in patients with diabetes mellitus. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB151. [CENTRAL: CN‐00602562] GuptaAK , GoverMD , LyndeCW . Pulse itraconazole vs. continuous terbinafine for the treatment of dermatophyte toenail onychomycosis in patients with diabetes mellitus. Journal of the European Academy of Dermatology and Venereology : JEADV2006;20(10):1188‐93. [PUBMED: 17062029] ">Gupta 2006</a>; <a href="./references#CD010031-bbs2-0023" title="GuptaAK , CooperEA , PaquetM . Recurrences of dermatophyte toenail onychomycosis during long‐term follow‐up after successful treatments with mono‐ and combined therapy of terbinafine and itraconazole. Journal of Cutaneous Medicine and Surgery2013;17(3):201‐6. [PUBMED: 23673304] GuptaAK , LynchLE , KoganN , CooperEA . The use of an intermittent terbinafine regimen for the treatment of dermatophyte toenail onychomycosis. Journal of the European Academy of Dermatology and Venereology2009;23(3):256‐62. [PUBMED: 19438818] ">Gupta 2009</a>; <a href="./references#CD010031-bbs2-0024" title="HavuV , HeikkilaH , KuokkanenK , NuutinenM , RantanenT , SaariS , et al. A double‐blind, randomized study to compare the efficacy and safety of terbinafine (Lamisil) with fluconazole (Diflucan) in the treatment of onychomycosis. British Journal of Dermatology2000;142(1):97‐102. [PUBMED: 10651701] SaloH , PekurinenM . Cost effectiveness of oral terbinafine (Lamisil) compared with oral fluconazole (Diflucan) in the treatment of patients with toenail onychomycosis. PharmacoEconomics2002;20(5):319‐24. [PUBMED: 11994041] ">Havu 2000</a>; <a href="./references#CD010031-bbs2-0027" title="HoneymanJF , Talarico FilhoS , ArrudaLHF , Pereira JrAC , SantamariaJR , SouzaEM , et al. Itraconazole versus terbinafine (Lamisil): which is better for the treatment of onychomycosis?. Journal of the European Academy of Dermatology and Venereology1997;9(3):215‐21. [EMBASE: 1998017627] ">Honeyman 1997</a>; <a href="./references#CD010031-bbs2-0029" title="KejdaJ . Itraconazole pulse therapy vs continuous terbinafine dosing for toenail onychomycosis. Postgraduate Medicine1999;Spec No:12‐5. [PUBMED: 10492661] ">Kejda 1999</a>; <a href="./references#CD010031-bbs2-0032" title="KouznetsovAV , PotekaevNN , BelenkoOV . Terbinafine and itraconazol in the treatment of onychomycosis: results of 3 years observation. Journal of the European Academy of Dermatology and Venereology2002;16(S1):242. [CENTRAL: CN‐00478618; DOI: 10.1046/j.1468‐3083.16.s1.1.x] ">Kouznetsov 2002</a>; <a href="./references#CD010031-bbs2-0039" title="RanawakaRR , NagahawatteA , GunasekaraTA , WeerakoonHS , deSilvaSH . Randomized, double‐blind, comparative study on efficacy and safety of itraconazole pulse therapy and terbinafine pulse therapy on nondermatophyte mold onychomycosis: A study with 90 patients. The Journal of dermatological treatment2016;27(4):364‐72. [PUBMED: 26651495] ">Ranawaka 2016</a>; <a href="./references#CD010031-bbs2-0041" title="EvansEG , SigurgeirssonB . Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. The LION Study Group. BMJ1999;318(7190):1031‐5. [PUBMED: 10205099] HeikkilaH , StubbS . Long‐term results in patients with onychomycosis treated with terbinafine or itraconazole. British Journal of Dermatology2002;146(2):250‐3. [PUBMED: 11903235] SigurgeirssonB , BillsteinS , RantanenT , RuzickaT , diFonzoE , VermeerBJ , et al. L.I.O.N. Study: efficacy and tolerability of continuous terbinafine (Lamisil) compared to intermittent itraconazole in the treatment of toenail onychomycosis. Lamisil vs. Itraconazole in Onychomycosis. British Journal of Dermatology1999;141(Suppl 56):5‐14. [PUBMED: 10730908] SigurgeirssonB , OlafssonJH , SteinssonJB , PaulC , BillsteinS , EvansEG . Long‐term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5‐year blinded prospective follow‐up study. Archives of Dermatology2002;138(3):353‐7. [PUBMED: 11902986] WarrickD , ChurchL . Continuous terbinafine versus intermittent itraconazole for toenail onychomycosis. Journal of Family Practice1999;48(7):492‐3. [PUBMED: 10428238] ">Sigurgeirsson 1999</a>; <a href="./references#CD010031-bbs2-0045" title="TostiA , PiracciniBM , StinchiC , ColomboMD . Relapses of onychomycosis after successful treatment with systemic antifungals: a three‐year follow‐up. Dermatology (Basel, Switzerland)1998;197(2):162‐6. [PUBMED: 9732167] TostiA , PiracciniBM , StinchiC , VenturoN , BardazziF , ColomboMD . Treatment of dermatophyte nail infections: an open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy. Journal of the American Academy of Dermatology1996;34(4):595‐600. [PUBMED: 8601647] ">Tosti 1996</a>; <a href="./references#CD010031-bbs2-0048" title="WonCH , LeeJ , LiK , MiRC , KimBJ , AnJS , et al. The long term efficacy and relapse rate of itraconazole pulse therapy versus terbinafine continuous therapy for toenail onychomycosis ‐ a 96‐week follow‐up study. Korean Journal of Medical Mycology2007;12(3):139‐47. [CENTRAL: CN‐00708731; EMBASE: 2008006956] ">Won 2007</a>), one study compared two different azoles (<a href="./references#CD010031-bbs2-0002" title="ArcaE , TastanHB , AkarA , KurumluZ , GurAR . An open, randomized, comparative study of oral fluconazole, itraconazole and terbinafine therapy in onychomycosis. Journal of Dermatological Treatment2002;13(1):3‐9. [PUBMED: 12006131] ">Arca 2002</a>), and one study compared terbinafine monotherapy with combination terbinafine plus azole therapy (<a href="./references#CD010031-bbs2-0020" title="GuptaAK , LyndeCW , KonnikovN . Single‐blind, randomized, prospective study of sequential itraconazole and terbinafine pulse compared with terbinafine pulse for the treatment of toenail onychomycosis. Journal of the American Academy of Dermatology2001;44(3):485‐91. [PUBMED: 11209119] ">Gupta 2001c</a>). Seven studies compared griseofulvin with either an azole or terbinafine (<a href="./references#CD010031-bbs2-0008" title="CullenSI , CullenMK . Ketoconazole and griseofulvin in the treatment of toenail dermatophyte onychomycosis. Current Therapeutic Research, Clinical and Experimental1987;41(1):24‐29. [EMBASE: 1987096720] ">Cullen 1987</a>; <a href="./references#CD010031-bbs2-0015" title="FaergemannJ , AndersonC , HersleK , HradilE , NordinP , KaamanT , et al. Double‐blind, parallel‐group comparison of terbinafine and griseofulvin in the treatment of toenail onychomycosis. Journal of the American Academy of Dermatology1995;32(5 Pt 1):750‐3. [PUBMED: 7722020] ">Faergemann 1995</a>; <a href="./references#CD010031-bbs2-0019" title="GuptaAK , Gregurek‐NovakT . Efficacy of itraconazole, terbinafine, fluconazole, griseofulvin and ketoconazole in the treatment of Scopulariopsis brevicaulis causing onychomycosis of the toes. Dermatology2001;202(3):235‐8. [PUBMED: 11385230] ">Gupta 2001b</a>; <a href="./references#CD010031-bbs2-0026" title="HofmannH , BrautigamM , WeidingerG , ZaunH . Treatment of toenail onychomycosis. A randomized, double‐blind study with terbinafine and griseofulvin. LAGOS II Study Group. Archives of Dermatology1995;131(8):919‐22. [PUBMED: 7632064] ">Hofmann 1995</a>; <a href="./references#CD010031-bbs2-0031" title="KortingHC , Schafer‐KortingM , ZienickeH , GeorgiiA , OllertMW . Treatment of tinea unguium with medium and high doses of ultramicrosize griseofulvin compared with that with itraconazole. Antimicrobial Agents and Chemotherapy1993;37(10):2064‐8. [PUBMED: 8257124] ">Korting 1993</a>; <a href="./references#CD010031-bbs2-0033" title="LaPlacaM , StinchiC , VenturoN , MorelliR , TostiA . Terbinafine vs griseofulvin in the treatment of dermatophyte onychomycosis [Terbinafina vs griseofulvina nella terapia delle onicomicosi da dermatofiti]. Giornale Italiano di Dermatologia e Venereologia1994;129(4):19‐22. [EMBASE: 1994255170] ">La Placa 1994</a>; <a href="./references#CD010031-bbs2-0043" title="SvejgaardE . Oral ketoconazole as an alternative to griseofulvin in recalcitrant dermatophyte infections and onychomycosis. Acta Dermato‐venereologica1985;65(2):143‐9. [PUBMED: 2408417] ">Svejgaard 1985</a>; <a href="./references#CD010031-bbs2-0046" title="WalsoeI , StangerupM , SvejgaardE . Itraconazole in onychomycosis. Open and double‐blind studies. Acta Dermato‐venereologica1990;70(2):137‐40. [PUBMED: 1969198] ">Walsoe 1990</a>). Study duration ranged from 4 months to 2 years, with most lasting 12 to 15 months. </p> </section> <section id="CD010031-sec-0090"> <h5 class="title">Outcome measures</h5> <p>All studies addressed one or both of our two primary outcomes of clinical and mycological cure. Most studies addressed adverse events. Only nine studies addressed recurrence rate (<a href="./references#CD010031-bbs2-0007" title="BrautigamM . Terbinafine versus itraconazole: a controlled clinical comparison in onychomycosis of the toenails. Journal of the American Academy of Dermatology1998;38(5 Pt 3):S53‐6. [PUBMED: 9594938] BrautigamM , NoltingS , SchopfRE , WeidingerG . German randomized double‐blind multicentre comparison of terbinafine and itraconazole for the treatment of toenail tinea infection. British Journal of Dermatology1996;134(Suppl 46):18‐21. [PUBMED: 8763463] BrautigamM , NoltingS , SchopfRE , WeidingerG . Randomised double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection. Seventh Lamisil German Onychomycosis Study Group. BMJ1995;311(7010):919‐22. [PUBMED: 7580551] BrautigamM , WeidingerG , NoltingS . Successful treatment of toenail mycosis with terbinafine and itraconazole gives long term benefits. BMJ1998;317(7165):1084. [PUBMED: 9774312] ">Brautigam 1995</a>; <a href="./references#CD010031-bbs2-0011" title="DrakeLA , ShearNH , ArletteJP , CloutierR , DanbyFW , ElewskiBE , et al. Oral terbinafine in the treatment of toenail onychomycosis: North American multicenter trial. Journal of the American Academy of Dermatology1997;37(5 Pt 1):740‐5. [PUBMED: 9366820] ">Drake 1997</a>; <a href="./references#CD010031-bbs2-0023" title="GuptaAK , CooperEA , PaquetM . Recurrences of dermatophyte toenail onychomycosis during long‐term follow‐up after successful treatments with mono‐ and combined therapy of terbinafine and itraconazole. Journal of Cutaneous Medicine and Surgery2013;17(3):201‐6. [PUBMED: 23673304] GuptaAK , LynchLE , KoganN , CooperEA . The use of an intermittent terbinafine regimen for the treatment of dermatophyte toenail onychomycosis. Journal of the European Academy of Dermatology and Venereology2009;23(3):256‐62. [PUBMED: 19438818] ">Gupta 2009</a>; <a href="./references#CD010031-bbs2-0028" title="JonesHE , ZaiasN . Double‐blind, randomized comparison of itraconazole capsules and placebo in onychomycosis of toenail. International Journal of Dermatology1996;35(8):589‐90. [PUBMED: 8854164] ">Jones 1996</a>; <a href="./references#CD010031-bbs2-0031" title="KortingHC , Schafer‐KortingM , ZienickeH , GeorgiiA , OllertMW . Treatment of tinea unguium with medium and high doses of ultramicrosize griseofulvin compared with that with itraconazole. Antimicrobial Agents and Chemotherapy1993;37(10):2064‐8. [PUBMED: 8257124] ">Korting 1993</a>; <a href="./references#CD010031-bbs2-0039" title="RanawakaRR , NagahawatteA , GunasekaraTA , WeerakoonHS , deSilvaSH . Randomized, double‐blind, comparative study on efficacy and safety of itraconazole pulse therapy and terbinafine pulse therapy on nondermatophyte mold onychomycosis: A study with 90 patients. The Journal of dermatological treatment2016;27(4):364‐72. [PUBMED: 26651495] ">Ranawaka 2016</a>; <a href="./references#CD010031-bbs2-0041" title="EvansEG , SigurgeirssonB . Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. The LION Study Group. BMJ1999;318(7190):1031‐5. [PUBMED: 10205099] HeikkilaH , StubbS . Long‐term results in patients with onychomycosis treated with terbinafine or itraconazole. British Journal of Dermatology2002;146(2):250‐3. [PUBMED: 11903235] SigurgeirssonB , BillsteinS , RantanenT , RuzickaT , diFonzoE , VermeerBJ , et al. L.I.O.N. Study: efficacy and tolerability of continuous terbinafine (Lamisil) compared to intermittent itraconazole in the treatment of toenail onychomycosis. Lamisil vs. Itraconazole in Onychomycosis. British Journal of Dermatology1999;141(Suppl 56):5‐14. [PUBMED: 10730908] SigurgeirssonB , OlafssonJH , SteinssonJB , PaulC , BillsteinS , EvansEG . Long‐term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5‐year blinded prospective follow‐up study. Archives of Dermatology2002;138(3):353‐7. [PUBMED: 11902986] WarrickD , ChurchL . Continuous terbinafine versus intermittent itraconazole for toenail onychomycosis. Journal of Family Practice1999;48(7):492‐3. [PUBMED: 10428238] ">Sigurgeirsson 1999</a>; <a href="./references#CD010031-bbs2-0045" title="TostiA , PiracciniBM , StinchiC , ColomboMD . Relapses of onychomycosis after successful treatment with systemic antifungals: a three‐year follow‐up. Dermatology (Basel, Switzerland)1998;197(2):162‐6. [PUBMED: 9732167] TostiA , PiracciniBM , StinchiC , VenturoN , BardazziF , ColomboMD . Treatment of dermatophyte nail infections: an open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy. Journal of the American Academy of Dermatology1996;34(4):595‐600. [PUBMED: 8601647] ">Tosti 1996</a>; <a href="./references#CD010031-bbs2-0047" title="EllisDH , WatsonAB , MarleyJE , WilliamsTG . Non‐dermatophytes in onychomycosis of the toenails. British Journal of Dermatology1997;136(4):490‐3. [PUBMED: 9155945] WatsonA , MarleyJ , EllisD , WilliamsT . Terbinafine in onychomycosis of the toenail: a novel treatment protocol. Journal of the American Academy of Dermatology1995;33(5 Pt 1):775‐9. [PUBMED: 7593777] ">Watson 1995</a>), and none addressed quality of life. </p> </section> </section> <section id="CD010031-sec-0091"> <h4 class="title">Excluded studies</h4> <p>We excluded 27 studies from the review (see <a href="./references#CD010031-sec-0184" title="">Characteristics of excluded studies</a> table). </p> <p>The most common reason for exclusion was that the study assessed the efficacy of different regimens of a single drug, without comparing different drugs or drugs and placebo. This applied to 19 of the excluded studies (<a href="./references#CD010031-bbs2-0050" title="AlpsoyE , YilmazE , BasaranE . Intermittent therapy with terbinafine for dermatophyte toe‐onychomycosis: a new approach. Journal of Dermatology1996;23(4):259‐62. [PUBMED: 8935341] ">Alpsoy 1996</a>; <a href="./references#CD010031-bbs2-0051" title="AvnerS , NirN , BaruchK , HenriT . Two novel itraconazole pulse therapies for onychomycosis: a 2‐year follow‐up. Journal of Dermatological Treatment2006;17(2):117‐20. [PUBMED: 16766337] ">Avner 2006a</a>; <a href="./references#CD010031-bbs2-0052" title="AvnerS , NathansohnN Trau H . Onychomycosis recurrence: Long term follow‐up of 2 oral terbinafine regimens and the effect of topical bifonazole solution. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB133. ">Avner 2006b</a>; <a href="./references#CD010031-bbs2-0053" title="ChenJ , LiaoW , WenH , WuJ , YaoZ . A comparison among four regimens of itraconazole treatment in onychomycosis. Mycoses1999;42(1‐2):93‐6. [PUBMED: 10394855] ">Chen 1999</a>; <a href="./references#CD010031-bbs2-0054" title="DeCuyperC . Long‐term evaluation of terbinafine 250 and 500 mg daily in a 16‐week oral treatment for toenail onychomycosis. British Journal of dermatology1996; Vol. 135, issue 1:156‐7. [PUBMED: 8776393] ">De Cuyper 1996</a>; <a href="./references#CD010031-bbs2-0055" title="DeDonckerP , DecroixJ , PierardGE , RoelantD , WoestenborghsR , JacqminP , et al. Antifungal pulse therapy for onychomycosis. A pharmacokinetic and pharmacodynamic investigation of monthly cycles of 1‐week pulse therapy with itraconazole. Archives of Dermatology1996;132(1):34‐41. [PUBMED: 8546481] ">De Doncker 1996</a>; <a href="./references#CD010031-bbs2-0057" title="FinlayAY , ThomasR , DykesPJ , SmithSG , JonesTC . Descriptive correlations between various doses of oral terbinafine and concentrations in nail. Journal of Dermatological Treatment1994;5(4):193‐7. [EMBASE: 1995029315] ">Finlay 1994</a>; <a href="./references#CD010031-bbs2-0060" title="HavuV , BrandtH , HeikkilaH , HollmenA , OksmanR , RantanenT , et al. A double‐blind, randomized study comparing itraconazole pulse therapy with continuous dosing for the treatment of toe‐nail onychomycosis. British Journal of Dermatology1997;136(2):230‐4. [PUBMED: 9068738] ">Havu 1997</a>; <a href="./references#CD010031-bbs2-0061" title="HavuV , BrandtH , HeikkilaH , HollmenA , OksmanR , RantanenT , et al. Continuous and intermittent itraconazole dosing schedules for the treatment of onychomycosis: a pharmacokinetic comparison. British Journal of Dermatology1999;140(1):96‐101. [PUBMED: 10215775] ">Havu 1999</a>; <a href="./references#CD010031-bbs2-0064" title="PollakR , BillsteinSA . Efficacy of terbinafine for toenail onychomycosis. A multicenter trial of various treatment durations. Journal of the American Podiatric Medical Association2001;91(3):127‐31. [PUBMED: 11266494] ">Pollak 2001</a>; <a href="./references#CD010031-bbs2-0066" title="SchatzF , BrautigamM , DobrowolskiE , EffendyI , HaberlH , MensingH , et al. Nail incorporation kinetics of terbinafine in onychomycosis patients. Clinical and Experimental Dermatology1995;20(5):377‐83. [PUBMED: 8593713] ">Schatz 1995</a>; <a href="./references#CD010031-bbs2-0067" title="ShemerA , NathansohnN , KaplanB , GilatD , NewmanN , TrauH . Open randomized comparison of different itraconazole regimens for the treatment of onychomycosis. Journal of Dermatological Treatment1999;10(4):245‐9. [EMBASE: 2000044216] ">Shemer 1999</a>; <a href="./references#CD010031-bbs2-0068" title="SommerS , Sheehan‐DareRA , GoodfieldMJ , EvansEG . Prediction of outcome in the treatment of onychomycosis. Clinical and Experimental Dermatology2003;28(4):425‐8. [PUBMED: 12823307] ">Sommer 2003</a>; <a href="./references#CD010031-bbs2-0069" title="TauschI , BrautigamM , WeidingerG , JonesTC . Evaluation of 6 weeks treatment of terbinafine in tinea unguium in a double‐blind trial comparing 6 and 12 weeks therapy. The Lagos V Study Group. British Journal of Dermatology1997;136(5):737‐42. [PUBMED: 9205509] ">Tausch 1997</a>; <a href="./references#CD010031-bbs2-0070" title="van derSchroeffJG , CirkelPK , CrijnsMB , VanDijkTJ , GovaertFJ , GroenewegDA , et al. A randomized treatment duration‐finding study of terbinafine in onychomycosis. British Journal of Dermatology1992;126(Suppl 39):36‐9. [PUBMED: 1531927] ">van der Schroeff 1992</a>; <a href="./references#CD010031-bbs2-0071" title="WarshawEM , CarverSM , ZielkeGR , AhmedDD . Intermittent terbinafine for toenail onychomycosis: is it effective? Results of a randomized pilot trial. Archives of Dermatology2001; Vol. 137, issue 9:1253. [PUBMED: 11559235] ">Warshaw 2001</a>; <a href="./references#CD010031-bbs2-0072" title="WarshawEM , FettDD , BloomfieldHE , GrillJP , NelsonDB , QuinteroV , et al. Pulse versus continuous terbinafine for onychomycosis: a randomized, double‐blind, controlled trial. Journal of the American Academy of Dermatology2005;53(4):578‐84. [PUBMED: 16198776] ">Warshaw 2005</a>; <a href="./references#CD010031-bbs2-0073" title="WatanabeS . Optimal dosages and cycles of itraconazole pulse therapy for onychomycosis. Japanese Journal of Medical Mycology2004;45(3):143‐7. [PUBMED: 15284828] ">Watanabe 2004</a>; <a href="./references#CD010031-bbs2-0074" title="YadavP , SingalA , PandhiD , DasS . Comparative efficacy of continuous and pulse dose terbinafine regimes in toenail dermatophytosis: A randomized double‐blind trial. Indian Journal of Dermatology, Venereology and Leprology2015;81(4):363‐9. [PUBMED: 26087080] ">Yadav 2015</a>). </p> <p>Two studies examined infections other than toenail onychomycosis; namely, tinea pedis in <a href="./references#CD010031-bbs2-0058" title="GomezM , ArenasR , SalazarJJ , GonzalezA , MoncadoB , RodriguezG . Tinea pedis. A multicenter trial to evaluate the efficacy and tolerance of a weekly dose of fluconazole [Tina de los pies. Estudio multicentrico para valorar la eficacia y tolerancia de una dosis semanal de fluconazol]. Dermatologia Revista Mexicana1996;40(4):251‐5. [EMBASE: 1996238297] ">Gomez 1996</a> and fungal skin infections in <a href="./references#CD010031-bbs2-0075" title="ZaiasN , DrachmanD . A method for the determination of drug effectiveness in onychomycosis. Trials with ketoconazole and griseofulvin ultramicrosize. Journal of the American Academy of Dermatology1983;9(6):912‐9. [PUBMED: 6315789] ">Zaias 1983</a>. Two studies examined the efficacy of adjuncts to oral anti‐fungal therapy, such as topical treatment (<a href="./references#CD010031-bbs2-0062" title="HayRJ , ClaytonYM , MooreMK . A comparison of tioconazole 28% nail solution versus base as an adjunct to oral griseofulvin in patients with onychomycosis. Clinical and Experimental Dermatology1987;12:175‐7. [EMBASE: 1987131271] ">Hay 1987</a>; <a href="./references#CD010031-bbs2-0063" title="MaleszkaR , AdamskiZ . The treatment of extensive onychomycosis in aged patients [Leczenie Rozleglej Grzybicy Dermatofitowej Paznokci U Pacjentow W Starszym Wieku]. Wiadomosci Parazytologiczne2001;47(4):817‐22. [EMBASE: 16886433] ">Maleszka 2001</a>), and one study compared oral anti‐fungal therapy to 'palliative care', which consisted of trimming, soaking, and cleaning (<a href="./references#CD010031-bbs2-0049" title="AlbreskiDA , GrossEG . The safety of itraconazole in the diabetic population. Journal of the American Podiatric Medical Association1999;89(7):339‐45. [PUBMED: 10423939] ">Albreski 1999</a>). </p> <p>There was also one study that measured drug concentration in healthy nails (<a href="./references#CD010031-bbs2-0056" title="FaergemannJ , LaufenH . Levels of fluconazole in normal and diseased nails during and after treatment of onychomycosis in toe‐nails with fluconazole 150mg once weekly. Acta Dermato‐venereologica1996;76(3):219‐21. [PUBMED: 8800303] ">Faergemann 1996</a>), one letter to the editor that did not report a trial (<a href="./references#CD010031-bbs2-0065" title="SaferLF . Randomized double‐blind comparison of short‐term itraconazole and terbinafine therapy for toenail onychomycosis. Acta Dermato‐venereologica2000;80(4):317. [EMBASE: 2000350111] ">Safer 2000</a>), and one study with no control group (<a href="./references#CD010031-bbs2-0059" title="GoodfieldMJD . Clinical results with terbinafine in onychomycosis. Journal of Dermatological Treatment1990;1(Suppl 2):55‐7. [EMBASE: 1990354009] ">Goodfield 1990</a>). </p> </section> </section> <section id="CD010031-sec-0092"> <h3 class="title">Risk of bias in included studies</h3> <p>Two review authors (SKK and LG, GK or KH) independently assessed each of the 48 included studies for risk of bias across six specific domains, using the Cochrane 'Risk of bias' assessment tool (<a href="./references#CD010031-bbs2-0103" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>), described in the Methods (see <a href="#CD010031-sec-0074">Assessment of risk of bias in included studies</a>). </p> <p>We report these assessments in the 'Risk of bias' table associated with each study, as well as the 'Risk of bias' summary (<a href="#CD010031-fig-0002">Figure 2</a>). We only assessed one study as being at low risk of bias in all domains (<a href="./references#CD010031-bbs2-0021" title="GuptaAK , LeonardiC , StoltzRR , PiercePF , ConettaB . A phase I/II randomized, double‐blind, placebo‐controlled, dose‐ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis. Journal of the European Academy of Dermatology and Venereology : JEADV2005;19(4):437‐43. [PUBMED: 15987289] ">Gupta 2005</a>), while we judged 18 studies to be at high risk of bias in at least one domain; 11 of these were at high risk in two or more domains (<a href="./references#CD010031-bbs2-0002" title="ArcaE , TastanHB , AkarA , KurumluZ , GurAR . An open, randomized, comparative study of oral fluconazole, itraconazole and terbinafine therapy in onychomycosis. Journal of Dermatological Treatment2002;13(1):3‐9. [PUBMED: 12006131] ">Arca 2002</a>; <a href="./references#CD010031-bbs2-0003" title="ArenasR , FernandezG , DominguezL . Onychomycosis treated with itraconazole or griseofulvin alone with and without a topical antimycotic or keratolytic agent. International Journal of Dermatology1991;30(8):586‐9. [PUBMED: 1657803] ">Arenas 1991</a>; <a href="./references#CD010031-bbs2-0004" title="ArenasR , Dominguez‐CheritJ , FernandezLM . Open randomized comparison of itraconazole versus terbinafine in onychomycosis. International Journal of Dermatology1995;34(2):138‐43. [PUBMED: 7737776] ">Arenas 1995</a>; <a href="./references#CD010031-bbs2-0019" title="GuptaAK , Gregurek‐NovakT . Efficacy of itraconazole, terbinafine, fluconazole, griseofulvin and ketoconazole in the treatment of Scopulariopsis brevicaulis causing onychomycosis of the toes. Dermatology2001;202(3):235‐8. [PUBMED: 11385230] ">Gupta 2001b</a>; <a href="./references#CD010031-bbs2-0029" title="KejdaJ . Itraconazole pulse therapy vs continuous terbinafine dosing for toenail onychomycosis. Postgraduate Medicine1999;Spec No:12‐5. [PUBMED: 10492661] ">Kejda 1999</a>; <a href="./references#CD010031-bbs2-0031" title="KortingHC , Schafer‐KortingM , ZienickeH , GeorgiiA , OllertMW . Treatment of tinea unguium with medium and high doses of ultramicrosize griseofulvin compared with that with itraconazole. Antimicrobial Agents and Chemotherapy1993;37(10):2064‐8. [PUBMED: 8257124] ">Korting 1993</a>; <a href="./references#CD010031-bbs2-0033" title="LaPlacaM , StinchiC , VenturoN , MorelliR , TostiA . Terbinafine vs griseofulvin in the treatment of dermatophyte onychomycosis [Terbinafina vs griseofulvina nella terapia delle onicomicosi da dermatofiti]. Giornale Italiano di Dermatologia e Venereologia1994;129(4):19‐22. [EMBASE: 1994255170] ">La Placa 1994</a>; <a href="./references#CD010031-bbs2-0037" title="MishraM , PandaPL . A comparative study of efficacy of oral itraconazole and terbinafine pulse therapy in the treatment of onychomycosis. Annales de Dermatologie et de Venereologie2002;129:IC1753. [CENTRAL: CN‐00454549] ">Mishra 2002</a>; <a href="./references#CD010031-bbs2-0038" title="PiepponenT , BlomqvistK , BrandtH , HavuV , HollmenA , KohtamakiK , et al. Efficacy and safety of itraconazole in the long‐term treatment of onychomycosis. Journal of Antimicrobial Chemotherapy1992;29(2):195‐205. [PUBMED: 1324238] ">Piepponen 1992</a>; <a href="./references#CD010031-bbs2-0045" title="TostiA , PiracciniBM , StinchiC , ColomboMD . Relapses of onychomycosis after successful treatment with systemic antifungals: a three‐year follow‐up. Dermatology (Basel, Switzerland)1998;197(2):162‐6. [PUBMED: 9732167] TostiA , PiracciniBM , StinchiC , VenturoN , BardazziF , ColomboMD . Treatment of dermatophyte nail infections: an open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy. Journal of the American Academy of Dermatology1996;34(4):595‐600. [PUBMED: 8601647] ">Tosti 1996</a>; <a href="./references#CD010031-bbs2-0048" title="WonCH , LeeJ , LiK , MiRC , KimBJ , AnJS , et al. The long term efficacy and relapse rate of itraconazole pulse therapy versus terbinafine continuous therapy for toenail onychomycosis ‐ a 96‐week follow‐up study. Korean Journal of Medical Mycology2007;12(3):139‐47. [CENTRAL: CN‐00708731; EMBASE: 2008006956] ">Won 2007</a>). The most common high risk domain was 'blinding of personnel and participants', for which 14 studies were deemed at high risk of bias. </p> <div class="figure" id="CD010031-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010031-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_n/nCD010031-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD010031-sec-0093"> <h4 class="title">Allocation</h4> <section id="CD010031-sec-0094"> <h5 class="title">Sequence generation</h5> <p>We judged eight studies to be at low risk for this domain (<a href="./references#CD010031-bbs2-0007" title="BrautigamM . Terbinafine versus itraconazole: a controlled clinical comparison in onychomycosis of the toenails. Journal of the American Academy of Dermatology1998;38(5 Pt 3):S53‐6. [PUBMED: 9594938] BrautigamM , NoltingS , SchopfRE , WeidingerG . German randomized double‐blind multicentre comparison of terbinafine and itraconazole for the treatment of toenail tinea infection. British Journal of Dermatology1996;134(Suppl 46):18‐21. [PUBMED: 8763463] BrautigamM , NoltingS , SchopfRE , WeidingerG . Randomised double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection. Seventh Lamisil German Onychomycosis Study Group. BMJ1995;311(7010):919‐22. [PUBMED: 7580551] BrautigamM , WeidingerG , NoltingS . Successful treatment of toenail mycosis with terbinafine and itraconazole gives long term benefits. BMJ1998;317(7165):1084. [PUBMED: 9774312] ">Brautigam 1995</a>; <a href="./references#CD010031-bbs2-0009" title="DeBackerM , DeVroeyC , LesaffreE , ScheysI , DeKeyserP . Twelve weeks of continuous oral therapy for toenail onychomycosis caused by dermatophytes: a double‐blind comparative trial of terbinafine 250 mg/day versus itraconazole 200 mg/day. Journal of the American Academy of Dermatology1998;38(5 Pt 3):S57‐63. [PUBMED: 9594939] DeCuyperC , HindryckxPH . Long‐term outcomes in the treatment of toenail onychomycosis. British Journal of Dermatology1999;141(Suppl 56):15‐20. [PUBMED: 10730909] ">De Backer 1998</a>; <a href="./references#CD010031-bbs2-0014" title="ElewskiB , PollakR , AshtonS , RichP , SchlessingerJ , TavakkolA . A randomized, placebo‐ and active‐controlled, parallel‐group, multicentre, investigator‐blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis. British Journal of Dermatology2012;166(2):389‐98. [PUBMED: 21967490] ElewskiB , TavakkolA , PollakR , AshtonS . A randomized, placebo‐ and active‐controlled, parallel‐group, multicenter,investigator‐blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis. Journal of American Academy of Dermatology2010;62(3 Suppl 1):AB76. [EMBASE: 70142781] ">Elewski 2012</a>; <a href="./references#CD010031-bbs2-0016" title="GoodfieldMJ . Short‐duration therapy with terbinafine for dermatophyte onychomycosis: a multicentre trial. British Journal of Dermatology1992;126(Suppl 39):33‐5. [PUBMED: 1531926] GoodfieldMJ , AndrewL , EvansEG . Short term treatment of dermatophyte onychomycosis with terbinafine. BMJ1992;304(6835):1151‐4. [PUBMED: 1392793] ">Goodfield 1992</a>; <a href="./references#CD010031-bbs2-0021" title="GuptaAK , LeonardiC , StoltzRR , PiercePF , ConettaB . A phase I/II randomized, double‐blind, placebo‐controlled, dose‐ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis. Journal of the European Academy of Dermatology and Venereology : JEADV2005;19(4):437‐43. [PUBMED: 15987289] ">Gupta 2005</a>; <a href="./references#CD010031-bbs2-0022" title="GuptaA , GoverM . Pulse itraconazole versus continuous terbinafine for the treatment of dermatophyte toenail onychomycosis in patients with diabetes mellitus. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB151. [CENTRAL: CN‐00602562] GuptaAK , GoverMD , LyndeCW . Pulse itraconazole vs. continuous terbinafine for the treatment of dermatophyte toenail onychomycosis in patients with diabetes mellitus. Journal of the European Academy of Dermatology and Venereology : JEADV2006;20(10):1188‐93. [PUBMED: 17062029] ">Gupta 2006</a>; <a href="./references#CD010031-bbs2-0036" title="MaddinS , QuiringJ , BulgerL . Randomised, placebo‐controlled, phase 3 study of itraconazole for the treatment of onychomycosis. Journal of Drugs in Dermatology2013;12(7):758‐763. [PUBMED: 23884486] ">Maddin 2013</a>; <a href="./references#CD010031-bbs2-0042" title="SigurgeirssonB , vanRossemK , MalahiasS , RaterinkK . A phase II, randomized, double‐blind, placebo‐controlled, parallel group, dose‐ranging study to investigate the efficacy and safety of 4 dose regimens of oral albaconazole in patients with distal subungual onychomycosis. Journal of the American Academy of Dermatology2013;69(3):416‐25. [PUBMED: 23706639] ">Sigurgeirsson 2013</a>). All clearly stated the method of sequence generation. For example, a "computer generated randomisation schedule in order of obtaining informed consent" in <a href="./references#CD010031-bbs2-0007" title="BrautigamM . Terbinafine versus itraconazole: a controlled clinical comparison in onychomycosis of the toenails. Journal of the American Academy of Dermatology1998;38(5 Pt 3):S53‐6. [PUBMED: 9594938] BrautigamM , NoltingS , SchopfRE , WeidingerG . German randomized double‐blind multicentre comparison of terbinafine and itraconazole for the treatment of toenail tinea infection. British Journal of Dermatology1996;134(Suppl 46):18‐21. [PUBMED: 8763463] BrautigamM , NoltingS , SchopfRE , WeidingerG . Randomised double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection. Seventh Lamisil German Onychomycosis Study Group. BMJ1995;311(7010):919‐22. [PUBMED: 7580551] BrautigamM , WeidingerG , NoltingS . Successful treatment of toenail mycosis with terbinafine and itraconazole gives long term benefits. BMJ1998;317(7165):1084. [PUBMED: 9774312] ">Brautigam 1995</a> or "random tables of Fisher and Yates" in <a href="./references#CD010031-bbs2-0016" title="GoodfieldMJ . Short‐duration therapy with terbinafine for dermatophyte onychomycosis: a multicentre trial. British Journal of Dermatology1992;126(Suppl 39):33‐5. [PUBMED: 1531926] GoodfieldMJ , AndrewL , EvansEG . Short term treatment of dermatophyte onychomycosis with terbinafine. BMJ1992;304(6835):1151‐4. [PUBMED: 1392793] ">Goodfield 1992</a>. We assessed 40 studies as being at unclear risk, as there was no mention of the method of sequence generation. </p> </section> <section id="CD010031-sec-0095"> <h5 class="title">Allocation concealment</h5> <p>We assessed three studies as being at low risk with regard to allocation concealment, as they had a clear description of their allocation concealment method (<a href="./references#CD010031-bbs2-0009" title="DeBackerM , DeVroeyC , LesaffreE , ScheysI , DeKeyserP . Twelve weeks of continuous oral therapy for toenail onychomycosis caused by dermatophytes: a double‐blind comparative trial of terbinafine 250 mg/day versus itraconazole 200 mg/day. Journal of the American Academy of Dermatology1998;38(5 Pt 3):S57‐63. [PUBMED: 9594939] DeCuyperC , HindryckxPH . Long‐term outcomes in the treatment of toenail onychomycosis. British Journal of Dermatology1999;141(Suppl 56):15‐20. [PUBMED: 10730909] ">De Backer 1998</a>; <a href="./references#CD010031-bbs2-0021" title="GuptaAK , LeonardiC , StoltzRR , PiercePF , ConettaB . A phase I/II randomized, double‐blind, placebo‐controlled, dose‐ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis. Journal of the European Academy of Dermatology and Venereology : JEADV2005;19(4):437‐43. [PUBMED: 15987289] ">Gupta 2005</a>; <a href="./references#CD010031-bbs2-0039" title="RanawakaRR , NagahawatteA , GunasekaraTA , WeerakoonHS , deSilvaSH . Randomized, double‐blind, comparative study on efficacy and safety of itraconazole pulse therapy and terbinafine pulse therapy on nondermatophyte mold onychomycosis: A study with 90 patients. The Journal of dermatological treatment2016;27(4):364‐72. [PUBMED: 26651495] ">Ranawaka 2016</a>). Forty‐three studies were at unclear risk because they provided no information regarding the method of allocation concealment. We assessed two studies as being at high risk (<a href="./references#CD010031-bbs2-0003" title="ArenasR , FernandezG , DominguezL . Onychomycosis treated with itraconazole or griseofulvin alone with and without a topical antimycotic or keratolytic agent. International Journal of Dermatology1991;30(8):586‐9. [PUBMED: 1657803] ">Arenas 1991</a>; <a href="./references#CD010031-bbs2-0045" title="TostiA , PiracciniBM , StinchiC , ColomboMD . Relapses of onychomycosis after successful treatment with systemic antifungals: a three‐year follow‐up. Dermatology (Basel, Switzerland)1998;197(2):162‐6. [PUBMED: 9732167] TostiA , PiracciniBM , StinchiC , VenturoN , BardazziF , ColomboMD . Treatment of dermatophyte nail infections: an open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy. Journal of the American Academy of Dermatology1996;34(4):595‐600. [PUBMED: 8601647] ">Tosti 1996</a>), as participants were "assigned sequentially to treatment". </p> </section> </section> <section id="CD010031-sec-0096"> <h4 class="title">Blinding</h4> <section id="CD010031-sec-0097"> <h5 class="title">Performance bias</h5> <p>There were 12 low‐risk studies for this domain (<a href="./references#CD010031-bbs2-0007" title="BrautigamM . Terbinafine versus itraconazole: a controlled clinical comparison in onychomycosis of the toenails. Journal of the American Academy of Dermatology1998;38(5 Pt 3):S53‐6. [PUBMED: 9594938] BrautigamM , NoltingS , SchopfRE , WeidingerG . German randomized double‐blind multicentre comparison of terbinafine and itraconazole for the treatment of toenail tinea infection. British Journal of Dermatology1996;134(Suppl 46):18‐21. [PUBMED: 8763463] BrautigamM , NoltingS , SchopfRE , WeidingerG . Randomised double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection. Seventh Lamisil German Onychomycosis Study Group. BMJ1995;311(7010):919‐22. [PUBMED: 7580551] BrautigamM , WeidingerG , NoltingS . Successful treatment of toenail mycosis with terbinafine and itraconazole gives long term benefits. BMJ1998;317(7165):1084. [PUBMED: 9774312] ">Brautigam 1995</a>; <a href="./references#CD010031-bbs2-0008" title="CullenSI , CullenMK . Ketoconazole and griseofulvin in the treatment of toenail dermatophyte onychomycosis. Current Therapeutic Research, Clinical and Experimental1987;41(1):24‐29. [EMBASE: 1987096720] ">Cullen 1987</a>; <a href="./references#CD010031-bbs2-0009" title="DeBackerM , DeVroeyC , LesaffreE , ScheysI , DeKeyserP . Twelve weeks of continuous oral therapy for toenail onychomycosis caused by dermatophytes: a double‐blind comparative trial of terbinafine 250 mg/day versus itraconazole 200 mg/day. Journal of the American Academy of Dermatology1998;38(5 Pt 3):S57‐63. [PUBMED: 9594939] DeCuyperC , HindryckxPH . Long‐term outcomes in the treatment of toenail onychomycosis. British Journal of Dermatology1999;141(Suppl 56):15‐20. [PUBMED: 10730909] ">De Backer 1998</a>; <a href="./references#CD010031-bbs2-0012" title="ElewskiBE , ScherRK , AlyR , DanielR3rd , JonesHE , OdomRB , et al. Double‐blind, randomized comparison of itraconazole capsules vs. placebo in the treatment of toenail onychomycosis. Cutis1997;59(4):217‐20. [PUBMED: 9104548] OdomR , DanielCR , AlyR . A double‐blind, randomized comparison of itraconazole capsules and placebo in the treatment of onychomycosis of the toenail. Journal of the American Academy of Dermatology1996;35(1):110‐1. [PUBMED: 8682945] ">Elewski 1997</a>; <a href="./references#CD010031-bbs2-0017" title="GuptaAK , MaddinS , ArletteJ , GirouxJ‐M , ShearNH . Itraconazole pulse therapy is effective in dermatophyte onychomycosis of the toenail: a double‐blind placebo‐controlled study. Journal of Dermatological Treatment2000;11(1):33‐7. [EMBASE: 2000114935] ">Gupta 2000</a>; <a href="./references#CD010031-bbs2-0021" title="GuptaAK , LeonardiC , StoltzRR , PiercePF , ConettaB . A phase I/II randomized, double‐blind, placebo‐controlled, dose‐ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis. Journal of the European Academy of Dermatology and Venereology : JEADV2005;19(4):437‐43. [PUBMED: 15987289] ">Gupta 2005</a>; <a href="./references#CD010031-bbs2-0024" title="HavuV , HeikkilaH , KuokkanenK , NuutinenM , RantanenT , SaariS , et al. A double‐blind, randomized study to compare the efficacy and safety of terbinafine (Lamisil) with fluconazole (Diflucan) in the treatment of onychomycosis. British Journal of Dermatology2000;142(1):97‐102. [PUBMED: 10651701] SaloH , PekurinenM . Cost effectiveness of oral terbinafine (Lamisil) compared with oral fluconazole (Diflucan) in the treatment of patients with toenail onychomycosis. PharmacoEconomics2002;20(5):319‐24. [PUBMED: 11994041] ">Havu 2000</a>; <a href="./references#CD010031-bbs2-0027" title="HoneymanJF , Talarico FilhoS , ArrudaLHF , Pereira JrAC , SantamariaJR , SouzaEM , et al. Itraconazole versus terbinafine (Lamisil): which is better for the treatment of onychomycosis?. Journal of the European Academy of Dermatology and Venereology1997;9(3):215‐21. [EMBASE: 1998017627] ">Honeyman 1997</a>; <a href="./references#CD010031-bbs2-0030" title="KempersS , QuiringJ , BulgerL , ScherR , BissonnetteR . A novel itraconazole tablet for the treatment of onychomycosis. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB87. [EMBASE: 70142824] ">Kempers 2010</a>; <a href="./references#CD010031-bbs2-0039" title="RanawakaRR , NagahawatteA , GunasekaraTA , WeerakoonHS , deSilvaSH . Randomized, double‐blind, comparative study on efficacy and safety of itraconazole pulse therapy and terbinafine pulse therapy on nondermatophyte mold onychomycosis: A study with 90 patients. The Journal of dermatological treatment2016;27(4):364‐72. [PUBMED: 26651495] ">Ranawaka 2016</a>; <a href="./references#CD010031-bbs2-0041" title="EvansEG , SigurgeirssonB . Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. The LION Study Group. BMJ1999;318(7190):1031‐5. [PUBMED: 10205099] HeikkilaH , StubbS . Long‐term results in patients with onychomycosis treated with terbinafine or itraconazole. British Journal of Dermatology2002;146(2):250‐3. [PUBMED: 11903235] SigurgeirssonB , BillsteinS , RantanenT , RuzickaT , diFonzoE , VermeerBJ , et al. L.I.O.N. Study: efficacy and tolerability of continuous terbinafine (Lamisil) compared to intermittent itraconazole in the treatment of toenail onychomycosis. Lamisil vs. Itraconazole in Onychomycosis. British Journal of Dermatology1999;141(Suppl 56):5‐14. [PUBMED: 10730908] SigurgeirssonB , OlafssonJH , SteinssonJB , PaulC , BillsteinS , EvansEG . Long‐term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5‐year blinded prospective follow‐up study. Archives of Dermatology2002;138(3):353‐7. [PUBMED: 11902986] WarrickD , ChurchL . Continuous terbinafine versus intermittent itraconazole for toenail onychomycosis. Journal of Family Practice1999;48(7):492‐3. [PUBMED: 10428238] ">Sigurgeirsson 1999</a>; <a href="./references#CD010031-bbs2-0042" title="SigurgeirssonB , vanRossemK , MalahiasS , RaterinkK . A phase II, randomized, double‐blind, placebo‐controlled, parallel group, dose‐ranging study to investigate the efficacy and safety of 4 dose regimens of oral albaconazole in patients with distal subungual onychomycosis. Journal of the American Academy of Dermatology2013;69(3):416‐25. [PUBMED: 23706639] ">Sigurgeirsson 2013</a>); these studies explicitly described the technique used for blinding, for instance the double‐dummy technique or "the active and placebo formulations were packaged so that both the participant and the investigator were blinded" (<a href="./references#CD010031-bbs2-0017" title="GuptaAK , MaddinS , ArletteJ , GirouxJ‐M , ShearNH . Itraconazole pulse therapy is effective in dermatophyte onychomycosis of the toenail: a double‐blind placebo‐controlled study. Journal of Dermatological Treatment2000;11(1):33‐7. [EMBASE: 2000114935] ">Gupta 2000</a>). We assessed 20 studies as being at unclear risk; of these, 19 studies did not describe a method of blinding, and the one remaining study stated that some of the treatment groups were blinded while others were not (<a href="./references#CD010031-bbs2-0014" title="ElewskiB , PollakR , AshtonS , RichP , SchlessingerJ , TavakkolA . A randomized, placebo‐ and active‐controlled, parallel‐group, multicentre, investigator‐blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis. British Journal of Dermatology2012;166(2):389‐98. [PUBMED: 21967490] ElewskiB , TavakkolA , PollakR , AshtonS . A randomized, placebo‐ and active‐controlled, parallel‐group, multicenter,investigator‐blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis. Journal of American Academy of Dermatology2010;62(3 Suppl 1):AB76. [EMBASE: 70142781] ">Elewski 2012</a>). We deemed 16 studies to be at high risk; these studies were predominantly open or single‐blind studies, and in one study there was no mention of blinding (<a href="./references#CD010031-bbs2-0032" title="KouznetsovAV , PotekaevNN , BelenkoOV . Terbinafine and itraconazol in the treatment of onychomycosis: results of 3 years observation. Journal of the European Academy of Dermatology and Venereology2002;16(S1):242. [CENTRAL: CN‐00478618; DOI: 10.1046/j.1468‐3083.16.s1.1.x] ">Kouznetsov 2002</a>). </p> </section> <section id="CD010031-sec-0098"> <h5 class="title">Detection bias</h5> <p>In terms of detection bias, there were nine studies we deemed to be at low risk, either because the authors specified that the outcome assessors were blinded (<a href="./references#CD010031-bbs2-0018" title="GuptaAK , KonnikovN , LyndeCW . Single‐blind, randomized, prospective study on terbinafine and itraconazole for treatment of dermatophyte toenail onychomycosis in the elderly. Journal of the American Academy of Dermatology2001;44(3):479‐84. [PUBMED: 11209118] ">Gupta 2001a</a>; <a href="./references#CD010031-bbs2-0020" title="GuptaAK , LyndeCW , KonnikovN . Single‐blind, randomized, prospective study of sequential itraconazole and terbinafine pulse compared with terbinafine pulse for the treatment of toenail onychomycosis. Journal of the American Academy of Dermatology2001;44(3):485‐91. [PUBMED: 11209119] ">Gupta 2001c</a>; <a href="./references#CD010031-bbs2-0021" title="GuptaAK , LeonardiC , StoltzRR , PiercePF , ConettaB . A phase I/II randomized, double‐blind, placebo‐controlled, dose‐ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis. Journal of the European Academy of Dermatology and Venereology : JEADV2005;19(4):437‐43. [PUBMED: 15987289] ">Gupta 2005</a>; <a href="./references#CD010031-bbs2-0022" title="GuptaA , GoverM . Pulse itraconazole versus continuous terbinafine for the treatment of dermatophyte toenail onychomycosis in patients with diabetes mellitus. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB151. [CENTRAL: CN‐00602562] GuptaAK , GoverMD , LyndeCW . Pulse itraconazole vs. continuous terbinafine for the treatment of dermatophyte toenail onychomycosis in patients with diabetes mellitus. Journal of the European Academy of Dermatology and Venereology : JEADV2006;20(10):1188‐93. [PUBMED: 17062029] ">Gupta 2006</a>; <a href="./references#CD010031-bbs2-0030" title="KempersS , QuiringJ , BulgerL , ScherR , BissonnetteR . A novel itraconazole tablet for the treatment of onychomycosis. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB87. [EMBASE: 70142824] ">Kempers 2010</a>; <a href="./references#CD010031-bbs2-0039" title="RanawakaRR , NagahawatteA , GunasekaraTA , WeerakoonHS , deSilvaSH . Randomized, double‐blind, comparative study on efficacy and safety of itraconazole pulse therapy and terbinafine pulse therapy on nondermatophyte mold onychomycosis: A study with 90 patients. The Journal of dermatological treatment2016;27(4):364‐72. [PUBMED: 26651495] ">Ranawaka 2016</a>; <a href="./references#CD010031-bbs2-0041" title="EvansEG , SigurgeirssonB . Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. The LION Study Group. BMJ1999;318(7190):1031‐5. [PUBMED: 10205099] HeikkilaH , StubbS . Long‐term results in patients with onychomycosis treated with terbinafine or itraconazole. British Journal of Dermatology2002;146(2):250‐3. [PUBMED: 11903235] SigurgeirssonB , BillsteinS , RantanenT , RuzickaT , diFonzoE , VermeerBJ , et al. L.I.O.N. Study: efficacy and tolerability of continuous terbinafine (Lamisil) compared to intermittent itraconazole in the treatment of toenail onychomycosis. Lamisil vs. Itraconazole in Onychomycosis. British Journal of Dermatology1999;141(Suppl 56):5‐14. [PUBMED: 10730908] SigurgeirssonB , OlafssonJH , SteinssonJB , PaulC , BillsteinS , EvansEG . Long‐term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5‐year blinded prospective follow‐up study. Archives of Dermatology2002;138(3):353‐7. [PUBMED: 11902986] WarrickD , ChurchL . Continuous terbinafine versus intermittent itraconazole for toenail onychomycosis. Journal of Family Practice1999;48(7):492‐3. [PUBMED: 10428238] ">Sigurgeirsson 1999</a>; <a href="./references#CD010031-bbs2-0042" title="SigurgeirssonB , vanRossemK , MalahiasS , RaterinkK . A phase II, randomized, double‐blind, placebo‐controlled, parallel group, dose‐ranging study to investigate the efficacy and safety of 4 dose regimens of oral albaconazole in patients with distal subungual onychomycosis. Journal of the American Academy of Dermatology2013;69(3):416‐25. [PUBMED: 23706639] ">Sigurgeirsson 2013</a>), or they described the method of blinding of the outcome assessors (<a href="./references#CD010031-bbs2-0023" title="GuptaAK , CooperEA , PaquetM . Recurrences of dermatophyte toenail onychomycosis during long‐term follow‐up after successful treatments with mono‐ and combined therapy of terbinafine and itraconazole. Journal of Cutaneous Medicine and Surgery2013;17(3):201‐6. [PUBMED: 23673304] GuptaAK , LynchLE , KoganN , CooperEA . The use of an intermittent terbinafine regimen for the treatment of dermatophyte toenail onychomycosis. Journal of the European Academy of Dermatology and Venereology2009;23(3):256‐62. [PUBMED: 19438818] ">Gupta 2009</a>). </p> <p>We assessed 27 studies as being at unclear risk, 26 of which did not specify whether the outcome assessors were blinded or how they were blinded. In the one remaining study (<a href="./references#CD010031-bbs2-0036" title="MaddinS , QuiringJ , BulgerL . Randomised, placebo‐controlled, phase 3 study of itraconazole for the treatment of onychomycosis. Journal of Drugs in Dermatology2013;12(7):758‐763. [PUBMED: 23884486] ">Maddin 2013</a>), there was a dedicated person to look after medication, but medications differed in appearance. </p> <p>We judged 12 studies to be at high risk: seven were open‐label studies (<a href="./references#CD010031-bbs2-0002" title="ArcaE , TastanHB , AkarA , KurumluZ , GurAR . An open, randomized, comparative study of oral fluconazole, itraconazole and terbinafine therapy in onychomycosis. Journal of Dermatological Treatment2002;13(1):3‐9. [PUBMED: 12006131] ">Arca 2002</a>; <a href="./references#CD010031-bbs2-0003" title="ArenasR , FernandezG , DominguezL . Onychomycosis treated with itraconazole or griseofulvin alone with and without a topical antimycotic or keratolytic agent. International Journal of Dermatology1991;30(8):586‐9. [PUBMED: 1657803] ">Arenas 1991</a>; <a href="./references#CD010031-bbs2-0004" title="ArenasR , Dominguez‐CheritJ , FernandezLM . Open randomized comparison of itraconazole versus terbinafine in onychomycosis. International Journal of Dermatology1995;34(2):138‐43. [PUBMED: 7737776] ">Arenas 1995</a>; <a href="./references#CD010031-bbs2-0031" title="KortingHC , Schafer‐KortingM , ZienickeH , GeorgiiA , OllertMW . Treatment of tinea unguium with medium and high doses of ultramicrosize griseofulvin compared with that with itraconazole. Antimicrobial Agents and Chemotherapy1993;37(10):2064‐8. [PUBMED: 8257124] ">Korting 1993</a>; <a href="./references#CD010031-bbs2-0045" title="TostiA , PiracciniBM , StinchiC , ColomboMD . Relapses of onychomycosis after successful treatment with systemic antifungals: a three‐year follow‐up. Dermatology (Basel, Switzerland)1998;197(2):162‐6. [PUBMED: 9732167] TostiA , PiracciniBM , StinchiC , VenturoN , BardazziF , ColomboMD . Treatment of dermatophyte nail infections: an open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy. Journal of the American Academy of Dermatology1996;34(4):595‐600. [PUBMED: 8601647] ">Tosti 1996</a>; <a href="./references#CD010031-bbs2-0048" title="WonCH , LeeJ , LiK , MiRC , KimBJ , AnJS , et al. The long term efficacy and relapse rate of itraconazole pulse therapy versus terbinafine continuous therapy for toenail onychomycosis ‐ a 96‐week follow‐up study. Korean Journal of Medical Mycology2007;12(3):139‐47. [CENTRAL: CN‐00708731; EMBASE: 2008006956] ">Won 2007</a>; <a href="./references#CD010031-bbs2-0029" title="KejdaJ . Itraconazole pulse therapy vs continuous terbinafine dosing for toenail onychomycosis. Postgraduate Medicine1999;Spec No:12‐5. [PUBMED: 10492661] ">Kejda 1999</a>), while five gave no information on blinding in the text (<a href="./references#CD010031-bbs2-0033" title="LaPlacaM , StinchiC , VenturoN , MorelliR , TostiA . Terbinafine vs griseofulvin in the treatment of dermatophyte onychomycosis [Terbinafina vs griseofulvina nella terapia delle onicomicosi da dermatofiti]. Giornale Italiano di Dermatologia e Venereologia1994;129(4):19‐22. [EMBASE: 1994255170] ">La Placa 1994</a>; <a href="./references#CD010031-bbs2-0032" title="KouznetsovAV , PotekaevNN , BelenkoOV . Terbinafine and itraconazol in the treatment of onychomycosis: results of 3 years observation. Journal of the European Academy of Dermatology and Venereology2002;16(S1):242. [CENTRAL: CN‐00478618; DOI: 10.1046/j.1468‐3083.16.s1.1.x] ">Kouznetsov 2002</a>; <a href="./references#CD010031-bbs2-0037" title="MishraM , PandaPL . A comparative study of efficacy of oral itraconazole and terbinafine pulse therapy in the treatment of onychomycosis. Annales de Dermatologie et de Venereologie2002;129:IC1753. [CENTRAL: CN‐00454549] ">Mishra 2002</a>; <a href="./references#CD010031-bbs2-0038" title="PiepponenT , BlomqvistK , BrandtH , HavuV , HollmenA , KohtamakiK , et al. Efficacy and safety of itraconazole in the long‐term treatment of onychomycosis. Journal of Antimicrobial Chemotherapy1992;29(2):195‐205. [PUBMED: 1324238] ">Piepponen 1992</a>; <a href="./references#CD010031-bbs2-0019" title="GuptaAK , Gregurek‐NovakT . Efficacy of itraconazole, terbinafine, fluconazole, griseofulvin and ketoconazole in the treatment of Scopulariopsis brevicaulis causing onychomycosis of the toes. Dermatology2001;202(3):235‐8. [PUBMED: 11385230] ">Gupta 2001b</a>). </p> </section> </section> <section id="CD010031-sec-0099"> <h4 class="title">Incomplete outcome data</h4> <p>We judged 36 studies to be at low risk because they accounted for all participants in the analysis (<a href="./references#CD010031-bbs2-0002" title="ArcaE , TastanHB , AkarA , KurumluZ , GurAR . An open, randomized, comparative study of oral fluconazole, itraconazole and terbinafine therapy in onychomycosis. Journal of Dermatological Treatment2002;13(1):3‐9. [PUBMED: 12006131] ">Arca 2002</a>; <a href="./references#CD010031-bbs2-0014" title="ElewskiB , PollakR , AshtonS , RichP , SchlessingerJ , TavakkolA . A randomized, placebo‐ and active‐controlled, parallel‐group, multicentre, investigator‐blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis. British Journal of Dermatology2012;166(2):389‐98. [PUBMED: 21967490] ElewskiB , TavakkolA , PollakR , AshtonS . A randomized, placebo‐ and active‐controlled, parallel‐group, multicenter,investigator‐blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis. Journal of American Academy of Dermatology2010;62(3 Suppl 1):AB76. [EMBASE: 70142781] ">Elewski 2012</a>; <a href="./references#CD010031-bbs2-0018" title="GuptaAK , KonnikovN , LyndeCW . Single‐blind, randomized, prospective study on terbinafine and itraconazole for treatment of dermatophyte toenail onychomycosis in the elderly. Journal of the American Academy of Dermatology2001;44(3):479‐84. [PUBMED: 11209118] ">Gupta 2001a</a>; <a href="./references#CD010031-bbs2-0019" title="GuptaAK , Gregurek‐NovakT . Efficacy of itraconazole, terbinafine, fluconazole, griseofulvin and ketoconazole in the treatment of Scopulariopsis brevicaulis causing onychomycosis of the toes. Dermatology2001;202(3):235‐8. [PUBMED: 11385230] ">Gupta 2001b</a>; <a href="./references#CD010031-bbs2-0022" title="GuptaA , GoverM . Pulse itraconazole versus continuous terbinafine for the treatment of dermatophyte toenail onychomycosis in patients with diabetes mellitus. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB151. [CENTRAL: CN‐00602562] GuptaAK , GoverMD , LyndeCW . Pulse itraconazole vs. continuous terbinafine for the treatment of dermatophyte toenail onychomycosis in patients with diabetes mellitus. Journal of the European Academy of Dermatology and Venereology : JEADV2006;20(10):1188‐93. [PUBMED: 17062029] ">Gupta 2006</a>; <a href="./references#CD010031-bbs2-0023" title="GuptaAK , CooperEA , PaquetM . Recurrences of dermatophyte toenail onychomycosis during long‐term follow‐up after successful treatments with mono‐ and combined therapy of terbinafine and itraconazole. Journal of Cutaneous Medicine and Surgery2013;17(3):201‐6. [PUBMED: 23673304] GuptaAK , LynchLE , KoganN , CooperEA . The use of an intermittent terbinafine regimen for the treatment of dermatophyte toenail onychomycosis. Journal of the European Academy of Dermatology and Venereology2009;23(3):256‐62. [PUBMED: 19438818] ">Gupta 2009</a>; <a href="./references#CD010031-bbs2-0024" title="HavuV , HeikkilaH , KuokkanenK , NuutinenM , RantanenT , SaariS , et al. A double‐blind, randomized study to compare the efficacy and safety of terbinafine (Lamisil) with fluconazole (Diflucan) in the treatment of onychomycosis. British Journal of Dermatology2000;142(1):97‐102. [PUBMED: 10651701] SaloH , PekurinenM . Cost effectiveness of oral terbinafine (Lamisil) compared with oral fluconazole (Diflucan) in the treatment of patients with toenail onychomycosis. PharmacoEconomics2002;20(5):319‐24. [PUBMED: 11994041] ">Havu 2000</a>; <a href="./references#CD010031-bbs2-0036" title="MaddinS , QuiringJ , BulgerL . Randomised, placebo‐controlled, phase 3 study of itraconazole for the treatment of onychomycosis. Journal of Drugs in Dermatology2013;12(7):758‐763. [PUBMED: 23884486] ">Maddin 2013</a>; <a href="./references#CD010031-bbs2-0041" title="EvansEG , SigurgeirssonB . Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. The LION Study Group. BMJ1999;318(7190):1031‐5. [PUBMED: 10205099] HeikkilaH , StubbS . Long‐term results in patients with onychomycosis treated with terbinafine or itraconazole. British Journal of Dermatology2002;146(2):250‐3. [PUBMED: 11903235] SigurgeirssonB , BillsteinS , RantanenT , RuzickaT , diFonzoE , VermeerBJ , et al. L.I.O.N. Study: efficacy and tolerability of continuous terbinafine (Lamisil) compared to intermittent itraconazole in the treatment of toenail onychomycosis. Lamisil vs. Itraconazole in Onychomycosis. British Journal of Dermatology1999;141(Suppl 56):5‐14. [PUBMED: 10730908] SigurgeirssonB , OlafssonJH , SteinssonJB , PaulC , BillsteinS , EvansEG . Long‐term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5‐year blinded prospective follow‐up study. Archives of Dermatology2002;138(3):353‐7. [PUBMED: 11902986] WarrickD , ChurchL . Continuous terbinafine versus intermittent itraconazole for toenail onychomycosis. Journal of Family Practice1999;48(7):492‐3. [PUBMED: 10428238] ">Sigurgeirsson 1999</a>; <a href="./references#CD010031-bbs2-0045" title="TostiA , PiracciniBM , StinchiC , ColomboMD . Relapses of onychomycosis after successful treatment with systemic antifungals: a three‐year follow‐up. Dermatology (Basel, Switzerland)1998;197(2):162‐6. [PUBMED: 9732167] TostiA , PiracciniBM , StinchiC , VenturoN , BardazziF , ColomboMD . Treatment of dermatophyte nail infections: an open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy. Journal of the American Academy of Dermatology1996;34(4):595‐600. [PUBMED: 8601647] ">Tosti 1996</a>; <a href="./references#CD010031-bbs2-0046" title="WalsoeI , StangerupM , SvejgaardE . Itraconazole in onychomycosis. Open and double‐blind studies. Acta Dermato‐venereologica1990;70(2):137‐40. [PUBMED: 1969198] ">Walsoe 1990</a>), all study dropouts were accounted for (<a href="./references#CD010031-bbs2-0004" title="ArenasR , Dominguez‐CheritJ , FernandezLM . Open randomized comparison of itraconazole versus terbinafine in onychomycosis. International Journal of Dermatology1995;34(2):138‐43. [PUBMED: 7737776] ">Arenas 1995</a>; <a href="./references#CD010031-bbs2-0006" title="BillsteinS , KianifardF , JusticeA . Terbinafine vs. placebo for onychomycosis in black patients. International Journal of Dermatology1999;38(5):377‐379. [PUBMED: 10369551] ">Billstein 1999</a>; <a href="./references#CD010031-bbs2-0008" title="CullenSI , CullenMK . Ketoconazole and griseofulvin in the treatment of toenail dermatophyte onychomycosis. Current Therapeutic Research, Clinical and Experimental1987;41(1):24‐29. [EMBASE: 1987096720] ">Cullen 1987</a>; <a href="./references#CD010031-bbs2-0010" title="DegreefH , delPalacioA , MygindS , GinterG , Pinto SoaresA , Zuluaga de CadenaA . Randomized double‐blind comparison of short‐term itraconazole and terbinafine therapy for toenail onychomycosis. Acta Dermato‐Venereologica1999;79(3):221‐3. [PUBMED: 10384922] ">Degreef 1999</a>; <a href="./references#CD010031-bbs2-0013" title="ElewskiBE , ElCharifM , CooperKD , GhannoumM , BirnbaumJE . Reactivity to trichophytin antigen in patients with onychomycosis: effect of terbinafine. Journal of the American Academy of Dermatology2002;46(3):371‐5. [PUBMED: 11862171] ">Elewski 2002</a>; <a href="./references#CD010031-bbs2-0015" title="FaergemannJ , AndersonC , HersleK , HradilE , NordinP , KaamanT , et al. Double‐blind, parallel‐group comparison of terbinafine and griseofulvin in the treatment of toenail onychomycosis. Journal of the American Academy of Dermatology1995;32(5 Pt 1):750‐3. [PUBMED: 7722020] ">Faergemann 1995</a>; <a href="./references#CD010031-bbs2-0016" title="GoodfieldMJ . Short‐duration therapy with terbinafine for dermatophyte onychomycosis: a multicentre trial. British Journal of Dermatology1992;126(Suppl 39):33‐5. [PUBMED: 1531926] GoodfieldMJ , AndrewL , EvansEG . Short term treatment of dermatophyte onychomycosis with terbinafine. BMJ1992;304(6835):1151‐4. [PUBMED: 1392793] ">Goodfield 1992</a>; <a href="./references#CD010031-bbs2-0017" title="GuptaAK , MaddinS , ArletteJ , GirouxJ‐M , ShearNH . Itraconazole pulse therapy is effective in dermatophyte onychomycosis of the toenail: a double‐blind placebo‐controlled study. Journal of Dermatological Treatment2000;11(1):33‐7. [EMBASE: 2000114935] ">Gupta 2000</a>; <a href="./references#CD010031-bbs2-0020" title="GuptaAK , LyndeCW , KonnikovN . Single‐blind, randomized, prospective study of sequential itraconazole and terbinafine pulse compared with terbinafine pulse for the treatment of toenail onychomycosis. Journal of the American Academy of Dermatology2001;44(3):485‐91. [PUBMED: 11209119] ">Gupta 2001c</a>; <a href="./references#CD010031-bbs2-0021" title="GuptaAK , LeonardiC , StoltzRR , PiercePF , ConettaB . A phase I/II randomized, double‐blind, placebo‐controlled, dose‐ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis. Journal of the European Academy of Dermatology and Venereology : JEADV2005;19(4):437‐43. [PUBMED: 15987289] ">Gupta 2005</a>; <a href="./references#CD010031-bbs2-0026" title="HofmannH , BrautigamM , WeidingerG , ZaunH . Treatment of toenail onychomycosis. A randomized, double‐blind study with terbinafine and griseofulvin. LAGOS II Study Group. Archives of Dermatology1995;131(8):919‐22. [PUBMED: 7632064] ">Hofmann 1995</a>; <a href="./references#CD010031-bbs2-0027" title="HoneymanJF , Talarico FilhoS , ArrudaLHF , Pereira JrAC , SantamariaJR , SouzaEM , et al. Itraconazole versus terbinafine (Lamisil): which is better for the treatment of onychomycosis?. Journal of the European Academy of Dermatology and Venereology1997;9(3):215‐21. [EMBASE: 1998017627] ">Honeyman 1997</a>; <a href="./references#CD010031-bbs2-0028" title="JonesHE , ZaiasN . Double‐blind, randomized comparison of itraconazole capsules and placebo in onychomycosis of toenail. International Journal of Dermatology1996;35(8):589‐90. [PUBMED: 8854164] ">Jones 1996</a>; <a href="./references#CD010031-bbs2-0029" title="KejdaJ . Itraconazole pulse therapy vs continuous terbinafine dosing for toenail onychomycosis. Postgraduate Medicine1999;Spec No:12‐5. [PUBMED: 10492661] ">Kejda 1999</a>; <a href="./references#CD010031-bbs2-0033" title="LaPlacaM , StinchiC , VenturoN , MorelliR , TostiA . Terbinafine vs griseofulvin in the treatment of dermatophyte onychomycosis [Terbinafina vs griseofulvina nella terapia delle onicomicosi da dermatofiti]. Giornale Italiano di Dermatologia e Venereologia1994;129(4):19‐22. [EMBASE: 1994255170] ">La Placa 1994</a>; <a href="./references#CD010031-bbs2-0035" title="LingMR , SwinyerLJ , JarrattMT , FaloL , MonroeEW , TharpM , et al. Once‐weekly fluconazole (450 mg) for 4, 6, or 9 months of treatment for distal subungual onychomycosis of the toenail. Journal of the American Academy of Dermatology1998;38(6 Pt 2):S95‐102. [PUBMED: 9631991] ">Ling 1998</a>; <a href="./references#CD010031-bbs2-0031" title="KortingHC , Schafer‐KortingM , ZienickeH , GeorgiiA , OllertMW . Treatment of tinea unguium with medium and high doses of ultramicrosize griseofulvin compared with that with itraconazole. Antimicrobial Agents and Chemotherapy1993;37(10):2064‐8. [PUBMED: 8257124] ">Korting 1993</a>; <a href="./references#CD010031-bbs2-0042" title="SigurgeirssonB , vanRossemK , MalahiasS , RaterinkK . A phase II, randomized, double‐blind, placebo‐controlled, parallel group, dose‐ranging study to investigate the efficacy and safety of 4 dose regimens of oral albaconazole in patients with distal subungual onychomycosis. Journal of the American Academy of Dermatology2013;69(3):416‐25. [PUBMED: 23706639] ">Sigurgeirsson 2013</a>; <a href="./references#CD010031-bbs2-0040" title="ElewskiBE . US experience with fluconazole in nail infections. Journal of the European Academy of Dermatology and Venereology1998;11(Suppl 2):S106. [CENTRAL: CN‐00478523; DOI: 10.1111/j.1468‐3083.1998.tb00994.x] RichP , ScherRK , BrenemanD , SavinRC , FeingoldDS , KonnikovN , et al. Pharmacokinetics of three doses of once‐weekly fluconazole (150, 300, and 450 mg) in distal subungual onychomycosis of the toenail. Journal of the American Academy of Dermatology1998;38(6 Pt 2):S103‐9. [PUBMED: 9631992] ScherRK , BrenemanD , RichP , SavinRC , FeingoldDS , KonnikovN , et al. Once‐weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail. Journal of the American Academy of Dermatology1998;38(6 Pt 2):S77‐86. [PUBMED: 9631989] ">Scher 1998</a>; <a href="./references#CD010031-bbs2-0043" title="SvejgaardE . Oral ketoconazole as an alternative to griseofulvin in recalcitrant dermatophyte infections and onychomycosis. Acta Dermato‐venereologica1985;65(2):143‐9. [PUBMED: 2408417] ">Svejgaard 1985</a>; <a href="./references#CD010031-bbs2-0047" title="EllisDH , WatsonAB , MarleyJE , WilliamsTG . Non‐dermatophytes in onychomycosis of the toenails. British Journal of Dermatology1997;136(4):490‐3. [PUBMED: 9155945] WatsonA , MarleyJ , EllisD , WilliamsT . Terbinafine in onychomycosis of the toenail: a novel treatment protocol. Journal of the American Academy of Dermatology1995;33(5 Pt 1):775‐9. [PUBMED: 7593777] ">Watson 1995</a>) or the number of participants unaccounted for was very low (<a href="./references#CD010031-bbs2-0007" title="BrautigamM . Terbinafine versus itraconazole: a controlled clinical comparison in onychomycosis of the toenails. Journal of the American Academy of Dermatology1998;38(5 Pt 3):S53‐6. [PUBMED: 9594938] BrautigamM , NoltingS , SchopfRE , WeidingerG . German randomized double‐blind multicentre comparison of terbinafine and itraconazole for the treatment of toenail tinea infection. British Journal of Dermatology1996;134(Suppl 46):18‐21. [PUBMED: 8763463] BrautigamM , NoltingS , SchopfRE , WeidingerG . Randomised double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection. Seventh Lamisil German Onychomycosis Study Group. BMJ1995;311(7010):919‐22. [PUBMED: 7580551] BrautigamM , WeidingerG , NoltingS . Successful treatment of toenail mycosis with terbinafine and itraconazole gives long term benefits. BMJ1998;317(7165):1084. [PUBMED: 9774312] ">Brautigam 1995</a> (two participants), <a href="./references#CD010031-bbs2-0025" title="HayRJ , ClaytonYM , GriffithsWA , DowdPM . A comparative double blind study of ketoconazole and griseofulvin in dermatophytosis. British Journal of Dermatology1985;112(6):691‐6. [PUBMED: 3890924] ">Hay 1985</a> (six participants), <a href="./references#CD010031-bbs2-0034" title="LebwohlMG , DanielCR , LeydenJ , MormonM , ShavinJS , TschenE , et al. Efficacy and safety of terbinafine for nondermatophyte and mixed nondermatophyte and dermatophyte toenail onychomycosis. International Journal of Dermatology2001;40(5):358‐60. [PUBMED: 11555003] ">Lebwohl 2001</a> (four participants), and <a href="./references#CD010031-bbs2-0044" title="BrandrupF , LarsenPO . Long‐term follow‐up of toe‐nail onychomycosis treated with terbinafine. Acta Dermato‐venereologica1997;77(3):238. [PUBMED: 9188883] SvejgaardEL , BrandrupF , KragballeK , LarsenPO , VeienNK , HolstM , et al. Oral terbinafine in toenail dermatophytosis. A double‐blind, placebo‐controlled multicenter study with 12 months' follow‐up. Acta Dermato‐venereologica1997;77(1):66‐9. [PUBMED: 9059684] ">Svejgaard 1997</a> (one participant)). </p> <p>We deemed eight studies to be at unclear risk. In four of these studies, there were unexplained dropouts, but the numbers of missing participants were similar across treatment groups (<a href="./references#CD010031-bbs2-0001" title="Al RubaieSM . Double blind comparison between terbinafine &amp; griseofulvin in the treatment of fingernail and toe nail onychomycosis. Australasian Journal of Dermatology1997;38(Suppl 2):289. [CENTRAL: CN‐00499326] ">Al Rubaie 1997</a>; <a href="./references#CD010031-bbs2-0009" title="DeBackerM , DeVroeyC , LesaffreE , ScheysI , DeKeyserP . Twelve weeks of continuous oral therapy for toenail onychomycosis caused by dermatophytes: a double‐blind comparative trial of terbinafine 250 mg/day versus itraconazole 200 mg/day. Journal of the American Academy of Dermatology1998;38(5 Pt 3):S57‐63. [PUBMED: 9594939] DeCuyperC , HindryckxPH . Long‐term outcomes in the treatment of toenail onychomycosis. British Journal of Dermatology1999;141(Suppl 56):15‐20. [PUBMED: 10730909] ">De Backer 1998</a>; <a href="./references#CD010031-bbs2-0011" title="DrakeLA , ShearNH , ArletteJP , CloutierR , DanbyFW , ElewskiBE , et al. Oral terbinafine in the treatment of toenail onychomycosis: North American multicenter trial. Journal of the American Academy of Dermatology1997;37(5 Pt 1):740‐5. [PUBMED: 9366820] ">Drake 1997</a>; <a href="./references#CD010031-bbs2-0048" title="WonCH , LeeJ , LiK , MiRC , KimBJ , AnJS , et al. The long term efficacy and relapse rate of itraconazole pulse therapy versus terbinafine continuous therapy for toenail onychomycosis ‐ a 96‐week follow‐up study. Korean Journal of Medical Mycology2007;12(3):139‐47. [CENTRAL: CN‐00708731; EMBASE: 2008006956] ">Won 2007</a>). In two studies the number of discontinuations was not clear from the text (<a href="./references#CD010031-bbs2-0030" title="KempersS , QuiringJ , BulgerL , ScherR , BissonnetteR . A novel itraconazole tablet for the treatment of onychomycosis. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB87. [EMBASE: 70142824] ">Kempers 2010</a>; <a href="./references#CD010031-bbs2-0032" title="KouznetsovAV , PotekaevNN , BelenkoOV . Terbinafine and itraconazol in the treatment of onychomycosis: results of 3 years observation. Journal of the European Academy of Dermatology and Venereology2002;16(S1):242. [CENTRAL: CN‐00478618; DOI: 10.1046/j.1468‐3083.16.s1.1.x] ">Kouznetsov 2002</a>), and in two studies the number of dropouts was dissimilar between the treatment arms (<a href="./references#CD010031-bbs2-0012" title="ElewskiBE , ScherRK , AlyR , DanielR3rd , JonesHE , OdomRB , et al. Double‐blind, randomized comparison of itraconazole capsules vs. placebo in the treatment of toenail onychomycosis. Cutis1997;59(4):217‐20. [PUBMED: 9104548] OdomR , DanielCR , AlyR . A double‐blind, randomized comparison of itraconazole capsules and placebo in the treatment of onychomycosis of the toenail. Journal of the American Academy of Dermatology1996;35(1):110‐1. [PUBMED: 8682945] ">Elewski 1997</a>; <a href="./references#CD010031-bbs2-0039" title="RanawakaRR , NagahawatteA , GunasekaraTA , WeerakoonHS , deSilvaSH . Randomized, double‐blind, comparative study on efficacy and safety of itraconazole pulse therapy and terbinafine pulse therapy on nondermatophyte mold onychomycosis: A study with 90 patients. The Journal of dermatological treatment2016;27(4):364‐72. [PUBMED: 26651495] ">Ranawaka 2016</a>). </p> <p>We assessed four studies as being at high risk (<a href="./references#CD010031-bbs2-0003" title="ArenasR , FernandezG , DominguezL . Onychomycosis treated with itraconazole or griseofulvin alone with and without a topical antimycotic or keratolytic agent. International Journal of Dermatology1991;30(8):586‐9. [PUBMED: 1657803] ">Arenas 1991</a>; <a href="./references#CD010031-bbs2-0005" title="BaranR . A multicentre double‐blind parallel group study comparing the efficacy, safety and tolerability of terbinafine (250 mg/day) with griseofulvin (1g/day) in the treatment of dermatophytic onychomycosis. Journal of the European Academy of Dermatology &amp; Venereology1995;5(Suppl 1):S79. [CENTRAL: CN‐00454083] BaranR , BelaichS , BeylotC , BonnetblancJ , CribierB , DanielF , et al. Comparative multicentre double‐blind study of terbinafine (250 mg per day) versus griseofulvin (1 g per day) in the treatment of dermatophyte onychomycosis. Journal of Dermatological Treatment1997;8(2):93‐97. [EMBASE: 1997242786] ">Baran 1995</a>; <a href="./references#CD010031-bbs2-0037" title="MishraM , PandaPL . A comparative study of efficacy of oral itraconazole and terbinafine pulse therapy in the treatment of onychomycosis. Annales de Dermatologie et de Venereologie2002;129:IC1753. [CENTRAL: CN‐00454549] ">Mishra 2002</a>; <a href="./references#CD010031-bbs2-0038" title="PiepponenT , BlomqvistK , BrandtH , HavuV , HollmenA , KohtamakiK , et al. Efficacy and safety of itraconazole in the long‐term treatment of onychomycosis. Journal of Antimicrobial Chemotherapy1992;29(2):195‐205. [PUBMED: 1324238] ">Piepponen 1992</a>). </p> </section> <section id="CD010031-sec-0100"> <h4 class="title">Selective reporting</h4> <p>We judged all 48 studies included in the review as being at low risk of reporting bias, as they reported all the outcomes they described in the Methods section, and all studies also had at least one of our primary outcomes (clinical cure and/or mycological cure) as their prespecified primary trial outcome. None of the trials used surrogate markers, and there was no indication of selective reporting of outcomes. </p> </section> <section id="CD010031-sec-0101"> <h4 class="title">Other potential sources of bias</h4> <p>We deemed 47 studies to be at low risk of other potential sources of bias. Other bias was unclear in the remaining study because of pharmaceutical sponsorship and heavy involvement in the study (<a href="./references#CD010031-bbs2-0035" title="LingMR , SwinyerLJ , JarrattMT , FaloL , MonroeEW , TharpM , et al. Once‐weekly fluconazole (450 mg) for 4, 6, or 9 months of treatment for distal subungual onychomycosis of the toenail. Journal of the American Academy of Dermatology1998;38(6 Pt 2):S95‐102. [PUBMED: 9631991] ">Ling 1998</a>): "For the evaluation of efficacy at the end of treatment and at the six‐month follow‐up, clinical success was arbitrarily defined by the sponsor of the study". </p> </section> </section> <section id="CD010031-sec-0102"> <h3 class="title" id="CD010031-sec-0102">Effects of interventions</h3> <p>See: <a href="./full#CD010031-tbl-0001"><b>Summary of findings for the main comparison</b> Azole compared to terbinafine for toenail onychomycosis</a>; <a href="./full#CD010031-tbl-0002"><b>Summary of findings 2</b> Terbinafine compared to placebo for toenail onychomycosis</a>; <a href="./full#CD010031-tbl-0003"><b>Summary of findings 3</b> Azole compared to placebo for toenail onychomycosis</a>; <a href="./full#CD010031-tbl-0004"><b>Summary of findings 4</b> Griseofulvin compared to azole for toenail onychomycosis</a>; <a href="./full#CD010031-tbl-0005"><b>Summary of findings 5</b> Griseofulvin compared to terbinafine for toenail onychomycosis</a>; <a href="./full#CD010031-tbl-0006"><b>Summary of findings 6</b> Combination terbinafine plus azole compared to terbinafine monotherapy for toenail onychomycosis</a> </p> <p>The following comparisons address our prespecified outcomes.</p> <p> <ol id="CD010031-list-0009"> <li> <p>Azole versus terbinafine.</p> </li> <li> <p>Terbinafine versus placebo.</p> </li> <li> <p>Azole versus placebo.</p> </li> <li> <p>Griseofulvin versus azole.</p> </li> <li> <p>Griseofulvin versus terbinafine.</p> </li> <li> <p>Terbinafine plus azole versus terbinafine monotherapy.</p> </li> </ol> </p> <p>For the clinical and mycological cure outcomes, we established subgroups based on duration of follow‐up (52 weeks and under or over 52 weeks of follow‐up including treatment duration). </p> <p>None of the studies addressed quality of life.</p> <section id="CD010031-sec-0103"> <h4 class="title">Comparison 1: azole versus terbinafine</h4> <p>See <a href="./full#CD010031-tbl-0001">summary of findings Table for the main comparison</a> for quality assessments for this comparison. </p> <p>Seventeen studies (1317 participants) compared azole with terbinafine (<a href="./references#CD010031-bbs2-0002" title="ArcaE , TastanHB , AkarA , KurumluZ , GurAR . An open, randomized, comparative study of oral fluconazole, itraconazole and terbinafine therapy in onychomycosis. Journal of Dermatological Treatment2002;13(1):3‐9. [PUBMED: 12006131] ">Arca 2002</a>; <a href="./references#CD010031-bbs2-0004" title="ArenasR , Dominguez‐CheritJ , FernandezLM . Open randomized comparison of itraconazole versus terbinafine in onychomycosis. International Journal of Dermatology1995;34(2):138‐43. [PUBMED: 7737776] ">Arenas 1995</a>; <a href="./references#CD010031-bbs2-0007" title="BrautigamM . Terbinafine versus itraconazole: a controlled clinical comparison in onychomycosis of the toenails. Journal of the American Academy of Dermatology1998;38(5 Pt 3):S53‐6. [PUBMED: 9594938] BrautigamM , NoltingS , SchopfRE , WeidingerG . German randomized double‐blind multicentre comparison of terbinafine and itraconazole for the treatment of toenail tinea infection. British Journal of Dermatology1996;134(Suppl 46):18‐21. [PUBMED: 8763463] BrautigamM , NoltingS , SchopfRE , WeidingerG . Randomised double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection. Seventh Lamisil German Onychomycosis Study Group. BMJ1995;311(7010):919‐22. [PUBMED: 7580551] BrautigamM , WeidingerG , NoltingS . Successful treatment of toenail mycosis with terbinafine and itraconazole gives long term benefits. BMJ1998;317(7165):1084. [PUBMED: 9774312] ">Brautigam 1995</a>; <a href="./references#CD010031-bbs2-0009" title="DeBackerM , DeVroeyC , LesaffreE , ScheysI , DeKeyserP . Twelve weeks of continuous oral therapy for toenail onychomycosis caused by dermatophytes: a double‐blind comparative trial of terbinafine 250 mg/day versus itraconazole 200 mg/day. Journal of the American Academy of Dermatology1998;38(5 Pt 3):S57‐63. [PUBMED: 9594939] DeCuyperC , HindryckxPH . Long‐term outcomes in the treatment of toenail onychomycosis. British Journal of Dermatology1999;141(Suppl 56):15‐20. [PUBMED: 10730909] ">De Backer 1998</a>; <a href="./references#CD010031-bbs2-0010" title="DegreefH , delPalacioA , MygindS , GinterG , Pinto SoaresA , Zuluaga de CadenaA . Randomized double‐blind comparison of short‐term itraconazole and terbinafine therapy for toenail onychomycosis. Acta Dermato‐Venereologica1999;79(3):221‐3. [PUBMED: 10384922] ">Degreef 1999</a>; <a href="./references#CD010031-bbs2-0014" title="ElewskiB , PollakR , AshtonS , RichP , SchlessingerJ , TavakkolA . A randomized, placebo‐ and active‐controlled, parallel‐group, multicentre, investigator‐blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis. British Journal of Dermatology2012;166(2):389‐98. [PUBMED: 21967490] ElewskiB , TavakkolA , PollakR , AshtonS . A randomized, placebo‐ and active‐controlled, parallel‐group, multicenter,investigator‐blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis. Journal of American Academy of Dermatology2010;62(3 Suppl 1):AB76. [EMBASE: 70142781] ">Elewski 2012</a>; <a href="./references#CD010031-bbs2-0018" title="GuptaAK , KonnikovN , LyndeCW . Single‐blind, randomized, prospective study on terbinafine and itraconazole for treatment of dermatophyte toenail onychomycosis in the elderly. Journal of the American Academy of Dermatology2001;44(3):479‐84. [PUBMED: 11209118] ">Gupta 2001a</a>; <a href="./references#CD010031-bbs2-0019" title="GuptaAK , Gregurek‐NovakT . Efficacy of itraconazole, terbinafine, fluconazole, griseofulvin and ketoconazole in the treatment of Scopulariopsis brevicaulis causing onychomycosis of the toes. Dermatology2001;202(3):235‐8. [PUBMED: 11385230] ">Gupta 2001b</a>; <a href="./references#CD010031-bbs2-0022" title="GuptaA , GoverM . Pulse itraconazole versus continuous terbinafine for the treatment of dermatophyte toenail onychomycosis in patients with diabetes mellitus. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB151. [CENTRAL: CN‐00602562] GuptaAK , GoverMD , LyndeCW . Pulse itraconazole vs. continuous terbinafine for the treatment of dermatophyte toenail onychomycosis in patients with diabetes mellitus. Journal of the European Academy of Dermatology and Venereology : JEADV2006;20(10):1188‐93. [PUBMED: 17062029] ">Gupta 2006</a>; <a href="./references#CD010031-bbs2-0023" title="GuptaAK , CooperEA , PaquetM . Recurrences of dermatophyte toenail onychomycosis during long‐term follow‐up after successful treatments with mono‐ and combined therapy of terbinafine and itraconazole. Journal of Cutaneous Medicine and Surgery2013;17(3):201‐6. [PUBMED: 23673304] GuptaAK , LynchLE , KoganN , CooperEA . The use of an intermittent terbinafine regimen for the treatment of dermatophyte toenail onychomycosis. Journal of the European Academy of Dermatology and Venereology2009;23(3):256‐62. [PUBMED: 19438818] ">Gupta 2009</a>; <a href="./references#CD010031-bbs2-0024" title="HavuV , HeikkilaH , KuokkanenK , NuutinenM , RantanenT , SaariS , et al. A double‐blind, randomized study to compare the efficacy and safety of terbinafine (Lamisil) with fluconazole (Diflucan) in the treatment of onychomycosis. British Journal of Dermatology2000;142(1):97‐102. [PUBMED: 10651701] SaloH , PekurinenM . Cost effectiveness of oral terbinafine (Lamisil) compared with oral fluconazole (Diflucan) in the treatment of patients with toenail onychomycosis. PharmacoEconomics2002;20(5):319‐24. [PUBMED: 11994041] ">Havu 2000</a>; <a href="./references#CD010031-bbs2-0027" title="HoneymanJF , Talarico FilhoS , ArrudaLHF , Pereira JrAC , SantamariaJR , SouzaEM , et al. Itraconazole versus terbinafine (Lamisil): which is better for the treatment of onychomycosis?. Journal of the European Academy of Dermatology and Venereology1997;9(3):215‐21. [EMBASE: 1998017627] ">Honeyman 1997</a>; <a href="./references#CD010031-bbs2-0029" title="KejdaJ . Itraconazole pulse therapy vs continuous terbinafine dosing for toenail onychomycosis. Postgraduate Medicine1999;Spec No:12‐5. [PUBMED: 10492661] ">Kejda 1999</a>; <a href="./references#CD010031-bbs2-0032" title="KouznetsovAV , PotekaevNN , BelenkoOV . Terbinafine and itraconazol in the treatment of onychomycosis: results of 3 years observation. Journal of the European Academy of Dermatology and Venereology2002;16(S1):242. [CENTRAL: CN‐00478618; DOI: 10.1046/j.1468‐3083.16.s1.1.x] ">Kouznetsov 2002</a>; <a href="./references#CD010031-bbs2-0041" title="EvansEG , SigurgeirssonB . Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. The LION Study Group. BMJ1999;318(7190):1031‐5. [PUBMED: 10205099] HeikkilaH , StubbS . Long‐term results in patients with onychomycosis treated with terbinafine or itraconazole. British Journal of Dermatology2002;146(2):250‐3. [PUBMED: 11903235] SigurgeirssonB , BillsteinS , RantanenT , RuzickaT , diFonzoE , VermeerBJ , et al. L.I.O.N. Study: efficacy and tolerability of continuous terbinafine (Lamisil) compared to intermittent itraconazole in the treatment of toenail onychomycosis. Lamisil vs. Itraconazole in Onychomycosis. British Journal of Dermatology1999;141(Suppl 56):5‐14. [PUBMED: 10730908] SigurgeirssonB , OlafssonJH , SteinssonJB , PaulC , BillsteinS , EvansEG . Long‐term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5‐year blinded prospective follow‐up study. Archives of Dermatology2002;138(3):353‐7. [PUBMED: 11902986] WarrickD , ChurchL . Continuous terbinafine versus intermittent itraconazole for toenail onychomycosis. Journal of Family Practice1999;48(7):492‐3. [PUBMED: 10428238] ">Sigurgeirsson 1999</a>; <a href="./references#CD010031-bbs2-0045" title="TostiA , PiracciniBM , StinchiC , ColomboMD . Relapses of onychomycosis after successful treatment with systemic antifungals: a three‐year follow‐up. Dermatology (Basel, Switzerland)1998;197(2):162‐6. [PUBMED: 9732167] TostiA , PiracciniBM , StinchiC , VenturoN , BardazziF , ColomboMD . Treatment of dermatophyte nail infections: an open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy. Journal of the American Academy of Dermatology1996;34(4):595‐600. [PUBMED: 8601647] ">Tosti 1996</a>; <a href="./references#CD010031-bbs2-0048" title="WonCH , LeeJ , LiK , MiRC , KimBJ , AnJS , et al. The long term efficacy and relapse rate of itraconazole pulse therapy versus terbinafine continuous therapy for toenail onychomycosis ‐ a 96‐week follow‐up study. Korean Journal of Medical Mycology2007;12(3):139‐47. [CENTRAL: CN‐00708731; EMBASE: 2008006956] ">Won 2007</a>). Azoles included fluconazole (<a href="./references#CD010031-bbs2-0024" title="HavuV , HeikkilaH , KuokkanenK , NuutinenM , RantanenT , SaariS , et al. A double‐blind, randomized study to compare the efficacy and safety of terbinafine (Lamisil) with fluconazole (Diflucan) in the treatment of onychomycosis. British Journal of Dermatology2000;142(1):97‐102. [PUBMED: 10651701] SaloH , PekurinenM . Cost effectiveness of oral terbinafine (Lamisil) compared with oral fluconazole (Diflucan) in the treatment of patients with toenail onychomycosis. PharmacoEconomics2002;20(5):319‐24. [PUBMED: 11994041] ">Havu 2000</a>); posaconazole (<a href="./references#CD010031-bbs2-0014" title="ElewskiB , PollakR , AshtonS , RichP , SchlessingerJ , TavakkolA . A randomized, placebo‐ and active‐controlled, parallel‐group, multicentre, investigator‐blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis. British Journal of Dermatology2012;166(2):389‐98. [PUBMED: 21967490] ElewskiB , TavakkolA , PollakR , AshtonS . A randomized, placebo‐ and active‐controlled, parallel‐group, multicenter,investigator‐blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis. Journal of American Academy of Dermatology2010;62(3 Suppl 1):AB76. [EMBASE: 70142781] ">Elewski 2012</a>); fluconazole and itraconazole in two arms (<a href="./references#CD010031-bbs2-0002" title="ArcaE , TastanHB , AkarA , KurumluZ , GurAR . An open, randomized, comparative study of oral fluconazole, itraconazole and terbinafine therapy in onychomycosis. Journal of Dermatological Treatment2002;13(1):3‐9. [PUBMED: 12006131] ">Arca 2002</a>); and itraconazole, ketoconazole and fluconazole in three arms (<a href="./references#CD010031-bbs2-0019" title="GuptaAK , Gregurek‐NovakT . Efficacy of itraconazole, terbinafine, fluconazole, griseofulvin and ketoconazole in the treatment of Scopulariopsis brevicaulis causing onychomycosis of the toes. Dermatology2001;202(3):235‐8. [PUBMED: 11385230] ">Gupta 2001b</a>). All other studies used itraconazole as the only azole. </p> <p>This is the main comparison for our review, and we present the results in the <a href="./full#CD010031-tbl-0001">summary of findings Table for the main comparison</a>, which includes a detailed discussion of the quality of the evidence using the GRADE framework as described in <a href="#CD010031-sec-0153">Quality of the evidence</a> section. </p> <section id="CD010031-sec-0104"> <h5 class="title">Primary outcomes</h5> <section id="CD010031-sec-0105"> <h6 class="title">Clinical cure</h6> <p>See <a href="./references#CD010031-fig-0005" title="">Analysis 1.1</a>. </p> <p>Fifteen studies reported clinical cure as an outcome (<a href="./references#CD010031-bbs2-0002" title="ArcaE , TastanHB , AkarA , KurumluZ , GurAR . An open, randomized, comparative study of oral fluconazole, itraconazole and terbinafine therapy in onychomycosis. Journal of Dermatological Treatment2002;13(1):3‐9. [PUBMED: 12006131] ">Arca 2002</a>; <a href="./references#CD010031-bbs2-0004" title="ArenasR , Dominguez‐CheritJ , FernandezLM . Open randomized comparison of itraconazole versus terbinafine in onychomycosis. International Journal of Dermatology1995;34(2):138‐43. [PUBMED: 7737776] ">Arenas 1995</a>; <a href="./references#CD010031-bbs2-0009" title="DeBackerM , DeVroeyC , LesaffreE , ScheysI , DeKeyserP . Twelve weeks of continuous oral therapy for toenail onychomycosis caused by dermatophytes: a double‐blind comparative trial of terbinafine 250 mg/day versus itraconazole 200 mg/day. Journal of the American Academy of Dermatology1998;38(5 Pt 3):S57‐63. [PUBMED: 9594939] DeCuyperC , HindryckxPH . Long‐term outcomes in the treatment of toenail onychomycosis. British Journal of Dermatology1999;141(Suppl 56):15‐20. [PUBMED: 10730909] ">De Backer 1998</a>; <a href="./references#CD010031-bbs2-0010" title="DegreefH , delPalacioA , MygindS , GinterG , Pinto SoaresA , Zuluaga de CadenaA . Randomized double‐blind comparison of short‐term itraconazole and terbinafine therapy for toenail onychomycosis. Acta Dermato‐Venereologica1999;79(3):221‐3. [PUBMED: 10384922] ">Degreef 1999</a>; <a href="./references#CD010031-bbs2-0014" title="ElewskiB , PollakR , AshtonS , RichP , SchlessingerJ , TavakkolA . A randomized, placebo‐ and active‐controlled, parallel‐group, multicentre, investigator‐blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis. British Journal of Dermatology2012;166(2):389‐98. [PUBMED: 21967490] ElewskiB , TavakkolA , PollakR , AshtonS . A randomized, placebo‐ and active‐controlled, parallel‐group, multicenter,investigator‐blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis. Journal of American Academy of Dermatology2010;62(3 Suppl 1):AB76. [EMBASE: 70142781] ">Elewski 2012</a>; <a href="./references#CD010031-bbs2-0018" title="GuptaAK , KonnikovN , LyndeCW . Single‐blind, randomized, prospective study on terbinafine and itraconazole for treatment of dermatophyte toenail onychomycosis in the elderly. Journal of the American Academy of Dermatology2001;44(3):479‐84. [PUBMED: 11209118] ">Gupta 2001a</a>; <a href="./references#CD010031-bbs2-0019" title="GuptaAK , Gregurek‐NovakT . Efficacy of itraconazole, terbinafine, fluconazole, griseofulvin and ketoconazole in the treatment of Scopulariopsis brevicaulis causing onychomycosis of the toes. Dermatology2001;202(3):235‐8. [PUBMED: 11385230] ">Gupta 2001b</a>; <a href="./references#CD010031-bbs2-0022" title="GuptaA , GoverM . Pulse itraconazole versus continuous terbinafine for the treatment of dermatophyte toenail onychomycosis in patients with diabetes mellitus. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB151. [CENTRAL: CN‐00602562] GuptaAK , GoverMD , LyndeCW . Pulse itraconazole vs. continuous terbinafine for the treatment of dermatophyte toenail onychomycosis in patients with diabetes mellitus. Journal of the European Academy of Dermatology and Venereology : JEADV2006;20(10):1188‐93. [PUBMED: 17062029] ">Gupta 2006</a>; <a href="./references#CD010031-bbs2-0023" title="GuptaAK , CooperEA , PaquetM . Recurrences of dermatophyte toenail onychomycosis during long‐term follow‐up after successful treatments with mono‐ and combined therapy of terbinafine and itraconazole. Journal of Cutaneous Medicine and Surgery2013;17(3):201‐6. [PUBMED: 23673304] GuptaAK , LynchLE , KoganN , CooperEA . The use of an intermittent terbinafine regimen for the treatment of dermatophyte toenail onychomycosis. Journal of the European Academy of Dermatology and Venereology2009;23(3):256‐62. [PUBMED: 19438818] ">Gupta 2009</a>; <a href="./references#CD010031-bbs2-0024" title="HavuV , HeikkilaH , KuokkanenK , NuutinenM , RantanenT , SaariS , et al. A double‐blind, randomized study to compare the efficacy and safety of terbinafine (Lamisil) with fluconazole (Diflucan) in the treatment of onychomycosis. British Journal of Dermatology2000;142(1):97‐102. [PUBMED: 10651701] SaloH , PekurinenM . Cost effectiveness of oral terbinafine (Lamisil) compared with oral fluconazole (Diflucan) in the treatment of patients with toenail onychomycosis. PharmacoEconomics2002;20(5):319‐24. [PUBMED: 11994041] ">Havu 2000</a>; <a href="./references#CD010031-bbs2-0027" title="HoneymanJF , Talarico FilhoS , ArrudaLHF , Pereira JrAC , SantamariaJR , SouzaEM , et al. Itraconazole versus terbinafine (Lamisil): which is better for the treatment of onychomycosis?. Journal of the European Academy of Dermatology and Venereology1997;9(3):215‐21. [EMBASE: 1998017627] ">Honeyman 1997</a><a href="./references#CD010031-bbs2-0029" title="KejdaJ . Itraconazole pulse therapy vs continuous terbinafine dosing for toenail onychomycosis. Postgraduate Medicine1999;Spec No:12‐5. [PUBMED: 10492661] ">Kejda 1999</a>; <a href="./references#CD010031-bbs2-0039" title="RanawakaRR , NagahawatteA , GunasekaraTA , WeerakoonHS , deSilvaSH . Randomized, double‐blind, comparative study on efficacy and safety of itraconazole pulse therapy and terbinafine pulse therapy on nondermatophyte mold onychomycosis: A study with 90 patients. The Journal of dermatological treatment2016;27(4):364‐72. [PUBMED: 26651495] ">Ranawaka 2016</a>; <a href="./references#CD010031-bbs2-0041" title="EvansEG , SigurgeirssonB . Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. The LION Study Group. BMJ1999;318(7190):1031‐5. [PUBMED: 10205099] HeikkilaH , StubbS . Long‐term results in patients with onychomycosis treated with terbinafine or itraconazole. British Journal of Dermatology2002;146(2):250‐3. [PUBMED: 11903235] SigurgeirssonB , BillsteinS , RantanenT , RuzickaT , diFonzoE , VermeerBJ , et al. L.I.O.N. Study: efficacy and tolerability of continuous terbinafine (Lamisil) compared to intermittent itraconazole in the treatment of toenail onychomycosis. Lamisil vs. Itraconazole in Onychomycosis. British Journal of Dermatology1999;141(Suppl 56):5‐14. [PUBMED: 10730908] SigurgeirssonB , OlafssonJH , SteinssonJB , PaulC , BillsteinS , EvansEG . Long‐term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5‐year blinded prospective follow‐up study. Archives of Dermatology2002;138(3):353‐7. [PUBMED: 11902986] WarrickD , ChurchL . Continuous terbinafine versus intermittent itraconazole for toenail onychomycosis. Journal of Family Practice1999;48(7):492‐3. [PUBMED: 10428238] ">Sigurgeirsson 1999</a>; <a href="./references#CD010031-bbs2-0048" title="WonCH , LeeJ , LiK , MiRC , KimBJ , AnJS , et al. The long term efficacy and relapse rate of itraconazole pulse therapy versus terbinafine continuous therapy for toenail onychomycosis ‐ a 96‐week follow‐up study. Korean Journal of Medical Mycology2007;12(3):139‐47. [CENTRAL: CN‐00708731; EMBASE: 2008006956] ">Won 2007</a>). </p> <p>In the pooled azole group, 521 (46%) participants achieved clinical cure compared to 598 (58%) participants in the combined terbinafine group. There was moderate‐quality evidence that participants in the azole group were 18% less likely to achieve clinical cure compared to participants receiving terbinafine (RR 0.82, 95% CI 0.72 to 0.95, 15 studies, 2168 participants; I² = 62%). </p> <p>Two studies caused statistical heterogeneity (<a href="./references#CD010031-bbs2-0024" title="HavuV , HeikkilaH , KuokkanenK , NuutinenM , RantanenT , SaariS , et al. A double‐blind, randomized study to compare the efficacy and safety of terbinafine (Lamisil) with fluconazole (Diflucan) in the treatment of onychomycosis. British Journal of Dermatology2000;142(1):97‐102. [PUBMED: 10651701] SaloH , PekurinenM . Cost effectiveness of oral terbinafine (Lamisil) compared with oral fluconazole (Diflucan) in the treatment of patients with toenail onychomycosis. PharmacoEconomics2002;20(5):319‐24. [PUBMED: 11994041] ">Havu 2000</a>; <a href="./references#CD010031-bbs2-0041" title="EvansEG , SigurgeirssonB . Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. The LION Study Group. BMJ1999;318(7190):1031‐5. [PUBMED: 10205099] HeikkilaH , StubbS . Long‐term results in patients with onychomycosis treated with terbinafine or itraconazole. British Journal of Dermatology2002;146(2):250‐3. [PUBMED: 11903235] SigurgeirssonB , BillsteinS , RantanenT , RuzickaT , diFonzoE , VermeerBJ , et al. L.I.O.N. Study: efficacy and tolerability of continuous terbinafine (Lamisil) compared to intermittent itraconazole in the treatment of toenail onychomycosis. Lamisil vs. Itraconazole in Onychomycosis. British Journal of Dermatology1999;141(Suppl 56):5‐14. [PUBMED: 10730908] SigurgeirssonB , OlafssonJH , SteinssonJB , PaulC , BillsteinS , EvansEG . Long‐term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5‐year blinded prospective follow‐up study. Archives of Dermatology2002;138(3):353‐7. [PUBMED: 11902986] WarrickD , ChurchL . Continuous terbinafine versus intermittent itraconazole for toenail onychomycosis. Journal of Family Practice1999;48(7):492‐3. [PUBMED: 10428238] ">Sigurgeirsson 1999</a>), and removing them from the analyses reduced the statistical heterogeneity to 0%. This did not change the direction of the effect but did reduce its magnitude (RR 0.89, 95% CI 0.82 to 0.97). We could not explain the statistical heterogeneity based on clinical differences between these studies and the rest of the studies. We suspect the outlier effect is due to the size of <a href="./references#CD010031-bbs2-0041" title="EvansEG , SigurgeirssonB . Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. The LION Study Group. BMJ1999;318(7190):1031‐5. [PUBMED: 10205099] HeikkilaH , StubbS . Long‐term results in patients with onychomycosis treated with terbinafine or itraconazole. British Journal of Dermatology2002;146(2):250‐3. [PUBMED: 11903235] SigurgeirssonB , BillsteinS , RantanenT , RuzickaT , diFonzoE , VermeerBJ , et al. L.I.O.N. Study: efficacy and tolerability of continuous terbinafine (Lamisil) compared to intermittent itraconazole in the treatment of toenail onychomycosis. Lamisil vs. Itraconazole in Onychomycosis. British Journal of Dermatology1999;141(Suppl 56):5‐14. [PUBMED: 10730908] SigurgeirssonB , OlafssonJH , SteinssonJB , PaulC , BillsteinS , EvansEG . Long‐term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5‐year blinded prospective follow‐up study. Archives of Dermatology2002;138(3):353‐7. [PUBMED: 11902986] WarrickD , ChurchL . Continuous terbinafine versus intermittent itraconazole for toenail onychomycosis. Journal of Family Practice1999;48(7):492‐3. [PUBMED: 10428238] ">Sigurgeirsson 1999</a> and the size of the effect estimate in <a href="./references#CD010031-bbs2-0024" title="HavuV , HeikkilaH , KuokkanenK , NuutinenM , RantanenT , SaariS , et al. A double‐blind, randomized study to compare the efficacy and safety of terbinafine (Lamisil) with fluconazole (Diflucan) in the treatment of onychomycosis. British Journal of Dermatology2000;142(1):97‐102. [PUBMED: 10651701] SaloH , PekurinenM . Cost effectiveness of oral terbinafine (Lamisil) compared with oral fluconazole (Diflucan) in the treatment of patients with toenail onychomycosis. PharmacoEconomics2002;20(5):319‐24. [PUBMED: 11994041] ">Havu 2000</a>. </p> <p>Because there were more than 10 RCTs in this comparison, we drew funnel plots (<a href="#CD010031-fig-0003">Figure 3</a>) to test for reporting bias as discussed in Chapter 10.4 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010031-bbs2-0103" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> <div class="figure" id="CD010031-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 3 Azole versus terbinafine, outcome: 3.1 Clinical cure." data-id="CD010031-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_n/nCD010031-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 3 Azole versus terbinafine, outcome: 3.1 Clinical cure.</p> </div> </div> </div> <p>When only including studies using itraconazole (<a href="./references#CD010031-bbs2-0004" title="ArenasR , Dominguez‐CheritJ , FernandezLM . Open randomized comparison of itraconazole versus terbinafine in onychomycosis. International Journal of Dermatology1995;34(2):138‐43. [PUBMED: 7737776] ">Arenas 1995</a>; <a href="./references#CD010031-bbs2-0009" title="DeBackerM , DeVroeyC , LesaffreE , ScheysI , DeKeyserP . Twelve weeks of continuous oral therapy for toenail onychomycosis caused by dermatophytes: a double‐blind comparative trial of terbinafine 250 mg/day versus itraconazole 200 mg/day. Journal of the American Academy of Dermatology1998;38(5 Pt 3):S57‐63. [PUBMED: 9594939] DeCuyperC , HindryckxPH . Long‐term outcomes in the treatment of toenail onychomycosis. British Journal of Dermatology1999;141(Suppl 56):15‐20. [PUBMED: 10730909] ">De Backer 1998</a>; <a href="./references#CD010031-bbs2-0010" title="DegreefH , delPalacioA , MygindS , GinterG , Pinto SoaresA , Zuluaga de CadenaA . Randomized double‐blind comparison of short‐term itraconazole and terbinafine therapy for toenail onychomycosis. Acta Dermato‐Venereologica1999;79(3):221‐3. [PUBMED: 10384922] ">Degreef 1999</a>; <a href="./references#CD010031-bbs2-0018" title="GuptaAK , KonnikovN , LyndeCW . Single‐blind, randomized, prospective study on terbinafine and itraconazole for treatment of dermatophyte toenail onychomycosis in the elderly. Journal of the American Academy of Dermatology2001;44(3):479‐84. [PUBMED: 11209118] ">Gupta 2001a</a>; <a href="./references#CD010031-bbs2-0022" title="GuptaA , GoverM . Pulse itraconazole versus continuous terbinafine for the treatment of dermatophyte toenail onychomycosis in patients with diabetes mellitus. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB151. [CENTRAL: CN‐00602562] GuptaAK , GoverMD , LyndeCW . Pulse itraconazole vs. continuous terbinafine for the treatment of dermatophyte toenail onychomycosis in patients with diabetes mellitus. Journal of the European Academy of Dermatology and Venereology : JEADV2006;20(10):1188‐93. [PUBMED: 17062029] ">Gupta 2006</a>; <a href="./references#CD010031-bbs2-0023" title="GuptaAK , CooperEA , PaquetM . Recurrences of dermatophyte toenail onychomycosis during long‐term follow‐up after successful treatments with mono‐ and combined therapy of terbinafine and itraconazole. Journal of Cutaneous Medicine and Surgery2013;17(3):201‐6. [PUBMED: 23673304] GuptaAK , LynchLE , KoganN , CooperEA . The use of an intermittent terbinafine regimen for the treatment of dermatophyte toenail onychomycosis. Journal of the European Academy of Dermatology and Venereology2009;23(3):256‐62. [PUBMED: 19438818] ">Gupta 2009</a>; <a href="./references#CD010031-bbs2-0027" title="HoneymanJF , Talarico FilhoS , ArrudaLHF , Pereira JrAC , SantamariaJR , SouzaEM , et al. Itraconazole versus terbinafine (Lamisil): which is better for the treatment of onychomycosis?. Journal of the European Academy of Dermatology and Venereology1997;9(3):215‐21. [EMBASE: 1998017627] ">Honeyman 1997</a><a href="./references#CD010031-bbs2-0029" title="KejdaJ . Itraconazole pulse therapy vs continuous terbinafine dosing for toenail onychomycosis. Postgraduate Medicine1999;Spec No:12‐5. [PUBMED: 10492661] ">Kejda 1999</a>; <a href="./references#CD010031-bbs2-0041" title="EvansEG , SigurgeirssonB . Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. The LION Study Group. BMJ1999;318(7190):1031‐5. [PUBMED: 10205099] HeikkilaH , StubbS . Long‐term results in patients with onychomycosis treated with terbinafine or itraconazole. British Journal of Dermatology2002;146(2):250‐3. [PUBMED: 11903235] SigurgeirssonB , BillsteinS , RantanenT , RuzickaT , diFonzoE , VermeerBJ , et al. L.I.O.N. Study: efficacy and tolerability of continuous terbinafine (Lamisil) compared to intermittent itraconazole in the treatment of toenail onychomycosis. Lamisil vs. Itraconazole in Onychomycosis. British Journal of Dermatology1999;141(Suppl 56):5‐14. [PUBMED: 10730908] SigurgeirssonB , OlafssonJH , SteinssonJB , PaulC , BillsteinS , EvansEG . Long‐term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5‐year blinded prospective follow‐up study. Archives of Dermatology2002;138(3):353‐7. [PUBMED: 11902986] WarrickD , ChurchL . Continuous terbinafine versus intermittent itraconazole for toenail onychomycosis. Journal of Family Practice1999;48(7):492‐3. [PUBMED: 10428238] ">Sigurgeirsson 1999</a>; <a href="./references#CD010031-bbs2-0048" title="WonCH , LeeJ , LiK , MiRC , KimBJ , AnJS , et al. The long term efficacy and relapse rate of itraconazole pulse therapy versus terbinafine continuous therapy for toenail onychomycosis ‐ a 96‐week follow‐up study. Korean Journal of Medical Mycology2007;12(3):139‐47. [CENTRAL: CN‐00708731; EMBASE: 2008006956] ">Won 2007</a>), the effect estimate remained similar (RR 0.85, 95% CI 0.74 to 0.96). </p> <p><a href="./references#CD010031-bbs2-0039" title="RanawakaRR , NagahawatteA , GunasekaraTA , WeerakoonHS , deSilvaSH . Randomized, double‐blind, comparative study on efficacy and safety of itraconazole pulse therapy and terbinafine pulse therapy on nondermatophyte mold onychomycosis: A study with 90 patients. The Journal of dermatological treatment2016;27(4):364‐72. [PUBMED: 26651495] ">Ranawaka 2016</a> looked at onychomycosis caused by non‐dermatophyte moulds only and found no difference when comparing azole to terbinafine (RR 1.41, 95% CI 0.82 to 2.42). When removing this study from the meta‐analysis, the overall results did not change (RR 0.81, 95% CI 0.70 to 0.92). </p> <p>When comparing subgroups based on short‐ or long‐term follow‐up, we observed low statistical heterogeneity (I² = 3.3%, P value for subgroup differences = 0.55). In studies with short‐term follow‐up, the azole group was 14% less likely to achieve clinical cure (RR 0.86, 95% CI 0.77 to 0.96), and with long‐term follow‐up the azole group was 20% less likely to achieve clinical cure (RR 0.80, 95% CI 0.63 to 1.00) compared to the terbinafine group. However, this difference was not statistically significant. </p> </section> <section id="CD010031-sec-0106"> <h6 class="title">Mycological cure</h6> <p>See <a href="./references#CD010031-fig-0006" title="">Analysis 1.2</a>. </p> <p>Seventeen studies reported mycological cure as an outcome (<a href="./references#CD010031-bbs2-0002" title="ArcaE , TastanHB , AkarA , KurumluZ , GurAR . An open, randomized, comparative study of oral fluconazole, itraconazole and terbinafine therapy in onychomycosis. Journal of Dermatological Treatment2002;13(1):3‐9. [PUBMED: 12006131] ">Arca 2002</a>; <a href="./references#CD010031-bbs2-0007" title="BrautigamM . Terbinafine versus itraconazole: a controlled clinical comparison in onychomycosis of the toenails. Journal of the American Academy of Dermatology1998;38(5 Pt 3):S53‐6. [PUBMED: 9594938] BrautigamM , NoltingS , SchopfRE , WeidingerG . German randomized double‐blind multicentre comparison of terbinafine and itraconazole for the treatment of toenail tinea infection. British Journal of Dermatology1996;134(Suppl 46):18‐21. [PUBMED: 8763463] BrautigamM , NoltingS , SchopfRE , WeidingerG . Randomised double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection. Seventh Lamisil German Onychomycosis Study Group. BMJ1995;311(7010):919‐22. [PUBMED: 7580551] BrautigamM , WeidingerG , NoltingS . Successful treatment of toenail mycosis with terbinafine and itraconazole gives long term benefits. BMJ1998;317(7165):1084. [PUBMED: 9774312] ">Brautigam 1995</a>; <a href="./references#CD010031-bbs2-0009" title="DeBackerM , DeVroeyC , LesaffreE , ScheysI , DeKeyserP . Twelve weeks of continuous oral therapy for toenail onychomycosis caused by dermatophytes: a double‐blind comparative trial of terbinafine 250 mg/day versus itraconazole 200 mg/day. Journal of the American Academy of Dermatology1998;38(5 Pt 3):S57‐63. [PUBMED: 9594939] DeCuyperC , HindryckxPH . Long‐term outcomes in the treatment of toenail onychomycosis. British Journal of Dermatology1999;141(Suppl 56):15‐20. [PUBMED: 10730909] ">De Backer 1998</a>; <a href="./references#CD010031-bbs2-0010" title="DegreefH , delPalacioA , MygindS , GinterG , Pinto SoaresA , Zuluaga de CadenaA . Randomized double‐blind comparison of short‐term itraconazole and terbinafine therapy for toenail onychomycosis. Acta Dermato‐Venereologica1999;79(3):221‐3. [PUBMED: 10384922] ">Degreef 1999</a>; <a href="./references#CD010031-bbs2-0014" title="ElewskiB , PollakR , AshtonS , RichP , SchlessingerJ , TavakkolA . A randomized, placebo‐ and active‐controlled, parallel‐group, multicentre, investigator‐blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis. British Journal of Dermatology2012;166(2):389‐98. [PUBMED: 21967490] ElewskiB , TavakkolA , PollakR , AshtonS . A randomized, placebo‐ and active‐controlled, parallel‐group, multicenter,investigator‐blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis. Journal of American Academy of Dermatology2010;62(3 Suppl 1):AB76. [EMBASE: 70142781] ">Elewski 2012</a>; <a href="./references#CD010031-bbs2-0018" title="GuptaAK , KonnikovN , LyndeCW . Single‐blind, randomized, prospective study on terbinafine and itraconazole for treatment of dermatophyte toenail onychomycosis in the elderly. Journal of the American Academy of Dermatology2001;44(3):479‐84. [PUBMED: 11209118] ">Gupta 2001a</a>; <a href="./references#CD010031-bbs2-0019" title="GuptaAK , Gregurek‐NovakT . Efficacy of itraconazole, terbinafine, fluconazole, griseofulvin and ketoconazole in the treatment of Scopulariopsis brevicaulis causing onychomycosis of the toes. Dermatology2001;202(3):235‐8. [PUBMED: 11385230] ">Gupta 2001b</a>; <a href="./references#CD010031-bbs2-0022" title="GuptaA , GoverM . Pulse itraconazole versus continuous terbinafine for the treatment of dermatophyte toenail onychomycosis in patients with diabetes mellitus. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB151. [CENTRAL: CN‐00602562] GuptaAK , GoverMD , LyndeCW . Pulse itraconazole vs. continuous terbinafine for the treatment of dermatophyte toenail onychomycosis in patients with diabetes mellitus. Journal of the European Academy of Dermatology and Venereology : JEADV2006;20(10):1188‐93. [PUBMED: 17062029] ">Gupta 2006</a>; <a href="./references#CD010031-bbs2-0023" title="GuptaAK , CooperEA , PaquetM . Recurrences of dermatophyte toenail onychomycosis during long‐term follow‐up after successful treatments with mono‐ and combined therapy of terbinafine and itraconazole. Journal of Cutaneous Medicine and Surgery2013;17(3):201‐6. [PUBMED: 23673304] GuptaAK , LynchLE , KoganN , CooperEA . The use of an intermittent terbinafine regimen for the treatment of dermatophyte toenail onychomycosis. Journal of the European Academy of Dermatology and Venereology2009;23(3):256‐62. [PUBMED: 19438818] ">Gupta 2009</a>; <a href="./references#CD010031-bbs2-0024" title="HavuV , HeikkilaH , KuokkanenK , NuutinenM , RantanenT , SaariS , et al. A double‐blind, randomized study to compare the efficacy and safety of terbinafine (Lamisil) with fluconazole (Diflucan) in the treatment of onychomycosis. British Journal of Dermatology2000;142(1):97‐102. [PUBMED: 10651701] SaloH , PekurinenM . Cost effectiveness of oral terbinafine (Lamisil) compared with oral fluconazole (Diflucan) in the treatment of patients with toenail onychomycosis. PharmacoEconomics2002;20(5):319‐24. [PUBMED: 11994041] ">Havu 2000</a>; <a href="./references#CD010031-bbs2-0027" title="HoneymanJF , Talarico FilhoS , ArrudaLHF , Pereira JrAC , SantamariaJR , SouzaEM , et al. Itraconazole versus terbinafine (Lamisil): which is better for the treatment of onychomycosis?. Journal of the European Academy of Dermatology and Venereology1997;9(3):215‐21. [EMBASE: 1998017627] ">Honeyman 1997</a>; <a href="./references#CD010031-bbs2-0029" title="KejdaJ . Itraconazole pulse therapy vs continuous terbinafine dosing for toenail onychomycosis. Postgraduate Medicine1999;Spec No:12‐5. [PUBMED: 10492661] ">Kejda 1999</a>; <a href="./references#CD010031-bbs2-0032" title="KouznetsovAV , PotekaevNN , BelenkoOV . Terbinafine and itraconazol in the treatment of onychomycosis: results of 3 years observation. Journal of the European Academy of Dermatology and Venereology2002;16(S1):242. [CENTRAL: CN‐00478618; DOI: 10.1046/j.1468‐3083.16.s1.1.x] ">Kouznetsov 2002</a>; <a href="./references#CD010031-bbs2-0039" title="RanawakaRR , NagahawatteA , GunasekaraTA , WeerakoonHS , deSilvaSH . Randomized, double‐blind, comparative study on efficacy and safety of itraconazole pulse therapy and terbinafine pulse therapy on nondermatophyte mold onychomycosis: A study with 90 patients. The Journal of dermatological treatment2016;27(4):364‐72. [PUBMED: 26651495] ">Ranawaka 2016</a>; <a href="./references#CD010031-bbs2-0041" title="EvansEG , SigurgeirssonB . Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. The LION Study Group. BMJ1999;318(7190):1031‐5. [PUBMED: 10205099] HeikkilaH , StubbS . Long‐term results in patients with onychomycosis treated with terbinafine or itraconazole. British Journal of Dermatology2002;146(2):250‐3. [PUBMED: 11903235] SigurgeirssonB , BillsteinS , RantanenT , RuzickaT , diFonzoE , VermeerBJ , et al. L.I.O.N. Study: efficacy and tolerability of continuous terbinafine (Lamisil) compared to intermittent itraconazole in the treatment of toenail onychomycosis. Lamisil vs. Itraconazole in Onychomycosis. British Journal of Dermatology1999;141(Suppl 56):5‐14. [PUBMED: 10730908] SigurgeirssonB , OlafssonJH , SteinssonJB , PaulC , BillsteinS , EvansEG . Long‐term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5‐year blinded prospective follow‐up study. Archives of Dermatology2002;138(3):353‐7. [PUBMED: 11902986] WarrickD , ChurchL . Continuous terbinafine versus intermittent itraconazole for toenail onychomycosis. Journal of Family Practice1999;48(7):492‐3. [PUBMED: 10428238] ">Sigurgeirsson 1999</a>; <a href="./references#CD010031-bbs2-0045" title="TostiA , PiracciniBM , StinchiC , ColomboMD . Relapses of onychomycosis after successful treatment with systemic antifungals: a three‐year follow‐up. Dermatology (Basel, Switzerland)1998;197(2):162‐6. [PUBMED: 9732167] TostiA , PiracciniBM , StinchiC , VenturoN , BardazziF , ColomboMD . Treatment of dermatophyte nail infections: an open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy. Journal of the American Academy of Dermatology1996;34(4):595‐600. [PUBMED: 8601647] ">Tosti 1996</a>; <a href="./references#CD010031-bbs2-0048" title="WonCH , LeeJ , LiK , MiRC , KimBJ , AnJS , et al. The long term efficacy and relapse rate of itraconazole pulse therapy versus terbinafine continuous therapy for toenail onychomycosis ‐ a 96‐week follow‐up study. Korean Journal of Medical Mycology2007;12(3):139‐47. [CENTRAL: CN‐00708731; EMBASE: 2008006956] ">Won 2007</a>). </p> <p>In the pooled azole group, 685 (52%) participants achieved mycological cure, compared to 831 (68%) participants in the pooled terbinafine group. There was moderate‐quality evidence that participants in the azole group were 23% less likely to achieve mycological cure compared to participants receiving terbinafine (RR 0.77, 95% CI 0.68 to 0.88, 17 studies, 2544 participants) (I² = 73%). </p> <p>We could not attribute statistical heterogeneity to specific studies.</p> <p>Because there were more than 10 RCTs, we drew funnel plots (<a href="#CD010031-fig-0004">Figure 4</a>) to test for reporting bias as discussed in chapter 10.4 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010031-bbs2-0103" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> <div class="figure" id="CD010031-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 3 Azole versus terbinafine, outcome: 3.2 Mycological cure." data-id="CD010031-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_n/nCD010031-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 3 Azole versus terbinafine, outcome: 3.2 Mycological cure.</p> </div> </div> </div> <p>When only including studies using the azole itraconazole (<a href="./references#CD010031-bbs2-0009" title="DeBackerM , DeVroeyC , LesaffreE , ScheysI , DeKeyserP . Twelve weeks of continuous oral therapy for toenail onychomycosis caused by dermatophytes: a double‐blind comparative trial of terbinafine 250 mg/day versus itraconazole 200 mg/day. Journal of the American Academy of Dermatology1998;38(5 Pt 3):S57‐63. [PUBMED: 9594939] DeCuyperC , HindryckxPH . Long‐term outcomes in the treatment of toenail onychomycosis. British Journal of Dermatology1999;141(Suppl 56):15‐20. [PUBMED: 10730909] ">De Backer 1998</a>; <a href="./references#CD010031-bbs2-0010" title="DegreefH , delPalacioA , MygindS , GinterG , Pinto SoaresA , Zuluaga de CadenaA . Randomized double‐blind comparison of short‐term itraconazole and terbinafine therapy for toenail onychomycosis. Acta Dermato‐Venereologica1999;79(3):221‐3. [PUBMED: 10384922] ">Degreef 1999</a>; <a href="./references#CD010031-bbs2-0018" title="GuptaAK , KonnikovN , LyndeCW . Single‐blind, randomized, prospective study on terbinafine and itraconazole for treatment of dermatophyte toenail onychomycosis in the elderly. Journal of the American Academy of Dermatology2001;44(3):479‐84. [PUBMED: 11209118] ">Gupta 2001a</a>; <a href="./references#CD010031-bbs2-0022" title="GuptaA , GoverM . Pulse itraconazole versus continuous terbinafine for the treatment of dermatophyte toenail onychomycosis in patients with diabetes mellitus. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB151. [CENTRAL: CN‐00602562] GuptaAK , GoverMD , LyndeCW . Pulse itraconazole vs. continuous terbinafine for the treatment of dermatophyte toenail onychomycosis in patients with diabetes mellitus. Journal of the European Academy of Dermatology and Venereology : JEADV2006;20(10):1188‐93. [PUBMED: 17062029] ">Gupta 2006</a>; <a href="./references#CD010031-bbs2-0023" title="GuptaAK , CooperEA , PaquetM . Recurrences of dermatophyte toenail onychomycosis during long‐term follow‐up after successful treatments with mono‐ and combined therapy of terbinafine and itraconazole. Journal of Cutaneous Medicine and Surgery2013;17(3):201‐6. [PUBMED: 23673304] GuptaAK , LynchLE , KoganN , CooperEA . The use of an intermittent terbinafine regimen for the treatment of dermatophyte toenail onychomycosis. Journal of the European Academy of Dermatology and Venereology2009;23(3):256‐62. [PUBMED: 19438818] ">Gupta 2009</a>; <a href="./references#CD010031-bbs2-0027" title="HoneymanJF , Talarico FilhoS , ArrudaLHF , Pereira JrAC , SantamariaJR , SouzaEM , et al. Itraconazole versus terbinafine (Lamisil): which is better for the treatment of onychomycosis?. Journal of the European Academy of Dermatology and Venereology1997;9(3):215‐21. [EMBASE: 1998017627] ">Honeyman 1997</a><a href="./references#CD010031-bbs2-0029" title="KejdaJ . Itraconazole pulse therapy vs continuous terbinafine dosing for toenail onychomycosis. Postgraduate Medicine1999;Spec No:12‐5. [PUBMED: 10492661] ">Kejda 1999</a>; <a href="./references#CD010031-bbs2-0041" title="EvansEG , SigurgeirssonB . Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. The LION Study Group. BMJ1999;318(7190):1031‐5. [PUBMED: 10205099] HeikkilaH , StubbS . Long‐term results in patients with onychomycosis treated with terbinafine or itraconazole. British Journal of Dermatology2002;146(2):250‐3. [PUBMED: 11903235] SigurgeirssonB , BillsteinS , RantanenT , RuzickaT , diFonzoE , VermeerBJ , et al. L.I.O.N. Study: efficacy and tolerability of continuous terbinafine (Lamisil) compared to intermittent itraconazole in the treatment of toenail onychomycosis. Lamisil vs. Itraconazole in Onychomycosis. British Journal of Dermatology1999;141(Suppl 56):5‐14. [PUBMED: 10730908] SigurgeirssonB , OlafssonJH , SteinssonJB , PaulC , BillsteinS , EvansEG . Long‐term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5‐year blinded prospective follow‐up study. Archives of Dermatology2002;138(3):353‐7. [PUBMED: 11902986] WarrickD , ChurchL . Continuous terbinafine versus intermittent itraconazole for toenail onychomycosis. Journal of Family Practice1999;48(7):492‐3. [PUBMED: 10428238] ">Sigurgeirsson 1999</a>; <a href="./references#CD010031-bbs2-0048" title="WonCH , LeeJ , LiK , MiRC , KimBJ , AnJS , et al. The long term efficacy and relapse rate of itraconazole pulse therapy versus terbinafine continuous therapy for toenail onychomycosis ‐ a 96‐week follow‐up study. Korean Journal of Medical Mycology2007;12(3):139‐47. [CENTRAL: CN‐00708731; EMBASE: 2008006956] ">Won 2007</a>), the effect estimate remained similar (RR 0.78, 95% CI 0.67 to 0.90). </p> <p>One study looked at onychomycosis caused by non‐dermatophyte moulds only and found no difference when comparing azole to terbinafine (RR 1.17, 95% CI 0.75 to 1.82; <a href="./references#CD010031-bbs2-0039" title="RanawakaRR , NagahawatteA , GunasekaraTA , WeerakoonHS , deSilvaSH . Randomized, double‐blind, comparative study on efficacy and safety of itraconazole pulse therapy and terbinafine pulse therapy on nondermatophyte mold onychomycosis: A study with 90 patients. The Journal of dermatological treatment2016;27(4):364‐72. [PUBMED: 26651495] ">Ranawaka 2016</a>). When removing this study from the meta‐analysis the overall results did not change (RR 0.76, 95% CI 0.67 to 0.86). </p> <p>When comparing subgroups based on short‐ or long‐term follow‐up, we saw no statistical heterogeneity (I² = 0%; P value for subgroup differences = 0.90). In studies with short‐term follow‐up, the azole group was 23% less likely to achieve clinical cure (RR 0.77, 95% CI 0.64 to 0.93), and with long‐term follow‐up the azole group was 23% less likely to achieve clinical cure (RR 0.78, 95% CI 0.64 to 0.95) compared to the terbinafine group. </p> </section> </section> <section id="CD010031-sec-0107"> <h5 class="title">Secondary outcomes</h5> <section id="CD010031-sec-0108"> <h6 class="title">Adverse events</h6> <p>See <a href="./references#CD010031-fig-0007" title="">Analysis 1.3</a>. </p> <p>Nine studies compared terbinafine therapy with azole therapy for adverse events (<a href="./references#CD010031-bbs2-0007" title="BrautigamM . Terbinafine versus itraconazole: a controlled clinical comparison in onychomycosis of the toenails. Journal of the American Academy of Dermatology1998;38(5 Pt 3):S53‐6. [PUBMED: 9594938] BrautigamM , NoltingS , SchopfRE , WeidingerG . German randomized double‐blind multicentre comparison of terbinafine and itraconazole for the treatment of toenail tinea infection. British Journal of Dermatology1996;134(Suppl 46):18‐21. [PUBMED: 8763463] BrautigamM , NoltingS , SchopfRE , WeidingerG . Randomised double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection. Seventh Lamisil German Onychomycosis Study Group. BMJ1995;311(7010):919‐22. [PUBMED: 7580551] BrautigamM , WeidingerG , NoltingS . Successful treatment of toenail mycosis with terbinafine and itraconazole gives long term benefits. BMJ1998;317(7165):1084. [PUBMED: 9774312] ">Brautigam 1995</a>; <a href="./references#CD010031-bbs2-0009" title="DeBackerM , DeVroeyC , LesaffreE , ScheysI , DeKeyserP . Twelve weeks of continuous oral therapy for toenail onychomycosis caused by dermatophytes: a double‐blind comparative trial of terbinafine 250 mg/day versus itraconazole 200 mg/day. Journal of the American Academy of Dermatology1998;38(5 Pt 3):S57‐63. [PUBMED: 9594939] DeCuyperC , HindryckxPH . Long‐term outcomes in the treatment of toenail onychomycosis. British Journal of Dermatology1999;141(Suppl 56):15‐20. [PUBMED: 10730909] ">De Backer 1998</a>; <a href="./references#CD010031-bbs2-0010" title="DegreefH , delPalacioA , MygindS , GinterG , Pinto SoaresA , Zuluaga de CadenaA . Randomized double‐blind comparison of short‐term itraconazole and terbinafine therapy for toenail onychomycosis. Acta Dermato‐Venereologica1999;79(3):221‐3. [PUBMED: 10384922] ">Degreef 1999</a>; <a href="./references#CD010031-bbs2-0014" title="ElewskiB , PollakR , AshtonS , RichP , SchlessingerJ , TavakkolA . A randomized, placebo‐ and active‐controlled, parallel‐group, multicentre, investigator‐blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis. British Journal of Dermatology2012;166(2):389‐98. [PUBMED: 21967490] ElewskiB , TavakkolA , PollakR , AshtonS . A randomized, placebo‐ and active‐controlled, parallel‐group, multicenter,investigator‐blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis. Journal of American Academy of Dermatology2010;62(3 Suppl 1):AB76. [EMBASE: 70142781] ">Elewski 2012</a>; <a href="./references#CD010031-bbs2-0018" title="GuptaAK , KonnikovN , LyndeCW . Single‐blind, randomized, prospective study on terbinafine and itraconazole for treatment of dermatophyte toenail onychomycosis in the elderly. Journal of the American Academy of Dermatology2001;44(3):479‐84. [PUBMED: 11209118] ">Gupta 2001a</a>; <a href="./references#CD010031-bbs2-0019" title="GuptaAK , Gregurek‐NovakT . Efficacy of itraconazole, terbinafine, fluconazole, griseofulvin and ketoconazole in the treatment of Scopulariopsis brevicaulis causing onychomycosis of the toes. Dermatology2001;202(3):235‐8. [PUBMED: 11385230] ">Gupta 2001b</a>; <a href="./references#CD010031-bbs2-0023" title="GuptaAK , CooperEA , PaquetM . Recurrences of dermatophyte toenail onychomycosis during long‐term follow‐up after successful treatments with mono‐ and combined therapy of terbinafine and itraconazole. Journal of Cutaneous Medicine and Surgery2013;17(3):201‐6. [PUBMED: 23673304] GuptaAK , LynchLE , KoganN , CooperEA . The use of an intermittent terbinafine regimen for the treatment of dermatophyte toenail onychomycosis. Journal of the European Academy of Dermatology and Venereology2009;23(3):256‐62. [PUBMED: 19438818] ">Gupta 2009</a>; <a href="./references#CD010031-bbs2-0029" title="KejdaJ . Itraconazole pulse therapy vs continuous terbinafine dosing for toenail onychomycosis. Postgraduate Medicine1999;Spec No:12‐5. [PUBMED: 10492661] ">Kejda 1999</a>; <a href="./references#CD010031-bbs2-0041" title="EvansEG , SigurgeirssonB . Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. The LION Study Group. BMJ1999;318(7190):1031‐5. [PUBMED: 10205099] HeikkilaH , StubbS . Long‐term results in patients with onychomycosis treated with terbinafine or itraconazole. British Journal of Dermatology2002;146(2):250‐3. [PUBMED: 11903235] SigurgeirssonB , BillsteinS , RantanenT , RuzickaT , diFonzoE , VermeerBJ , et al. L.I.O.N. Study: efficacy and tolerability of continuous terbinafine (Lamisil) compared to intermittent itraconazole in the treatment of toenail onychomycosis. Lamisil vs. Itraconazole in Onychomycosis. British Journal of Dermatology1999;141(Suppl 56):5‐14. [PUBMED: 10730908] SigurgeirssonB , OlafssonJH , SteinssonJB , PaulC , BillsteinS , EvansEG . Long‐term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5‐year blinded prospective follow‐up study. Archives of Dermatology2002;138(3):353‐7. [PUBMED: 11902986] WarrickD , ChurchL . Continuous terbinafine versus intermittent itraconazole for toenail onychomycosis. Journal of Family Practice1999;48(7):492‐3. [PUBMED: 10428238] ">Sigurgeirsson 1999</a>). There were 881 participants in the combined terbinafine groups and 881 participants in the combined azole groups. </p> <p>In the combined terbinafine group, 305 (35%) participants experienced an adverse event compared to 336 (38%) in the terbinafine group. This difference was not statistically significant (RR 1.00, 95% CI 0.86 to 1.17, 9 studies, 1762 participants; I² = 19%; moderate‐quality evidence). </p> <p>The most common adverse events amongst terbinafine‐treated participants included headache, viral infection, dyspepsia, taste disorders, flu‐like symptoms, nausea, fatigue, and rash/urticaria. The most common adverse events amongst azole‐treated participants included headache, viral infection, diarrhoea, constipation, nausea, abdominal pain, abnormal liver function tests, dizziness, and rash. </p> <p>Two studies reported only adverse event data for events serious enough to cause discontinuation (<a href="./references#CD010031-bbs2-0024" title="HavuV , HeikkilaH , KuokkanenK , NuutinenM , RantanenT , SaariS , et al. A double‐blind, randomized study to compare the efficacy and safety of terbinafine (Lamisil) with fluconazole (Diflucan) in the treatment of onychomycosis. British Journal of Dermatology2000;142(1):97‐102. [PUBMED: 10651701] SaloH , PekurinenM . Cost effectiveness of oral terbinafine (Lamisil) compared with oral fluconazole (Diflucan) in the treatment of patients with toenail onychomycosis. PharmacoEconomics2002;20(5):319‐24. [PUBMED: 11994041] ">Havu 2000</a>; <a href="./references#CD010031-bbs2-0027" title="HoneymanJF , Talarico FilhoS , ArrudaLHF , Pereira JrAC , SantamariaJR , SouzaEM , et al. Itraconazole versus terbinafine (Lamisil): which is better for the treatment of onychomycosis?. Journal of the European Academy of Dermatology and Venereology1997;9(3):215‐21. [EMBASE: 1998017627] ">Honeyman 1997</a>), so we excluded them from the above analysis. In <a href="./references#CD010031-bbs2-0027" title="HoneymanJF , Talarico FilhoS , ArrudaLHF , Pereira JrAC , SantamariaJR , SouzaEM , et al. Itraconazole versus terbinafine (Lamisil): which is better for the treatment of onychomycosis?. Journal of the European Academy of Dermatology and Venereology1997;9(3):215‐21. [EMBASE: 1998017627] ">Honeyman 1997</a>, none of the 84 terbinafine participants and 6 of 95 itraconazole participants (6%) dropped out due to adverse events. In <a href="./references#CD010031-bbs2-0024" title="HavuV , HeikkilaH , KuokkanenK , NuutinenM , RantanenT , SaariS , et al. A double‐blind, randomized study to compare the efficacy and safety of terbinafine (Lamisil) with fluconazole (Diflucan) in the treatment of onychomycosis. British Journal of Dermatology2000;142(1):97‐102. [PUBMED: 10651701] SaloH , PekurinenM . Cost effectiveness of oral terbinafine (Lamisil) compared with oral fluconazole (Diflucan) in the treatment of patients with toenail onychomycosis. PharmacoEconomics2002;20(5):319‐24. [PUBMED: 11994041] ">Havu 2000</a>, 1 of 48 terbinafine participants (2%) and 3 of 89 azole participants (3%) dropped out due to adverse events. </p> </section> <section id="CD010031-sec-0109"> <h6 class="title">Recurrence rate</h6> <p>See <a href="./references#CD010031-fig-0008" title="">Analysis 1.4</a>. </p> <p>Five studies comparing terbinafine and azole therapies assessed the recurrence rate (<a href="./references#CD010031-bbs2-0007" title="BrautigamM . Terbinafine versus itraconazole: a controlled clinical comparison in onychomycosis of the toenails. Journal of the American Academy of Dermatology1998;38(5 Pt 3):S53‐6. [PUBMED: 9594938] BrautigamM , NoltingS , SchopfRE , WeidingerG . German randomized double‐blind multicentre comparison of terbinafine and itraconazole for the treatment of toenail tinea infection. British Journal of Dermatology1996;134(Suppl 46):18‐21. [PUBMED: 8763463] BrautigamM , NoltingS , SchopfRE , WeidingerG . Randomised double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection. Seventh Lamisil German Onychomycosis Study Group. BMJ1995;311(7010):919‐22. [PUBMED: 7580551] BrautigamM , WeidingerG , NoltingS . Successful treatment of toenail mycosis with terbinafine and itraconazole gives long term benefits. BMJ1998;317(7165):1084. [PUBMED: 9774312] ">Brautigam 1995;</a><a href="./references#CD010031-bbs2-0023" title="GuptaAK , CooperEA , PaquetM . Recurrences of dermatophyte toenail onychomycosis during long‐term follow‐up after successful treatments with mono‐ and combined therapy of terbinafine and itraconazole. Journal of Cutaneous Medicine and Surgery2013;17(3):201‐6. [PUBMED: 23673304] GuptaAK , LynchLE , KoganN , CooperEA . The use of an intermittent terbinafine regimen for the treatment of dermatophyte toenail onychomycosis. Journal of the European Academy of Dermatology and Venereology2009;23(3):256‐62. [PUBMED: 19438818] ">Gupta 2009;</a><a href="./references#CD010031-bbs2-0039" title="RanawakaRR , NagahawatteA , GunasekaraTA , WeerakoonHS , deSilvaSH . Randomized, double‐blind, comparative study on efficacy and safety of itraconazole pulse therapy and terbinafine pulse therapy on nondermatophyte mold onychomycosis: A study with 90 patients. The Journal of dermatological treatment2016;27(4):364‐72. [PUBMED: 26651495] ">Ranawaka 2016</a>; <a href="./references#CD010031-bbs2-0041" title="EvansEG , SigurgeirssonB . Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. The LION Study Group. BMJ1999;318(7190):1031‐5. [PUBMED: 10205099] HeikkilaH , StubbS . Long‐term results in patients with onychomycosis treated with terbinafine or itraconazole. British Journal of Dermatology2002;146(2):250‐3. [PUBMED: 11903235] SigurgeirssonB , BillsteinS , RantanenT , RuzickaT , diFonzoE , VermeerBJ , et al. L.I.O.N. Study: efficacy and tolerability of continuous terbinafine (Lamisil) compared to intermittent itraconazole in the treatment of toenail onychomycosis. Lamisil vs. Itraconazole in Onychomycosis. British Journal of Dermatology1999;141(Suppl 56):5‐14. [PUBMED: 10730908] SigurgeirssonB , OlafssonJH , SteinssonJB , PaulC , BillsteinS , EvansEG . Long‐term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5‐year blinded prospective follow‐up study. Archives of Dermatology2002;138(3):353‐7. [PUBMED: 11902986] WarrickD , ChurchL . Continuous terbinafine versus intermittent itraconazole for toenail onychomycosis. Journal of Family Practice1999;48(7):492‐3. [PUBMED: 10428238] ">Sigurgeirsson 1999;</a><a href="./references#CD010031-bbs2-0045" title="TostiA , PiracciniBM , StinchiC , ColomboMD . Relapses of onychomycosis after successful treatment with systemic antifungals: a three‐year follow‐up. Dermatology (Basel, Switzerland)1998;197(2):162‐6. [PUBMED: 9732167] TostiA , PiracciniBM , StinchiC , VenturoN , BardazziF , ColomboMD . Treatment of dermatophyte nail infections: an open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy. Journal of the American Academy of Dermatology1996;34(4):595‐600. [PUBMED: 8601647] ">Tosti 1996</a>). In terms of clinical heterogeneity, the inclusion criteria for these studies are similar, and all studies compared terbinafine and itraconazole therapy, albeit in varying doses. </p> <p>There was no statistically significant difference in the recurrence rate between participants receiving terbinafine or azole (RR 1.11, 95% CI 0.68 to 1.79, 5 studies, 282 participants; I² = 39%; low‐quality evidence). </p> <p>One study looked at onychomycosis caused only by non‐dermatophyte moulds and found no difference in recurrence rate when comparing azole to terbinafine (RR 1.14, 95% CI 0.22 to 6.05; <a href="./references#CD010031-bbs2-0039" title="RanawakaRR , NagahawatteA , GunasekaraTA , WeerakoonHS , deSilvaSH . Randomized, double‐blind, comparative study on efficacy and safety of itraconazole pulse therapy and terbinafine pulse therapy on nondermatophyte mold onychomycosis: A study with 90 patients. The Journal of dermatological treatment2016;27(4):364‐72. [PUBMED: 26651495] ">Ranawaka 2016</a>). When removing this study from the meta‐analysis the overall results did not change (RR 1.11, 95% CI 0.64 to 1.92). </p> </section> </section> </section> <section id="CD010031-sec-0110"> <h4 class="title">Comparison 2: terbinafine versus placebo</h4> <p>See <a href="./full#CD010031-tbl-0002">summary of findings Table 2</a> for quality assessments for this comparison. </p> <p>Eight studies (N = 1006) comparing terbinafine (N = 682) with placebo (N = 324) provided data for this comparison (<a href="./references#CD010031-bbs2-0006" title="BillsteinS , KianifardF , JusticeA . Terbinafine vs. placebo for onychomycosis in black patients. International Journal of Dermatology1999;38(5):377‐379. [PUBMED: 10369551] ">Billstein 1999</a>; <a href="./references#CD010031-bbs2-0011" title="DrakeLA , ShearNH , ArletteJP , CloutierR , DanbyFW , ElewskiBE , et al. Oral terbinafine in the treatment of toenail onychomycosis: North American multicenter trial. Journal of the American Academy of Dermatology1997;37(5 Pt 1):740‐5. [PUBMED: 9366820] ">Drake 1997</a>; <a href="./references#CD010031-bbs2-0013" title="ElewskiBE , ElCharifM , CooperKD , GhannoumM , BirnbaumJE . Reactivity to trichophytin antigen in patients with onychomycosis: effect of terbinafine. Journal of the American Academy of Dermatology2002;46(3):371‐5. [PUBMED: 11862171] ">Elewski 2002</a>; <a href="./references#CD010031-bbs2-0014" title="ElewskiB , PollakR , AshtonS , RichP , SchlessingerJ , TavakkolA . A randomized, placebo‐ and active‐controlled, parallel‐group, multicentre, investigator‐blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis. British Journal of Dermatology2012;166(2):389‐98. [PUBMED: 21967490] ElewskiB , TavakkolA , PollakR , AshtonS . A randomized, placebo‐ and active‐controlled, parallel‐group, multicenter,investigator‐blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis. Journal of American Academy of Dermatology2010;62(3 Suppl 1):AB76. [EMBASE: 70142781] ">Elewski 2012</a>; <a href="./references#CD010031-bbs2-0016" title="GoodfieldMJ . Short‐duration therapy with terbinafine for dermatophyte onychomycosis: a multicentre trial. British Journal of Dermatology1992;126(Suppl 39):33‐5. [PUBMED: 1531926] GoodfieldMJ , AndrewL , EvansEG . Short term treatment of dermatophyte onychomycosis with terbinafine. BMJ1992;304(6835):1151‐4. [PUBMED: 1392793] ">Goodfield 1992</a>; <a href="./references#CD010031-bbs2-0034" title="LebwohlMG , DanielCR , LeydenJ , MormonM , ShavinJS , TschenE , et al. Efficacy and safety of terbinafine for nondermatophyte and mixed nondermatophyte and dermatophyte toenail onychomycosis. International Journal of Dermatology2001;40(5):358‐60. [PUBMED: 11555003] ">Lebwohl 2001</a>; <a href="./references#CD010031-bbs2-0044" title="BrandrupF , LarsenPO . Long‐term follow‐up of toe‐nail onychomycosis treated with terbinafine. Acta Dermato‐venereologica1997;77(3):238. [PUBMED: 9188883] SvejgaardEL , BrandrupF , KragballeK , LarsenPO , VeienNK , HolstM , et al. Oral terbinafine in toenail dermatophytosis. A double‐blind, placebo‐controlled multicenter study with 12 months' follow‐up. Acta Dermato‐venereologica1997;77(1):66‐9. [PUBMED: 9059684] ">Svejgaard 1997</a>; <a href="./references#CD010031-bbs2-0047" title="EllisDH , WatsonAB , MarleyJE , WilliamsTG . Non‐dermatophytes in onychomycosis of the toenails. British Journal of Dermatology1997;136(4):490‐3. [PUBMED: 9155945] WatsonA , MarleyJ , EllisD , WilliamsT . Terbinafine in onychomycosis of the toenail: a novel treatment protocol. Journal of the American Academy of Dermatology1995;33(5 Pt 1):775‐9. [PUBMED: 7593777] ">Watson 1995</a>). All studies used terbinafine 250 mg daily for 12 to 24 weeks. </p> <section id="CD010031-sec-0111"> <h5 class="title">Primary outcomes</h5> <section id="CD010031-sec-0112"> <h6 class="title">Clinical cure</h6> <p>See <a href="./references#CD010031-fig-0009" title="">Analysis 2.1</a>. </p> <p>All eight studies reported clinical cure as an outcome. Six studies assessed the nail for clinical cure at 52 weeks or less from start of treatment (<a href="./references#CD010031-bbs2-0011" title="DrakeLA , ShearNH , ArletteJP , CloutierR , DanbyFW , ElewskiBE , et al. Oral terbinafine in the treatment of toenail onychomycosis: North American multicenter trial. Journal of the American Academy of Dermatology1997;37(5 Pt 1):740‐5. [PUBMED: 9366820] ">Drake 1997</a>; <a href="./references#CD010031-bbs2-0013" title="ElewskiBE , ElCharifM , CooperKD , GhannoumM , BirnbaumJE . Reactivity to trichophytin antigen in patients with onychomycosis: effect of terbinafine. Journal of the American Academy of Dermatology2002;46(3):371‐5. [PUBMED: 11862171] ">Elewski 2002</a>; <a href="./references#CD010031-bbs2-0014" title="ElewskiB , PollakR , AshtonS , RichP , SchlessingerJ , TavakkolA . A randomized, placebo‐ and active‐controlled, parallel‐group, multicentre, investigator‐blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis. British Journal of Dermatology2012;166(2):389‐98. [PUBMED: 21967490] ElewskiB , TavakkolA , PollakR , AshtonS . A randomized, placebo‐ and active‐controlled, parallel‐group, multicenter,investigator‐blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis. Journal of American Academy of Dermatology2010;62(3 Suppl 1):AB76. [EMBASE: 70142781] ">Elewski 2012</a>; <a href="./references#CD010031-bbs2-0016" title="GoodfieldMJ . Short‐duration therapy with terbinafine for dermatophyte onychomycosis: a multicentre trial. British Journal of Dermatology1992;126(Suppl 39):33‐5. [PUBMED: 1531926] GoodfieldMJ , AndrewL , EvansEG . Short term treatment of dermatophyte onychomycosis with terbinafine. BMJ1992;304(6835):1151‐4. [PUBMED: 1392793] ">Goodfield 1992</a>; <a href="./references#CD010031-bbs2-0044" title="BrandrupF , LarsenPO . Long‐term follow‐up of toe‐nail onychomycosis treated with terbinafine. Acta Dermato‐venereologica1997;77(3):238. [PUBMED: 9188883] SvejgaardEL , BrandrupF , KragballeK , LarsenPO , VeienNK , HolstM , et al. Oral terbinafine in toenail dermatophytosis. A double‐blind, placebo‐controlled multicenter study with 12 months' follow‐up. Acta Dermato‐venereologica1997;77(1):66‐9. [PUBMED: 9059684] ">Svejgaard 1997</a>; <a href="./references#CD010031-bbs2-0047" title="EllisDH , WatsonAB , MarleyJE , WilliamsTG . Non‐dermatophytes in onychomycosis of the toenails. British Journal of Dermatology1997;136(4):490‐3. [PUBMED: 9155945] WatsonA , MarleyJ , EllisD , WilliamsT . Terbinafine in onychomycosis of the toenail: a novel treatment protocol. Journal of the American Academy of Dermatology1995;33(5 Pt 1):775‐9. [PUBMED: 7593777] ">Watson 1995</a>), and two studies assessed nails at 72 weeks and 78 weeks, respectively (<a href="./references#CD010031-bbs2-0006" title="BillsteinS , KianifardF , JusticeA . Terbinafine vs. placebo for onychomycosis in black patients. International Journal of Dermatology1999;38(5):377‐379. [PUBMED: 10369551] ">Billstein 1999</a>; <a href="./references#CD010031-bbs2-0034" title="LebwohlMG , DanielCR , LeydenJ , MormonM , ShavinJS , TschenE , et al. Efficacy and safety of terbinafine for nondermatophyte and mixed nondermatophyte and dermatophyte toenail onychomycosis. International Journal of Dermatology2001;40(5):358‐60. [PUBMED: 11555003] ">Lebwohl 2001</a>). </p> <p>In the pooled placebo group, 20 (6%) participants achieved clinical cure compared to 329 participants in the pooled terbinafine group (48%). People treated with terbinafine were six times more likely achieve clinical cure compared with people receiving placebo (RR 6.00, 95% CI 3.96 to 9.08, 8 studies, 1006 participants; I² = 0%; high‐quality evidence). </p> <p>When comparing subgroups based on short‐ or long‐term follow‐up, we identified some heterogeneity (I² = 56%, P value for subgroup differences = 0.13) due to the differences in placebo cure rate (8.5% in the short‐term follow‐up and 0% in the long‐term follow‐up). The estimated effect for short‐term follow‐up was RR 5.60 (95% CI 3.66 to 8.55) and for long‐term follow‐up, RR 26.01 (95% CI 3.69 to 183.44). </p> <p>We did not assess any studies as being at high risk of bias, so we did not perform sensitivity analysis based on that consideration. </p> </section> <section id="CD010031-sec-0113"> <h6 class="title">Mycological cure</h6> <p>See <a href="./references#CD010031-fig-0010" title="">Analysis 2.2</a>. </p> <p>All eight studies reported mycological cure.</p> <p>In the pooled placebo group, 54 (16.7%) participants achieved mycological cure compared to 401 participants in the intervention group (58.8%). There was moderate statistical heterogeneity as confirmed by an I² of 72%. There was no obvious clinical heterogeneity: the interventions were similar across studies, and no study examined a particular subset of the population. There was high‐quality evidence that participants in the terbinafine group were 4.5 times more likely to achieve mycological cure compared to participants receiving placebo (RR 4.53, 95% CI 2.47 to 8.33, 8 studies, 1006 participants; I² = 72%). </p> <p>When comparing subgroups based on short‐ or long‐term follow‐up, we did not identify any heterogeneity (I² = 0%, P value for subgroup differences = 0.73). In studies with short‐term follow‐up the intervention group was 4.6 times as likely to achieve mycological cure (RR 4.60, 95% CI 2.26 to 9.36), and with long‐term follow‐up the intervention group was 7.79 times as likely to achieve mycological cure (RR 7.79, 95% CI 0.42 to 144.44). </p> <p>We did not assess any studies as being at high risk of bias, so we did not perform sensitivity analysis based on that consideration. </p> </section> </section> <section id="CD010031-sec-0114"> <h5 class="title">Secondary outcomes</h5> <section id="CD010031-sec-0115"> <h6 class="title">Adverse events</h6> <p>See <a href="./references#CD010031-fig-0011" title="">Analysis 2.3</a>. </p> <p>Four studies compared terbinafine therapy with placebo for adverse events (<a href="./references#CD010031-bbs2-0014" title="ElewskiB , PollakR , AshtonS , RichP , SchlessingerJ , TavakkolA . A randomized, placebo‐ and active‐controlled, parallel‐group, multicentre, investigator‐blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis. British Journal of Dermatology2012;166(2):389‐98. [PUBMED: 21967490] ElewskiB , TavakkolA , PollakR , AshtonS . A randomized, placebo‐ and active‐controlled, parallel‐group, multicenter,investigator‐blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis. Journal of American Academy of Dermatology2010;62(3 Suppl 1):AB76. [EMBASE: 70142781] ">Elewski 2012</a>; <a href="./references#CD010031-bbs2-0034" title="LebwohlMG , DanielCR , LeydenJ , MormonM , ShavinJS , TschenE , et al. Efficacy and safety of terbinafine for nondermatophyte and mixed nondermatophyte and dermatophyte toenail onychomycosis. International Journal of Dermatology2001;40(5):358‐60. [PUBMED: 11555003] ">Lebwohl 2001</a>; <a href="./references#CD010031-bbs2-0044" title="BrandrupF , LarsenPO . Long‐term follow‐up of toe‐nail onychomycosis treated with terbinafine. Acta Dermato‐venereologica1997;77(3):238. [PUBMED: 9188883] SvejgaardEL , BrandrupF , KragballeK , LarsenPO , VeienNK , HolstM , et al. Oral terbinafine in toenail dermatophytosis. A double‐blind, placebo‐controlled multicenter study with 12 months' follow‐up. Acta Dermato‐venereologica1997;77(1):66‐9. [PUBMED: 9059684] ">Svejgaard 1997</a>; <a href="./references#CD010031-bbs2-0047" title="EllisDH , WatsonAB , MarleyJE , WilliamsTG . Non‐dermatophytes in onychomycosis of the toenails. British Journal of Dermatology1997;136(4):490‐3. [PUBMED: 9155945] WatsonA , MarleyJ , EllisD , WilliamsT . Terbinafine in onychomycosis of the toenail: a novel treatment protocol. Journal of the American Academy of Dermatology1995;33(5 Pt 1):775‐9. [PUBMED: 7593777] ">Watson 1995</a>). There were 217 participants in the pooled terbinafine groups and 182 participants in the pooled placebo groups. </p> <p>In the pooled terbinafine group 117 (54%) participants experienced an adverse event compared to 78 (43%) in the placebo group. This difference was not statistically significant (RR 1.13, 95% CI 0.87 to 1.47, 4 studies, 399 participants; I² = 48%; moderate‐quality evidence). </p> <p>The most common adverse events amongst terbinafine‐treated participants included gastrointestinal symptoms (diarrhoea, dyspepsia, abdominal pain, flatulence), infections (e.g. upper respiratory tract infection), headache, fatigue and disturbance of taste/smell. </p> <p>One other study reported adverse event data for events serious enough to cause discontinuation; however, authors provided no information for the placebo group, limiting the interpretation and precluding inclusion of the data in the analysis (<a href="./references#CD010031-bbs2-0011" title="DrakeLA , ShearNH , ArletteJP , CloutierR , DanbyFW , ElewskiBE , et al. Oral terbinafine in the treatment of toenail onychomycosis: North American multicenter trial. Journal of the American Academy of Dermatology1997;37(5 Pt 1):740‐5. [PUBMED: 9366820] ">Drake 1997</a>). Of 287 participants receiving terbinafine, nine experienced 'severe' adverse events (rash, diarrhoea, abdominal pain), with five withdrew from the study as a result. </p> <p>Although we found no evidence of increased adverse events when comparing terbinafine with placebo, readers should interpret this result with caution due to the low number of studies. </p> </section> <section id="CD010031-sec-0116"> <h6 class="title">Recurrence rate</h6> <p>See <a href="./references#CD010031-fig-0012" title="">Analysis 2.4</a>. </p> <p>Two studies compared the recurrence rate between those treated with terbinafine and placebo (<a href="./references#CD010031-bbs2-0011" title="DrakeLA , ShearNH , ArletteJP , CloutierR , DanbyFW , ElewskiBE , et al. Oral terbinafine in the treatment of toenail onychomycosis: North American multicenter trial. Journal of the American Academy of Dermatology1997;37(5 Pt 1):740‐5. [PUBMED: 9366820] ">Drake 1997</a>, <a href="./references#CD010031-bbs2-0047" title="EllisDH , WatsonAB , MarleyJE , WilliamsTG . Non‐dermatophytes in onychomycosis of the toenails. British Journal of Dermatology1997;136(4):490‐3. [PUBMED: 9155945] WatsonA , MarleyJ , EllisD , WilliamsT . Terbinafine in onychomycosis of the toenail: a novel treatment protocol. Journal of the American Academy of Dermatology1995;33(5 Pt 1):775‐9. [PUBMED: 7593777] ">Watson 1995</a>). <a href="./references#CD010031-bbs2-0011" title="DrakeLA , ShearNH , ArletteJP , CloutierR , DanbyFW , ElewskiBE , et al. Oral terbinafine in the treatment of toenail onychomycosis: North American multicenter trial. Journal of the American Academy of Dermatology1997;37(5 Pt 1):740‐5. [PUBMED: 9366820] ">Drake 1997</a> did not report the recurrence rate for the placebo group; therefore, we could not calculate relative risk for this study or pool the outcome data. Of the 157 participants who achieved cure and were followed up after the primary endpoint of the study, 11% had recurrence. In <a href="./references#CD010031-bbs2-0047" title="EllisDH , WatsonAB , MarleyJE , WilliamsTG . Non‐dermatophytes in onychomycosis of the toenails. British Journal of Dermatology1997;136(4):490‐3. [PUBMED: 9155945] WatsonA , MarleyJ , EllisD , WilliamsT . Terbinafine in onychomycosis of the toenail: a novel treatment protocol. Journal of the American Academy of Dermatology1995;33(5 Pt 1):775‐9. [PUBMED: 7593777] ">Watson 1995</a>, participants receiving terbinafine therapy had a recurrence rate of 3.1% (1 of 32 participants that achieved cure had a recurrence), compared to 67% (2 of 3 participants) recurrence in the placebo group (RR 0.05, 95% CI 0.01 to 0.38, 1 study, 35 participants, low‐quality evidence). </p> </section> </section> </section> <section id="CD010031-sec-0117"> <h4 class="title">Comparison 3: azole versus placebo</h4> <p>See <a href="./full#CD010031-tbl-0003">summary of findings Table 3</a> for quality assessments for this comparison. </p> <p>Nine studies (N = 3440) compared azole (N = 2651) with placebo (N = 789), including four studies with itraconazole, (<a href="./references#CD010031-bbs2-0012" title="ElewskiBE , ScherRK , AlyR , DanielR3rd , JonesHE , OdomRB , et al. Double‐blind, randomized comparison of itraconazole capsules vs. placebo in the treatment of toenail onychomycosis. Cutis1997;59(4):217‐20. [PUBMED: 9104548] OdomR , DanielCR , AlyR . A double‐blind, randomized comparison of itraconazole capsules and placebo in the treatment of onychomycosis of the toenail. Journal of the American Academy of Dermatology1996;35(1):110‐1. [PUBMED: 8682945] ">Elewski 1997</a>; <a href="./references#CD010031-bbs2-0017" title="GuptaAK , MaddinS , ArletteJ , GirouxJ‐M , ShearNH . Itraconazole pulse therapy is effective in dermatophyte onychomycosis of the toenail: a double‐blind placebo‐controlled study. Journal of Dermatological Treatment2000;11(1):33‐7. [EMBASE: 2000114935] ">Gupta 2000</a>; <a href="./references#CD010031-bbs2-0028" title="JonesHE , ZaiasN . Double‐blind, randomized comparison of itraconazole capsules and placebo in onychomycosis of toenail. International Journal of Dermatology1996;35(8):589‐90. [PUBMED: 8854164] ">Jones 1996</a>; <a href="./references#CD010031-bbs2-0036" title="MaddinS , QuiringJ , BulgerL . Randomised, placebo‐controlled, phase 3 study of itraconazole for the treatment of onychomycosis. Journal of Drugs in Dermatology2013;12(7):758‐763. [PUBMED: 23884486] ">Maddin 2013</a>), two studies with fluconazole (<a href="./references#CD010031-bbs2-0035" title="LingMR , SwinyerLJ , JarrattMT , FaloL , MonroeEW , TharpM , et al. Once‐weekly fluconazole (450 mg) for 4, 6, or 9 months of treatment for distal subungual onychomycosis of the toenail. Journal of the American Academy of Dermatology1998;38(6 Pt 2):S95‐102. [PUBMED: 9631991] ">Ling 1998</a>; <a href="./references#CD010031-bbs2-0040" title="ElewskiBE . US experience with fluconazole in nail infections. Journal of the European Academy of Dermatology and Venereology1998;11(Suppl 2):S106. [CENTRAL: CN‐00478523; DOI: 10.1111/j.1468‐3083.1998.tb00994.x] RichP , ScherRK , BrenemanD , SavinRC , FeingoldDS , KonnikovN , et al. Pharmacokinetics of three doses of once‐weekly fluconazole (150, 300, and 450 mg) in distal subungual onychomycosis of the toenail. Journal of the American Academy of Dermatology1998;38(6 Pt 2):S103‐9. [PUBMED: 9631992] ScherRK , BrenemanD , RichP , SavinRC , FeingoldDS , KonnikovN , et al. Once‐weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail. Journal of the American Academy of Dermatology1998;38(6 Pt 2):S77‐86. [PUBMED: 9631989] ">Scher 1998</a>), and one study each for posaconazole (<a href="./references#CD010031-bbs2-0014" title="ElewskiB , PollakR , AshtonS , RichP , SchlessingerJ , TavakkolA . A randomized, placebo‐ and active‐controlled, parallel‐group, multicentre, investigator‐blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis. British Journal of Dermatology2012;166(2):389‐98. [PUBMED: 21967490] ElewskiB , TavakkolA , PollakR , AshtonS . A randomized, placebo‐ and active‐controlled, parallel‐group, multicenter,investigator‐blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis. Journal of American Academy of Dermatology2010;62(3 Suppl 1):AB76. [EMBASE: 70142781] ">Elewski 2012</a>), albaconazole (<a href="./references#CD010031-bbs2-0042" title="SigurgeirssonB , vanRossemK , MalahiasS , RaterinkK . A phase II, randomized, double‐blind, placebo‐controlled, parallel group, dose‐ranging study to investigate the efficacy and safety of 4 dose regimens of oral albaconazole in patients with distal subungual onychomycosis. Journal of the American Academy of Dermatology2013;69(3):416‐25. [PUBMED: 23706639] ">Sigurgeirsson 2013</a>), and ravuconazole (<a href="./references#CD010031-bbs2-0021" title="GuptaAK , LeonardiC , StoltzRR , PiercePF , ConettaB . A phase I/II randomized, double‐blind, placebo‐controlled, dose‐ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis. Journal of the European Academy of Dermatology and Venereology : JEADV2005;19(4):437‐43. [PUBMED: 15987289] ">Gupta 2005</a>). Albaconazole and ravuconazole are drugs under development which are not commercially available at present. Therefore, we present the results with and without these two studies. </p> <section id="CD010031-sec-0118"> <h5 class="title">Primary outcomes</h5> <section id="CD010031-sec-0119"> <h6 class="title">Clinical cure</h6> <p>See <a href="./references#CD010031-fig-0013" title="">Analysis 3.1</a>. </p> <p>All nine studies reported clinical cure as outcome (<a href="./references#CD010031-bbs2-0012" title="ElewskiBE , ScherRK , AlyR , DanielR3rd , JonesHE , OdomRB , et al. Double‐blind, randomized comparison of itraconazole capsules vs. placebo in the treatment of toenail onychomycosis. Cutis1997;59(4):217‐20. [PUBMED: 9104548] OdomR , DanielCR , AlyR . A double‐blind, randomized comparison of itraconazole capsules and placebo in the treatment of onychomycosis of the toenail. Journal of the American Academy of Dermatology1996;35(1):110‐1. [PUBMED: 8682945] ">Elewski 1997</a>; <a href="./references#CD010031-bbs2-0014" title="ElewskiB , PollakR , AshtonS , RichP , SchlessingerJ , TavakkolA . A randomized, placebo‐ and active‐controlled, parallel‐group, multicentre, investigator‐blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis. British Journal of Dermatology2012;166(2):389‐98. [PUBMED: 21967490] ElewskiB , TavakkolA , PollakR , AshtonS . A randomized, placebo‐ and active‐controlled, parallel‐group, multicenter,investigator‐blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis. Journal of American Academy of Dermatology2010;62(3 Suppl 1):AB76. [EMBASE: 70142781] ">Elewski 2012</a>; <a href="./references#CD010031-bbs2-0017" title="GuptaAK , MaddinS , ArletteJ , GirouxJ‐M , ShearNH . Itraconazole pulse therapy is effective in dermatophyte onychomycosis of the toenail: a double‐blind placebo‐controlled study. Journal of Dermatological Treatment2000;11(1):33‐7. [EMBASE: 2000114935] ">Gupta 2000</a>; <a href="./references#CD010031-bbs2-0021" title="GuptaAK , LeonardiC , StoltzRR , PiercePF , ConettaB . A phase I/II randomized, double‐blind, placebo‐controlled, dose‐ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis. Journal of the European Academy of Dermatology and Venereology : JEADV2005;19(4):437‐43. [PUBMED: 15987289] ">Gupta 2005</a>; <a href="./references#CD010031-bbs2-0028" title="JonesHE , ZaiasN . Double‐blind, randomized comparison of itraconazole capsules and placebo in onychomycosis of toenail. International Journal of Dermatology1996;35(8):589‐90. [PUBMED: 8854164] ">Jones 1996</a>; <a href="./references#CD010031-bbs2-0035" title="LingMR , SwinyerLJ , JarrattMT , FaloL , MonroeEW , TharpM , et al. Once‐weekly fluconazole (450 mg) for 4, 6, or 9 months of treatment for distal subungual onychomycosis of the toenail. Journal of the American Academy of Dermatology1998;38(6 Pt 2):S95‐102. [PUBMED: 9631991] ">Ling 1998</a>; <a href="./references#CD010031-bbs2-0036" title="MaddinS , QuiringJ , BulgerL . Randomised, placebo‐controlled, phase 3 study of itraconazole for the treatment of onychomycosis. Journal of Drugs in Dermatology2013;12(7):758‐763. [PUBMED: 23884486] ">Maddin 2013</a>; <a href="./references#CD010031-bbs2-0040" title="ElewskiBE . US experience with fluconazole in nail infections. Journal of the European Academy of Dermatology and Venereology1998;11(Suppl 2):S106. [CENTRAL: CN‐00478523; DOI: 10.1111/j.1468‐3083.1998.tb00994.x] RichP , ScherRK , BrenemanD , SavinRC , FeingoldDS , KonnikovN , et al. Pharmacokinetics of three doses of once‐weekly fluconazole (150, 300, and 450 mg) in distal subungual onychomycosis of the toenail. Journal of the American Academy of Dermatology1998;38(6 Pt 2):S103‐9. [PUBMED: 9631992] ScherRK , BrenemanD , RichP , SavinRC , FeingoldDS , KonnikovN , et al. Once‐weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail. Journal of the American Academy of Dermatology1998;38(6 Pt 2):S77‐86. [PUBMED: 9631989] ">Scher 1998</a>; <a href="./references#CD010031-bbs2-0042" title="SigurgeirssonB , vanRossemK , MalahiasS , RaterinkK . A phase II, randomized, double‐blind, placebo‐controlled, parallel group, dose‐ranging study to investigate the efficacy and safety of 4 dose regimens of oral albaconazole in patients with distal subungual onychomycosis. Journal of the American Academy of Dermatology2013;69(3):416‐25. [PUBMED: 23706639] ">Sigurgeirsson 2013</a>). </p> <p>In the pooled placebo group, 11 (13.9%) participants achieved clinical cure compared to 810 (30.5%) participants in the pooled azole group. There was high‐quality evidence that participants in the azole group were 22 times more likely to achieve clinical cure compared to participants receiving placebo (RR 22.18, 95% CI 12.63 to 38.95, 9 studies, 3440 participants; I² = 0%). </p> <p>When excluding the studies using unregistered medications (<a href="./references#CD010031-bbs2-0021" title="GuptaAK , LeonardiC , StoltzRR , PiercePF , ConettaB . A phase I/II randomized, double‐blind, placebo‐controlled, dose‐ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis. Journal of the European Academy of Dermatology and Venereology : JEADV2005;19(4):437‐43. [PUBMED: 15987289] ">Gupta 2005</a>; <a href="./references#CD010031-bbs2-0042" title="SigurgeirssonB , vanRossemK , MalahiasS , RaterinkK . A phase II, randomized, double‐blind, placebo‐controlled, parallel group, dose‐ranging study to investigate the efficacy and safety of 4 dose regimens of oral albaconazole in patients with distal subungual onychomycosis. Journal of the American Academy of Dermatology2013;69(3):416‐25. [PUBMED: 23706639] ">Sigurgeirsson 2013</a>), participants in the azole group were 25 times more likely to achieve clinical cure compared to participants receiving placebo (RR 25.28, 95% CI 13.64 to 46.85). </p> <p>When comparing subgroups based on short‐ or long‐term follow‐up, we did not observe any statistical heterogeneity (I² = 0%, P value for subgroup differences = 0.71). In studies with short‐term follow‐up the intervention group was 23 times as likely to achieve clinical cure (RR 23.89, 95% CI 11.99 to 47.64), and with long‐term follow‐up the intervention group was 19 times as likely to achieve clinical cure (RR 19.11, 95% CI 7.21 to 50.65). </p> <p>We assessed two studies as being at high risk of bias in at least one domain (<a href="./references#CD010031-bbs2-0035" title="LingMR , SwinyerLJ , JarrattMT , FaloL , MonroeEW , TharpM , et al. Once‐weekly fluconazole (450 mg) for 4, 6, or 9 months of treatment for distal subungual onychomycosis of the toenail. Journal of the American Academy of Dermatology1998;38(6 Pt 2):S95‐102. [PUBMED: 9631991] ">Ling 1998</a>; <a href="./references#CD010031-bbs2-0036" title="MaddinS , QuiringJ , BulgerL . Randomised, placebo‐controlled, phase 3 study of itraconazole for the treatment of onychomycosis. Journal of Drugs in Dermatology2013;12(7):758‐763. [PUBMED: 23884486] ">Maddin 2013</a>); however, sensitivity analyses excluding these two studies did not change the direction or magnitude of the treatment effect (RR 20.62, 95% CI 10.76 to 39.52). </p> </section> <section id="CD010031-sec-0120"> <h6 class="title">Mycological cure</h6> <p>See <a href="./references#CD010031-fig-0014" title="">Analysis 3.2</a>. </p> <p>All nine studies reported mycological cure as an outcome (<a href="./references#CD010031-bbs2-0012" title="ElewskiBE , ScherRK , AlyR , DanielR3rd , JonesHE , OdomRB , et al. Double‐blind, randomized comparison of itraconazole capsules vs. placebo in the treatment of toenail onychomycosis. Cutis1997;59(4):217‐20. [PUBMED: 9104548] OdomR , DanielCR , AlyR . A double‐blind, randomized comparison of itraconazole capsules and placebo in the treatment of onychomycosis of the toenail. Journal of the American Academy of Dermatology1996;35(1):110‐1. [PUBMED: 8682945] ">Elewski 1997</a>; <a href="./references#CD010031-bbs2-0014" title="ElewskiB , PollakR , AshtonS , RichP , SchlessingerJ , TavakkolA . A randomized, placebo‐ and active‐controlled, parallel‐group, multicentre, investigator‐blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis. British Journal of Dermatology2012;166(2):389‐98. [PUBMED: 21967490] ElewskiB , TavakkolA , PollakR , AshtonS . A randomized, placebo‐ and active‐controlled, parallel‐group, multicenter,investigator‐blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis. Journal of American Academy of Dermatology2010;62(3 Suppl 1):AB76. [EMBASE: 70142781] ">Elewski 2012</a>; <a href="./references#CD010031-bbs2-0017" title="GuptaAK , MaddinS , ArletteJ , GirouxJ‐M , ShearNH . Itraconazole pulse therapy is effective in dermatophyte onychomycosis of the toenail: a double‐blind placebo‐controlled study. Journal of Dermatological Treatment2000;11(1):33‐7. [EMBASE: 2000114935] ">Gupta 2000</a>; <a href="./references#CD010031-bbs2-0021" title="GuptaAK , LeonardiC , StoltzRR , PiercePF , ConettaB . A phase I/II randomized, double‐blind, placebo‐controlled, dose‐ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis. Journal of the European Academy of Dermatology and Venereology : JEADV2005;19(4):437‐43. [PUBMED: 15987289] ">Gupta 2005</a>; <a href="./references#CD010031-bbs2-0028" title="JonesHE , ZaiasN . Double‐blind, randomized comparison of itraconazole capsules and placebo in onychomycosis of toenail. International Journal of Dermatology1996;35(8):589‐90. [PUBMED: 8854164] ">Jones 1996</a>; <a href="./references#CD010031-bbs2-0035" title="LingMR , SwinyerLJ , JarrattMT , FaloL , MonroeEW , TharpM , et al. Once‐weekly fluconazole (450 mg) for 4, 6, or 9 months of treatment for distal subungual onychomycosis of the toenail. Journal of the American Academy of Dermatology1998;38(6 Pt 2):S95‐102. [PUBMED: 9631991] ">Ling 1998</a>; <a href="./references#CD010031-bbs2-0036" title="MaddinS , QuiringJ , BulgerL . Randomised, placebo‐controlled, phase 3 study of itraconazole for the treatment of onychomycosis. Journal of Drugs in Dermatology2013;12(7):758‐763. [PUBMED: 23884486] ">Maddin 2013</a>; <a href="./references#CD010031-bbs2-0040" title="ElewskiBE . US experience with fluconazole in nail infections. Journal of the European Academy of Dermatology and Venereology1998;11(Suppl 2):S106. [CENTRAL: CN‐00478523; DOI: 10.1111/j.1468‐3083.1998.tb00994.x] RichP , ScherRK , BrenemanD , SavinRC , FeingoldDS , KonnikovN , et al. Pharmacokinetics of three doses of once‐weekly fluconazole (150, 300, and 450 mg) in distal subungual onychomycosis of the toenail. Journal of the American Academy of Dermatology1998;38(6 Pt 2):S103‐9. [PUBMED: 9631992] ScherRK , BrenemanD , RichP , SavinRC , FeingoldDS , KonnikovN , et al. Once‐weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail. Journal of the American Academy of Dermatology1998;38(6 Pt 2):S77‐86. [PUBMED: 9631989] ">Scher 1998</a>; <a href="./references#CD010031-bbs2-0042" title="SigurgeirssonB , vanRossemK , MalahiasS , RaterinkK . A phase II, randomized, double‐blind, placebo‐controlled, parallel group, dose‐ranging study to investigate the efficacy and safety of 4 dose regimens of oral albaconazole in patients with distal subungual onychomycosis. Journal of the American Academy of Dermatology2013;69(3):416‐25. [PUBMED: 23706639] ">Sigurgeirsson 2013</a>). </p> <p>In the pooled placebo group, 58 (7.4%) participants achieved mycological cure compared to 924 (34.8%) participants in the intervention groups. </p> <p>Statistical heterogeneity was high as confirmed by an I² of 76%. The main clinical difference was the use of different subtypes of azole medications, although these were similar in pharmacological action. However, subgroup analyses for itraconazole‐only studies did not reduce statistical heterogeneity (I² = 89%). </p> <p>There was high‐quality evidence that participants in the azole group were almost six times more likely to achieve mycological cure compared to participants receiving placebo (RR 5.86, 95% CI 3.23 to 10.62, 9 studies, 3440 participants; I² = 76%). </p> <p>Three studies seemed to contribute to statistical heterogeneity (<a href="./references#CD010031-bbs2-0017" title="GuptaAK , MaddinS , ArletteJ , GirouxJ‐M , ShearNH . Itraconazole pulse therapy is effective in dermatophyte onychomycosis of the toenail: a double‐blind placebo‐controlled study. Journal of Dermatological Treatment2000;11(1):33‐7. [EMBASE: 2000114935] ">Gupta 2000</a>; <a href="./references#CD010031-bbs2-0021" title="GuptaAK , LeonardiC , StoltzRR , PiercePF , ConettaB . A phase I/II randomized, double‐blind, placebo‐controlled, dose‐ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis. Journal of the European Academy of Dermatology and Venereology : JEADV2005;19(4):437‐43. [PUBMED: 15987289] ">Gupta 2005</a>; <a href="./references#CD010031-bbs2-0040" title="ElewskiBE . US experience with fluconazole in nail infections. Journal of the European Academy of Dermatology and Venereology1998;11(Suppl 2):S106. [CENTRAL: CN‐00478523; DOI: 10.1111/j.1468‐3083.1998.tb00994.x] RichP , ScherRK , BrenemanD , SavinRC , FeingoldDS , KonnikovN , et al. Pharmacokinetics of three doses of once‐weekly fluconazole (150, 300, and 450 mg) in distal subungual onychomycosis of the toenail. Journal of the American Academy of Dermatology1998;38(6 Pt 2):S103‐9. [PUBMED: 9631992] ScherRK , BrenemanD , RichP , SavinRC , FeingoldDS , KonnikovN , et al. Once‐weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail. Journal of the American Academy of Dermatology1998;38(6 Pt 2):S77‐86. [PUBMED: 9631989] ">Scher 1998</a>). Removing these from the analyses reduced the statistical heterogeneity to 0%. This did not change the direction of the effect but did increase the effect size (RR 8.99, 95% CI 5.98 to 13.52). </p> <p>When excluding the studies using unregistered medication (<a href="./references#CD010031-bbs2-0021" title="GuptaAK , LeonardiC , StoltzRR , PiercePF , ConettaB . A phase I/II randomized, double‐blind, placebo‐controlled, dose‐ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis. Journal of the European Academy of Dermatology and Venereology : JEADV2005;19(4):437‐43. [PUBMED: 15987289] ">Gupta 2005</a>; <a href="./references#CD010031-bbs2-0042" title="SigurgeirssonB , vanRossemK , MalahiasS , RaterinkK . A phase II, randomized, double‐blind, placebo‐controlled, parallel group, dose‐ranging study to investigate the efficacy and safety of 4 dose regimens of oral albaconazole in patients with distal subungual onychomycosis. Journal of the American Academy of Dermatology2013;69(3):416‐25. [PUBMED: 23706639] ">Sigurgeirsson 2013</a>), participants in the azole group were 6.6 times more likely to achieve mycological cure compared to participants receiving placebo (RR 6.62, 95% CI 3.23 to 13.57). </p> <p>When comparing subgroups based on short‐ or long‐term follow‐up, we saw low statistical heterogeneity (I² = 0%, P value for subgroup differences = 0.34). In studies with short‐term follow‐up the intervention group was seven times as likely to achieve mycological cure (RR 7.05, 95% CI 2.91 to 17.07), and with long‐term follow‐up the intervention group was four times as likely to achieve mycological cure (RR 4.22, 95% CI 2.34 to 7.59). </p> <p>We assessed two studies as being at high risk of bias in at least one domain (<a href="./references#CD010031-bbs2-0035" title="LingMR , SwinyerLJ , JarrattMT , FaloL , MonroeEW , TharpM , et al. Once‐weekly fluconazole (450 mg) for 4, 6, or 9 months of treatment for distal subungual onychomycosis of the toenail. Journal of the American Academy of Dermatology1998;38(6 Pt 2):S95‐102. [PUBMED: 9631991] ">Ling 1998</a>; <a href="./references#CD010031-bbs2-0036" title="MaddinS , QuiringJ , BulgerL . Randomised, placebo‐controlled, phase 3 study of itraconazole for the treatment of onychomycosis. Journal of Drugs in Dermatology2013;12(7):758‐763. [PUBMED: 23884486] ">Maddin 2013</a>); however, sensitivity analyses excluding these two studies did not change the direction or magnitude of the treatment effect (RR 4.93, 95% CI 2.68 to 9.07). </p> </section> </section> <section id="CD010031-sec-0121"> <h5 class="title">Secondary outcomes</h5> <section id="CD010031-sec-0122"> <h6 class="title">Adverse events</h6> <p>See <a href="./references#CD010031-fig-0015" title="">Analysis 3.3</a>. </p> <p>Nine studies compared azole therapy with placebo for adverse events (<a href="./references#CD010031-bbs2-0012" title="ElewskiBE , ScherRK , AlyR , DanielR3rd , JonesHE , OdomRB , et al. Double‐blind, randomized comparison of itraconazole capsules vs. placebo in the treatment of toenail onychomycosis. Cutis1997;59(4):217‐20. [PUBMED: 9104548] OdomR , DanielCR , AlyR . A double‐blind, randomized comparison of itraconazole capsules and placebo in the treatment of onychomycosis of the toenail. Journal of the American Academy of Dermatology1996;35(1):110‐1. [PUBMED: 8682945] ">Elewski 1997</a>; <a href="./references#CD010031-bbs2-0014" title="ElewskiB , PollakR , AshtonS , RichP , SchlessingerJ , TavakkolA . A randomized, placebo‐ and active‐controlled, parallel‐group, multicentre, investigator‐blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis. British Journal of Dermatology2012;166(2):389‐98. [PUBMED: 21967490] ElewskiB , TavakkolA , PollakR , AshtonS . A randomized, placebo‐ and active‐controlled, parallel‐group, multicenter,investigator‐blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis. Journal of American Academy of Dermatology2010;62(3 Suppl 1):AB76. [EMBASE: 70142781] ">Elewski 2012</a>; <a href="./references#CD010031-bbs2-0017" title="GuptaAK , MaddinS , ArletteJ , GirouxJ‐M , ShearNH . Itraconazole pulse therapy is effective in dermatophyte onychomycosis of the toenail: a double‐blind placebo‐controlled study. Journal of Dermatological Treatment2000;11(1):33‐7. [EMBASE: 2000114935] ">Gupta 2000</a>; <a href="./references#CD010031-bbs2-0021" title="GuptaAK , LeonardiC , StoltzRR , PiercePF , ConettaB . A phase I/II randomized, double‐blind, placebo‐controlled, dose‐ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis. Journal of the European Academy of Dermatology and Venereology : JEADV2005;19(4):437‐43. [PUBMED: 15987289] ">Gupta 2005</a>; <a href="./references#CD010031-bbs2-0028" title="JonesHE , ZaiasN . Double‐blind, randomized comparison of itraconazole capsules and placebo in onychomycosis of toenail. International Journal of Dermatology1996;35(8):589‐90. [PUBMED: 8854164] ">Jones 1996</a>; <a href="./references#CD010031-bbs2-0036" title="MaddinS , QuiringJ , BulgerL . Randomised, placebo‐controlled, phase 3 study of itraconazole for the treatment of onychomycosis. Journal of Drugs in Dermatology2013;12(7):758‐763. [PUBMED: 23884486] ">Maddin 2013</a>; <a href="./references#CD010031-bbs2-0042" title="SigurgeirssonB , vanRossemK , MalahiasS , RaterinkK . A phase II, randomized, double‐blind, placebo‐controlled, parallel group, dose‐ranging study to investigate the efficacy and safety of 4 dose regimens of oral albaconazole in patients with distal subungual onychomycosis. Journal of the American Academy of Dermatology2013;69(3):416‐25. [PUBMED: 23706639] ">Sigurgeirsson 2013</a>; <a href="./references#CD010031-bbs2-0035" title="LingMR , SwinyerLJ , JarrattMT , FaloL , MonroeEW , TharpM , et al. Once‐weekly fluconazole (450 mg) for 4, 6, or 9 months of treatment for distal subungual onychomycosis of the toenail. Journal of the American Academy of Dermatology1998;38(6 Pt 2):S95‐102. [PUBMED: 9631991] ">Ling 1998</a>; <a href="./references#CD010031-bbs2-0040" title="ElewskiBE . US experience with fluconazole in nail infections. Journal of the European Academy of Dermatology and Venereology1998;11(Suppl 2):S106. [CENTRAL: CN‐00478523; DOI: 10.1111/j.1468‐3083.1998.tb00994.x] RichP , ScherRK , BrenemanD , SavinRC , FeingoldDS , KonnikovN , et al. Pharmacokinetics of three doses of once‐weekly fluconazole (150, 300, and 450 mg) in distal subungual onychomycosis of the toenail. Journal of the American Academy of Dermatology1998;38(6 Pt 2):S103‐9. [PUBMED: 9631992] ScherRK , BrenemanD , RichP , SavinRC , FeingoldDS , KonnikovN , et al. Once‐weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail. Journal of the American Academy of Dermatology1998;38(6 Pt 2):S77‐86. [PUBMED: 9631989] ">Scher 1998</a>). There were 2652 participants in the pooled azole groups and 789 participants in the pooled placebo groups. </p> <p>In the pooled azole group, 1558 (59%) participants experienced an adverse event compared to 424 (54%) in the placebo group. This difference was not statistically significant (RR 1.04, 95% CI 0.97 to 1.12; 9 studies, 3441 participants, I² = 13%; moderate‐quality evidence). The most common adverse events amongst azole‐treated participants included headache, upper respiratory tract infections (URTI)/rhinitis/sinusitis, flu‐like symptoms, nausea, fatigue, abdominal pain, diarrhoea, dizziness, rash, and elevated liver function tests. </p> </section> <section id="CD010031-sec-0123"> <h6 class="title">Recurrence rate</h6> <p>See <a href="./references#CD010031-fig-0016" title="">Analysis 3.4</a>. </p> <p>One study compared the recurrence rate between azole therapy and placebo, showing that 46% (11 of 24 participants) of participants receiving azole therapy had a recurrence, while 100% (2 of 2 participants) receiving placebo had a recurrence (RR 0.55, 95% CI 0.29 to 1.07, 26 participants; low‐quality evidence; <a href="./references#CD010031-bbs2-0028" title="JonesHE , ZaiasN . Double‐blind, randomized comparison of itraconazole capsules and placebo in onychomycosis of toenail. International Journal of Dermatology1996;35(8):589‐90. [PUBMED: 8854164] ">Jones 1996</a>). </p> </section> </section> </section> <section id="CD010031-sec-0124"> <h4 class="title">Comparison 4: griseofulvin versus azole</h4> <p>See <a href="./full#CD010031-tbl-0004">summary of findings Table 4</a> for quality assessments for this comparison. </p> <p>Five studies (222 participants) compared griseofulvin (N = 125) with an azole (N = 97) (<a href="./references#CD010031-bbs2-0008" title="CullenSI , CullenMK . Ketoconazole and griseofulvin in the treatment of toenail dermatophyte onychomycosis. Current Therapeutic Research, Clinical and Experimental1987;41(1):24‐29. [EMBASE: 1987096720] ">Cullen 1987</a>; <a href="./references#CD010031-bbs2-0019" title="GuptaAK , Gregurek‐NovakT . Efficacy of itraconazole, terbinafine, fluconazole, griseofulvin and ketoconazole in the treatment of Scopulariopsis brevicaulis causing onychomycosis of the toes. Dermatology2001;202(3):235‐8. [PUBMED: 11385230] ">Gupta 2001b</a>; <a href="./references#CD010031-bbs2-0031" title="KortingHC , Schafer‐KortingM , ZienickeH , GeorgiiA , OllertMW . Treatment of tinea unguium with medium and high doses of ultramicrosize griseofulvin compared with that with itraconazole. Antimicrobial Agents and Chemotherapy1993;37(10):2064‐8. [PUBMED: 8257124] ">Korting 1993</a>; <a href="./references#CD010031-bbs2-0043" title="SvejgaardE . Oral ketoconazole as an alternative to griseofulvin in recalcitrant dermatophyte infections and onychomycosis. Acta Dermato‐venereologica1985;65(2):143‐9. [PUBMED: 2408417] ">Svejgaard 1985</a>; <a href="./references#CD010031-bbs2-0046" title="WalsoeI , StangerupM , SvejgaardE . Itraconazole in onychomycosis. Open and double‐blind studies. Acta Dermato‐venereologica1990;70(2):137‐40. [PUBMED: 1969198] ">Walsoe 1990</a>). All studies used itraconazole, with one study using two azole arms, ketoconazole and itraconazole (<a href="./references#CD010031-bbs2-0019" title="GuptaAK , Gregurek‐NovakT . Efficacy of itraconazole, terbinafine, fluconazole, griseofulvin and ketoconazole in the treatment of Scopulariopsis brevicaulis causing onychomycosis of the toes. Dermatology2001;202(3):235‐8. [PUBMED: 11385230] ">Gupta 2001b</a>). Griseofulvin doses ranged from 500 mg to 1200 mg per day. </p> <section id="CD010031-sec-0125"> <h5 class="title">Primary outcomes</h5> <section id="CD010031-sec-0126"> <h6 class="title">Clinical cure</h6> <p>See <a href="./references#CD010031-fig-0017" title="">Analysis 4.1</a>. </p> <p>Five studies reported clinical cure as an outcome (<a href="./references#CD010031-bbs2-0008" title="CullenSI , CullenMK . Ketoconazole and griseofulvin in the treatment of toenail dermatophyte onychomycosis. Current Therapeutic Research, Clinical and Experimental1987;41(1):24‐29. [EMBASE: 1987096720] ">Cullen 1987</a>; <a href="./references#CD010031-bbs2-0019" title="GuptaAK , Gregurek‐NovakT . Efficacy of itraconazole, terbinafine, fluconazole, griseofulvin and ketoconazole in the treatment of Scopulariopsis brevicaulis causing onychomycosis of the toes. Dermatology2001;202(3):235‐8. [PUBMED: 11385230] ">Gupta 2001b</a>; <a href="./references#CD010031-bbs2-0031" title="KortingHC , Schafer‐KortingM , ZienickeH , GeorgiiA , OllertMW . Treatment of tinea unguium with medium and high doses of ultramicrosize griseofulvin compared with that with itraconazole. Antimicrobial Agents and Chemotherapy1993;37(10):2064‐8. [PUBMED: 8257124] ">Korting 1993</a>; <a href="./references#CD010031-bbs2-0043" title="SvejgaardE . Oral ketoconazole as an alternative to griseofulvin in recalcitrant dermatophyte infections and onychomycosis. Acta Dermato‐venereologica1985;65(2):143‐9. [PUBMED: 2408417] ">Svejgaard 1985</a>; <a href="./references#CD010031-bbs2-0046" title="WalsoeI , StangerupM , SvejgaardE . Itraconazole in onychomycosis. Open and double‐blind studies. Acta Dermato‐venereologica1990;70(2):137‐40. [PUBMED: 1969198] ">Walsoe 1990</a>). </p> <p>In the pooled griseofulvin group, 13 (10%) participants achieved clinical cure compared to 14 (10.4%) participants in the azole group. There was no statistically significant difference in the chance of achieving clinical cure between the griseofulvin and the azole group (RR 0.94, 95% CI 0.45 to 1.96, 5 studies, 222 participants; I² = 0%; moderate‐quality evidence). </p> <p>When comparing subgroups based on short‐ or long‐term follow‐up, we observed no statistical heterogeneity between groups (I² = 0%, P value for subgroup differences = 0.87). In studies with both short‐ and long‐term follow‐up, we saw no statistically significant difference between the two treatment groups (RR 0.89, 95% CI 0.32 to 2.35 and RR 1.00, 95% CI 0.34 to 2.91, respectively). </p> </section> <section id="CD010031-sec-0127"> <h6 class="title">Mycological cure</h6> <p>See <a href="./references#CD010031-fig-0018" title="">Analysis 4.2</a>. </p> <p>Five studies reported mycological cure as an outcome (<a href="./references#CD010031-bbs2-0008" title="CullenSI , CullenMK . Ketoconazole and griseofulvin in the treatment of toenail dermatophyte onychomycosis. Current Therapeutic Research, Clinical and Experimental1987;41(1):24‐29. [EMBASE: 1987096720] ">Cullen 1987</a>; <a href="./references#CD010031-bbs2-0019" title="GuptaAK , Gregurek‐NovakT . Efficacy of itraconazole, terbinafine, fluconazole, griseofulvin and ketoconazole in the treatment of Scopulariopsis brevicaulis causing onychomycosis of the toes. Dermatology2001;202(3):235‐8. [PUBMED: 11385230] ">Gupta 2001b</a>; <a href="./references#CD010031-bbs2-0031" title="KortingHC , Schafer‐KortingM , ZienickeH , GeorgiiA , OllertMW . Treatment of tinea unguium with medium and high doses of ultramicrosize griseofulvin compared with that with itraconazole. Antimicrobial Agents and Chemotherapy1993;37(10):2064‐8. [PUBMED: 8257124] ">Korting 1993</a>; <a href="./references#CD010031-bbs2-0043" title="SvejgaardE . Oral ketoconazole as an alternative to griseofulvin in recalcitrant dermatophyte infections and onychomycosis. Acta Dermato‐venereologica1985;65(2):143‐9. [PUBMED: 2408417] ">Svejgaard 1985</a>; <a href="./references#CD010031-bbs2-0046" title="WalsoeI , StangerupM , SvejgaardE . Itraconazole in onychomycosis. Open and double‐blind studies. Acta Dermato‐venereologica1990;70(2):137‐40. [PUBMED: 1969198] ">Walsoe 1990</a>). </p> <p>In the pooled griseofulvin group, 14 (11.2%) participants achieved mycological cure compared to 18 (18.6%) participants in the azole group. There was no statistically significant difference in the chance of achieving mycological cure between the griseofulvin and the azole group (RR 0.87, 95% CI 0.50 to 1.51, 5 studies, 222 participants; I² = 0%; moderate‐quality evidence). </p> <p>When comparing subgroups based on short‐ or long‐term follow‐up, we saw no statistical heterogeneity between groups (I² = 0%, P value for subgroup differences = 0.49). In both studies with short‐ and long‐term follow‐up, we saw no statistically significant difference between the two treatment groups (RR 0.96, 95% CI 0.52 to 1.76 and RR 0.58, 95% CI 0.16 to 2.10, respectively). </p> </section> </section> <section id="CD010031-sec-0128"> <h5 class="title">Secondary outcomes</h5> <section id="CD010031-sec-0129"> <h6 class="title">Adverse events</h6> <p>See <a href="./references#CD010031-fig-0019" title="">Analysis 4.3</a>. </p> <p>Two studies compared griseofulvin with azole treatment for adverse events (<a href="./references#CD010031-bbs2-0019" title="GuptaAK , Gregurek‐NovakT . Efficacy of itraconazole, terbinafine, fluconazole, griseofulvin and ketoconazole in the treatment of Scopulariopsis brevicaulis causing onychomycosis of the toes. Dermatology2001;202(3):235‐8. [PUBMED: 11385230] ">Gupta 2001b</a>; <a href="./references#CD010031-bbs2-0031" title="KortingHC , Schafer‐KortingM , ZienickeH , GeorgiiA , OllertMW . Treatment of tinea unguium with medium and high doses of ultramicrosize griseofulvin compared with that with itraconazole. Antimicrobial Agents and Chemotherapy1993;37(10):2064‐8. [PUBMED: 8257124] ">Korting 1993</a>). There were 85 participants in the pooled griseofulvin group and 58 participants in the pooled azole group. </p> <p>In the pooled griseofulvin group, 51 (60%) participants experienced an adverse event compared to 16 (28%) in the azole group. Participants receiving griseofulvin were more than twice as likely to experience an adverse event compared to participants receiving azole (RR 2.41, 95% CI 1.56 to 3.73, 2 studies, 143 participants; I² = 0%; moderate‐quality evidence). The most common adverse events amongst griseofulvin‐treated participants included gastrointestinal disturbance, changes in hepatic and renal function, allergic reaction, and photodermatitis. The most common adverse events amongst azole‐treated participants included nausea, vomiting, and changes in liver function. </p> <p>Two studies only reported adverse event data for events serious enough to cause discontinuation (<a href="./references#CD010031-bbs2-0008" title="CullenSI , CullenMK . Ketoconazole and griseofulvin in the treatment of toenail dermatophyte onychomycosis. Current Therapeutic Research, Clinical and Experimental1987;41(1):24‐29. [EMBASE: 1987096720] ">Cullen 1987</a>; <a href="./references#CD010031-bbs2-0046" title="WalsoeI , StangerupM , SvejgaardE . Itraconazole in onychomycosis. Open and double‐blind studies. Acta Dermato‐venereologica1990;70(2):137‐40. [PUBMED: 1969198] ">Walsoe 1990</a>), precluding their inclusion in the above analysis. In <a href="./references#CD010031-bbs2-0008" title="CullenSI , CullenMK . Ketoconazole and griseofulvin in the treatment of toenail dermatophyte onychomycosis. Current Therapeutic Research, Clinical and Experimental1987;41(1):24‐29. [EMBASE: 1987096720] ">Cullen 1987</a>, 8 of 20 (40%) participants treated with griseofulvin discontinued due to adverse events compared to 4 of 20 (20%) participants treated with azole. In <a href="./references#CD010031-bbs2-0046" title="WalsoeI , StangerupM , SvejgaardE . Itraconazole in onychomycosis. Open and double‐blind studies. Acta Dermato‐venereologica1990;70(2):137‐40. [PUBMED: 1969198] ">Walsoe 1990</a>, 1 of 10 (10%) participants in the griseofulvin group discontinued due to adverse events compared to 2 of 9 (22%) participants treated with azoles. </p> </section> <section id="CD010031-sec-0130"> <h6 class="title">Recurrence rate</h6> <p>See <a href="./references#CD010031-fig-0020" title="">Analysis 4.4</a>. </p> <p>One study compared the recurrence rate between azole therapies and griseofulvin (<a href="./references#CD010031-bbs2-0031" title="KortingHC , Schafer‐KortingM , ZienickeH , GeorgiiA , OllertMW . Treatment of tinea unguium with medium and high doses of ultramicrosize griseofulvin compared with that with itraconazole. Antimicrobial Agents and Chemotherapy1993;37(10):2064‐8. [PUBMED: 8257124] ">Korting 1993</a>). In the griseofulvin group two of the four participants that achieved cure had a recurrence, while none of the three participants that achieved cure on azole treatment had a recurrence. This difference was not statistically significant (RR 4.00, 95% CI 0.26 to 61.76, 1 study, 7 participants; very low‐quality evidence). </p> </section> </section> </section> <section id="CD010031-sec-0131"> <h4 class="title">Comparison 5: griseofulvin versus terbinafine</h4> <p>See <a href="./full#CD010031-tbl-0005">summary of findings Table 5</a> for quality assessments for this comparison. </p> <p>Five studies (465 participants) compared griseofulvin (N = 236) with terbinafine (N = 229) (<a href="./references#CD010031-bbs2-0005" title="BaranR . A multicentre double‐blind parallel group study comparing the efficacy, safety and tolerability of terbinafine (250 mg/day) with griseofulvin (1g/day) in the treatment of dermatophytic onychomycosis. Journal of the European Academy of Dermatology &amp; Venereology1995;5(Suppl 1):S79. [CENTRAL: CN‐00454083] BaranR , BelaichS , BeylotC , BonnetblancJ , CribierB , DanielF , et al. Comparative multicentre double‐blind study of terbinafine (250 mg per day) versus griseofulvin (1 g per day) in the treatment of dermatophyte onychomycosis. Journal of Dermatological Treatment1997;8(2):93‐97. [EMBASE: 1997242786] ">Baran 1995</a>; <a href="./references#CD010031-bbs2-0015" title="FaergemannJ , AndersonC , HersleK , HradilE , NordinP , KaamanT , et al. Double‐blind, parallel‐group comparison of terbinafine and griseofulvin in the treatment of toenail onychomycosis. Journal of the American Academy of Dermatology1995;32(5 Pt 1):750‐3. [PUBMED: 7722020] ">Faergemann 1995</a>; <a href="./references#CD010031-bbs2-0019" title="GuptaAK , Gregurek‐NovakT . Efficacy of itraconazole, terbinafine, fluconazole, griseofulvin and ketoconazole in the treatment of Scopulariopsis brevicaulis causing onychomycosis of the toes. Dermatology2001;202(3):235‐8. [PUBMED: 11385230] ">Gupta 2001b</a>; <a href="./references#CD010031-bbs2-0026" title="HofmannH , BrautigamM , WeidingerG , ZaunH . Treatment of toenail onychomycosis. A randomized, double‐blind study with terbinafine and griseofulvin. LAGOS II Study Group. Archives of Dermatology1995;131(8):919‐22. [PUBMED: 7632064] ">Hofmann 1995</a>; <a href="./references#CD010031-bbs2-0033" title="LaPlacaM , StinchiC , VenturoN , MorelliR , TostiA . Terbinafine vs griseofulvin in the treatment of dermatophyte onychomycosis [Terbinafina vs griseofulvina nella terapia delle onicomicosi da dermatofiti]. Giornale Italiano di Dermatologia e Venereologia1994;129(4):19‐22. [EMBASE: 1994255170] ">La Placa 1994</a>). All studies used terbinafine 250 mg daily, and the daily dose of griseofulvin varied from 500 mg to 1200 mg. </p> <section id="CD010031-sec-0132"> <h5 class="title">Primary outcomes</h5> <section id="CD010031-sec-0133"> <h6 class="title">Clinical cure</h6> <p>See <a href="./references#CD010031-fig-0021" title="">Analysis 5.1</a>. </p> <p>Four studies reported clinical cure as an outcome (<a href="./references#CD010031-bbs2-0005" title="BaranR . A multicentre double‐blind parallel group study comparing the efficacy, safety and tolerability of terbinafine (250 mg/day) with griseofulvin (1g/day) in the treatment of dermatophytic onychomycosis. Journal of the European Academy of Dermatology &amp; Venereology1995;5(Suppl 1):S79. [CENTRAL: CN‐00454083] BaranR , BelaichS , BeylotC , BonnetblancJ , CribierB , DanielF , et al. Comparative multicentre double‐blind study of terbinafine (250 mg per day) versus griseofulvin (1 g per day) in the treatment of dermatophyte onychomycosis. Journal of Dermatological Treatment1997;8(2):93‐97. [EMBASE: 1997242786] ">Baran 1995</a>; <a href="./references#CD010031-bbs2-0015" title="FaergemannJ , AndersonC , HersleK , HradilE , NordinP , KaamanT , et al. Double‐blind, parallel‐group comparison of terbinafine and griseofulvin in the treatment of toenail onychomycosis. Journal of the American Academy of Dermatology1995;32(5 Pt 1):750‐3. [PUBMED: 7722020] ">Faergemann 1995</a>; <a href="./references#CD010031-bbs2-0019" title="GuptaAK , Gregurek‐NovakT . Efficacy of itraconazole, terbinafine, fluconazole, griseofulvin and ketoconazole in the treatment of Scopulariopsis brevicaulis causing onychomycosis of the toes. Dermatology2001;202(3):235‐8. [PUBMED: 11385230] ">Gupta 2001b</a>; <a href="./references#CD010031-bbs2-0033" title="LaPlacaM , StinchiC , VenturoN , MorelliR , TostiA . Terbinafine vs griseofulvin in the treatment of dermatophyte onychomycosis [Terbinafina vs griseofulvina nella terapia delle onicomicosi da dermatofiti]. Giornale Italiano di Dermatologia e Venereologia1994;129(4):19‐22. [EMBASE: 1994255170] ">La Placa 1994</a>). </p> <p>In the pooled griseofulvin group, 30 (21.7%) participants achieved clinical cure compared to 74 (56%) participants in the terbinafine group. The chance of achieving clinical cure was 68% lower in the griseofulvin group when compared to the terbinafine group (RR 0.32, 95% CI 0.14 to 0.72, 4 studies, 270 participants; I² = 63%; low‐quality evidence). </p> <p>One study caused statistical heterogeneity (<a href="./references#CD010031-bbs2-0015" title="FaergemannJ , AndersonC , HersleK , HradilE , NordinP , KaamanT , et al. Double‐blind, parallel‐group comparison of terbinafine and griseofulvin in the treatment of toenail onychomycosis. Journal of the American Academy of Dermatology1995;32(5 Pt 1):750‐3. [PUBMED: 7722020] ">Faergemann 1995</a>). Removing this study from the analyses reduced the statistical heterogeneity to 0%. This did not change the direction of the effect but did reduce the size of the effect (RR 0.50, 95% CI 0.35 to 0.70). </p> <p>Only one study had short‐term follow‐up (<a href="./references#CD010031-bbs2-0015" title="FaergemannJ , AndersonC , HersleK , HradilE , NordinP , KaamanT , et al. Double‐blind, parallel‐group comparison of terbinafine and griseofulvin in the treatment of toenail onychomycosis. Journal of the American Academy of Dermatology1995;32(5 Pt 1):750‐3. [PUBMED: 7722020] ">Faergemann 1995</a>), and only one participant in this study achieved clinical cure, resulting in an RR of 0.05 (95% CI 0.01 to 0.39). </p> <p>In the long‐term follow‐up the griseofulvin group had a 49% lower chance of achieving clinical cure when compared to the terbinafine group (RR 0.51, 95% CI 0.36 to 0.71). </p> </section> <section id="CD010031-sec-0134"> <h6 class="title">Mycological cure</h6> <p>See <a href="./references#CD010031-fig-0022" title="">Analysis 5.2</a>. </p> <p>Five studies reported mycological cure as an outcome (<a href="./references#CD010031-bbs2-0005" title="BaranR . A multicentre double‐blind parallel group study comparing the efficacy, safety and tolerability of terbinafine (250 mg/day) with griseofulvin (1g/day) in the treatment of dermatophytic onychomycosis. Journal of the European Academy of Dermatology &amp; Venereology1995;5(Suppl 1):S79. [CENTRAL: CN‐00454083] BaranR , BelaichS , BeylotC , BonnetblancJ , CribierB , DanielF , et al. Comparative multicentre double‐blind study of terbinafine (250 mg per day) versus griseofulvin (1 g per day) in the treatment of dermatophyte onychomycosis. Journal of Dermatological Treatment1997;8(2):93‐97. [EMBASE: 1997242786] ">Baran 1995</a>; <a href="./references#CD010031-bbs2-0015" title="FaergemannJ , AndersonC , HersleK , HradilE , NordinP , KaamanT , et al. Double‐blind, parallel‐group comparison of terbinafine and griseofulvin in the treatment of toenail onychomycosis. Journal of the American Academy of Dermatology1995;32(5 Pt 1):750‐3. [PUBMED: 7722020] ">Faergemann 1995</a>; <a href="./references#CD010031-bbs2-0019" title="GuptaAK , Gregurek‐NovakT . Efficacy of itraconazole, terbinafine, fluconazole, griseofulvin and ketoconazole in the treatment of Scopulariopsis brevicaulis causing onychomycosis of the toes. Dermatology2001;202(3):235‐8. [PUBMED: 11385230] ">Gupta 2001b</a>; <a href="./references#CD010031-bbs2-0026" title="HofmannH , BrautigamM , WeidingerG , ZaunH . Treatment of toenail onychomycosis. A randomized, double‐blind study with terbinafine and griseofulvin. LAGOS II Study Group. Archives of Dermatology1995;131(8):919‐22. [PUBMED: 7632064] ">Hofmann 1995</a>; <a href="./references#CD010031-bbs2-0033" title="LaPlacaM , StinchiC , VenturoN , MorelliR , TostiA . Terbinafine vs griseofulvin in the treatment of dermatophyte onychomycosis [Terbinafina vs griseofulvina nella terapia delle onicomicosi da dermatofiti]. Giornale Italiano di Dermatologia e Venereologia1994;129(4):19‐22. [EMBASE: 1994255170] ">La Placa 1994</a>). </p> <p>In the pooled griseofulvin group, 119 (50.4%) participants achieved mycological cure, compared to 164 (71.6%) participants in the terbinafine group. The chance of achieving mycological cure was 36% lower in the griseofulvin group when compared to the terbinafine group (RR 0.64, 95% CI 0.46 to 0.90, 5 studies, 465 participants; I² = 68%; low‐quality evidence). </p> <p>Two studies caused statistical heterogeneity (<a href="./references#CD010031-bbs2-0005" title="BaranR . A multicentre double‐blind parallel group study comparing the efficacy, safety and tolerability of terbinafine (250 mg/day) with griseofulvin (1g/day) in the treatment of dermatophytic onychomycosis. Journal of the European Academy of Dermatology &amp; Venereology1995;5(Suppl 1):S79. [CENTRAL: CN‐00454083] BaranR , BelaichS , BeylotC , BonnetblancJ , CribierB , DanielF , et al. Comparative multicentre double‐blind study of terbinafine (250 mg per day) versus griseofulvin (1 g per day) in the treatment of dermatophyte onychomycosis. Journal of Dermatological Treatment1997;8(2):93‐97. [EMBASE: 1997242786] ">Baran 1995</a>; <a href="./references#CD010031-bbs2-0026" title="HofmannH , BrautigamM , WeidingerG , ZaunH . Treatment of toenail onychomycosis. A randomized, double‐blind study with terbinafine and griseofulvin. LAGOS II Study Group. Archives of Dermatology1995;131(8):919‐22. [PUBMED: 7632064] ">Hofmann 1995</a>). Removing these two studies from the analyses reduced the statistical heterogeneity to 7%. This did not change the direction of the effect but did increase the magnitude of the effect (RR 0.46, 95% CI 0.31 to 0.68). </p> <p>When comparing subgroups based on short‐ or long‐term follow‐up, we saw no statistical heterogeneity between groups (I² = 0%, P value for subgroup differences = 0.45). In studies with both short‐ and long‐term follow‐up, there were no statistical differences between the griseofulvin and the terbinafine groups (RR 0.70, 95% CI 0.40 to 1.20 and RR 0.48, 95% CI 0.21 to 1.09, respectively). </p> </section> </section> <section id="CD010031-sec-0135"> <h5 class="title">Secondary outcomes</h5> <section id="CD010031-sec-0136"> <h6 class="title">Adverse events</h6> <p>See <a href="./references#CD010031-fig-0023" title="">Analysis 5.3</a>. </p> <p>Two studies comparing griseofulvin therapy with terbinafine therapy reported adverse events (<a href="./references#CD010031-bbs2-0015" title="FaergemannJ , AndersonC , HersleK , HradilE , NordinP , KaamanT , et al. Double‐blind, parallel‐group comparison of terbinafine and griseofulvin in the treatment of toenail onychomycosis. Journal of the American Academy of Dermatology1995;32(5 Pt 1):750‐3. [PUBMED: 7722020] ">Faergemann 1995</a>; <a href="./references#CD010031-bbs2-0019" title="GuptaAK , Gregurek‐NovakT . Efficacy of itraconazole, terbinafine, fluconazole, griseofulvin and ketoconazole in the treatment of Scopulariopsis brevicaulis causing onychomycosis of the toes. Dermatology2001;202(3):235‐8. [PUBMED: 11385230] ">Gupta 2001b</a>). There were 50 participants in the pooled griseofulvin groups and 50 participants in the pooled terbinafine groups. </p> <p>In the pooled griseofulvin group, 18 (36%) participants experienced an adverse event compared to 8 (16%) in the terbinafine group. Participants receiving griseofulvin were 2.3 times more likely to experience an adverse event compared to participants receiving terbinafine (RR 2.09, 95% CI 1.15 to 3.82, 2 studies, 100 participants; I² = 0%; low‐quality evidence). The most common adverse events amongst griseofulvin‐treated participants included gastrointestinal disturbance, headache, changes in hepatic and renal function, nausea, URTI, allergic reaction, urticaria, and photodermatitis. The most common adverse events amongst terbinafine‐treated participants included gastrointestinal disturbance, loss of taste, nausea, vertigo, and increased sweating. </p> <p>One study only reported adverse event data for events serious enough to cause discontinuation, precluding its inclusion in the above analysis (<a href="./references#CD010031-bbs2-0026" title="HofmannH , BrautigamM , WeidingerG , ZaunH . Treatment of toenail onychomycosis. A randomized, double‐blind study with terbinafine and griseofulvin. LAGOS II Study Group. Archives of Dermatology1995;131(8):919‐22. [PUBMED: 7632064] ">Hofmann 1995</a>). Of 98 participants receiving griseofulvin, 16 (16%) experienced adverse events that necessitated withdrawal from the study, compared to 10 of 97 (10%) participants treated with terbinafine who withdrew due to adverse events. </p> </section> <section id="CD010031-sec-0137"> <h6 class="title">Recurrence rate</h6> <p>We did not identify any studies that addressed the recurrence rate.</p> </section> </section> </section> <section id="CD010031-sec-0138"> <h4 class="title">Comparison 6: terbinafine plus azole versus terbinafine monotherapy</h4> <p>See <a href="./full#CD010031-tbl-0006">summary of findings Table 6</a> for quality assessments for this comparison. </p> <p>One study in 176 participants compared terbinafine plus azole (N = 81) versus terbinafine monotherapy (N = 95) (<a href="./references#CD010031-bbs2-0020" title="GuptaAK , LyndeCW , KonnikovN . Single‐blind, randomized, prospective study of sequential itraconazole and terbinafine pulse compared with terbinafine pulse for the treatment of toenail onychomycosis. Journal of the American Academy of Dermatology2001;44(3):485‐91. [PUBMED: 11209119] ">Gupta 2001c</a>), using repeat pulses of itraconazole (200 mg twice daily for a week) followed by one pulse of terbinafine (250 mg twice daily for a week) versus one week of 250 mg terbinafine twice a day, followed by a three‐week, treatment‐free interval. </p> <section id="CD010031-sec-0139"> <h5 class="title">Primary outcomes</h5> <section id="CD010031-sec-0140"> <h6 class="title">Clinical cure</h6> <p>See <a href="./references#CD010031-fig-0024" title="">Analysis 6.1</a>. </p> <p>In the pooled azole plus terbinafine group, 42 (51.9%) participants achieved clinical cure compared to 35 (36.8%) in the terbinafine‐only group. </p> <p>Therefore, the combination group had a 41% higher chance of achieving clinical cure (RR 1.41, 95% CI 1.01 to 1.97, 1 study, 176 participants, very low‐quality evidence). </p> </section> <section id="CD010031-sec-0141"> <h6 class="title">Mycological cure</h6> <p>See <a href="./references#CD010031-fig-0025" title="">Analysis 6.2</a>. </p> <p>In the pooled azole plus terbinafine group, 54 (66.7%) achieved mycological cure compared to 45 (47.4%) in the terbinafine‐only group. </p> <p>Therefore, the combination group had a 41% higher chance of achieving mycological cure (RR 1.41, 95% CI 1.08 to 1.83, 1 study, 176 participants, very low‐quality evidence). </p> </section> </section> <section id="CD010031-sec-0142"> <h5 class="title">Secondary outcomes</h5> <section id="CD010031-sec-0143"> <h6 class="title">Adverse events</h6> <p>See <a href="./references#CD010031-fig-0026" title="">Analysis 6.3</a>. </p> <p>In the combination therapy group, 12 (15%) participants experienced an adverse event compared to 22 (23%) in the terbinafine monotherapy group. This difference was not statistically significant (RR 0.64, 95% CI 0.34 to 1.21, 1 study, 176 participants; low‐quality evidence). </p> <p>The most common adverse events in the combination group were gastrointestinal complaints, headache, fatigue, cutaneous eruption, drowsiness, and elevated liver function tests. The most common adverse events in the terbinafine monotherapy group were gastrointestinal, taste loss/disturbance, headache, and elevated liver function tests. </p> </section> <section id="CD010031-sec-0144"> <h6 class="title">Recurrence rate</h6> <p>The trial did not report the recurrence rate.</p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010031-sec-0145" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010031-sec-0145"></div> <section id="CD010031-sec-0146"> <h3 class="title" id="CD010031-sec-0146">Summary of main results</h3> <p>This review included 48 studies with 10,200 participants, and we could extract data from 43 studies with 9730 participants. Most of the studies were published in 2000 or earlier, and half were multicentre studies in a dermatology outpatient setting. </p> <section id="CD010031-sec-0147"> <h4 class="title">Azoles versus terbinafine</h4> <p>See <a href="./full#CD010031-tbl-0001">summary of findings Table for the main comparison</a>. </p> <p>When comparing azoles and terbinafine directly, there was moderate‐quality evidence that terbinafine was probably more effective in achieving mycological (15 studies) and clinical cure (17 studies). We performed sensitivity analyses: excluding one study with non‐dermatophyte onychomycosis, excluding studies that contributed to significant statistical heterogeneity, and including studies using itraconazole only; these analyses confirmed the robustness of our estimates. Comparing the two treatments, there was probably no difference in the risk of adverse events (moderate‐quality evidence), and there may be no difference in the recurrence rate (low‐quality evidence). Common adverse events in both groups included headache, viral infection, and nausea. </p> </section> <section id="CD010031-sec-0148"> <h4 class="title">Terbinafine versus placebo</h4> <p>See <a href="./full#CD010031-tbl-0002">summary of findings Table 2</a>. </p> <p>Eight studies in just over 1000 participants provided high‐quality evidence that terbinafine was more effective for achieving clinical and mycological cure in onychomycosis when compared to placebo. Moderate‐quality evidence found that there was probably no difference in the number of adverse events reported. Common adverse events amongst terbinafine‐treated participants included gastrointestinal symptoms, infections, and headache. Low‐quality evidence suggested that terbinafine may lower the recurrence rate when compared to placebo. </p> </section> <section id="CD010031-sec-0149"> <h4 class="title">Azoles versus placebo</h4> <p>See <a href="./full#CD010031-tbl-0003">summary of findings Table 3</a>. </p> <p>We found azoles to be more effective than placebo in achieving mycological and clinical cure (nine studies provided high‐quality evidence). We performed sensitivity analyses excluding studies at high risk of bias, confirming the robustness of our estimate. Participants in the azole group experienced slightly more adverse events, but the difference was probably not significant (moderate‐quality evidence). The most common adverse events amongst azole‐treated participants included headache, flu‐like symptoms, and nausea. Azoles may lower the recurrence rate when compared to placebo (low‐quality evidence). </p> <p>When looking at the estimates for azoles versus placebo and terbinafine versus placebo, the effect estimate for azoles is higher than the effect estimate for terbinafine (clinical cure: RR 22.18 for azoles versus RR 6.00 for terbinafine, and mycological cure: RR 5.86 for azoles versus RR 4.53 for terbinafine). However, differences in the study populations or other factors might influence an indirect comparison. Hence, we have more confidence in the above direct comparison between terbinafine and azoles. </p> <p>Other comparisons included azole versus griseofulvin (comparison 4) and terbinafine versus griseofulvin (comparison 5). </p> </section> <section id="CD010031-sec-0150"> <h4 class="title">Azole versus griseofulvin</h4> <p>See <a href="./full#CD010031-tbl-0004">summary of findings Table 4</a>. </p> <p>Two hundred twenty‐two participants from five studies provided moderate‐quality evidence that azole and griseofulvin probably had the same effect on clinical and mycological cure. However, the risk of adverse events was probably much higher in the griseofulvin group (moderate‐quality evidence). The most common adverse events amongst griseofulvin‐treated participants included gastrointestinal disturbance and allergic reaction, and amongst azole‐treated participants, they included nausea and vomiting. Very low‐quality evidence means we are uncertain how griseofulvin impacts the recurrence rate compared to azole. </p> </section> <section id="CD010031-sec-0151"> <h4 class="title">Terbinafine versus griseofulvin</h4> <p>See <a href="./full#CD010031-tbl-0005">summary of findings Table 5</a>. </p> <p>Compared to griseofulvin, low‐quality evidence showed that terbinafine may improve the outcomes of clinical cure (four studies provided data) and mycological cure (five studies provided data). We performed sensitivity analyses removing studies that contributed to significant statistical heterogeneity and confirmed the robustness of our estimates. Griseofulvin was also associated with a higher risk of adverse events, although this result was based on low‐quality evidence. Common adverse events in the griseofulvin group included headache and gastrointestinal issues, whereas common adverse events in the terbinafine group included taste loss and nausea. None of our included studies addressed recurrence rate for this comparison. </p> <p>Compared with placebo, we found a clear treatment benefit to using the oral antifungal treatments terbinafine and azole, without excess harm (as measured by the adverse events rate). However, slight uncertainty remains around the possible harms of treatment, because even though there was no difference in the number of adverse events for azoles or terbinafine, the quality of the evidence for this outcome was moderate. For griseofulvin, there were indications of excess harm as the number of adverse events was considerably higher when compared to terbinafine or azole treatment, although the quality of the evidence for these treatments was low to moderate, respectively. </p> <p>None of the included studies addressed quality of life, so this remains an outstanding uncertainty. Not all of the comparisons addressed the outcome of recurrence rate, and those that did provided quite uncertain to very uncertain evidence. </p> <p>Please see <a href="./full#CD010031-tbl-0006">summary of findings Table 6</a> for details of our sixth comparison. </p> </section> </section> <section id="CD010031-sec-0152"> <h3 class="title" id="CD010031-sec-0152">Overall completeness and applicability of evidence</h3> <p>We were able to look at all relevant and currently used oral antifungal treatments, as a large number of the included studies used them all. Many studies addressed our primary outcomes, which resulted in an effect estimate with narrow confidence margins. The study population was representative of the general population, and the results are applicable to clinical practice. Most studies included participants with <i>T rubrum</i> and <i>T mentagrophytes</i> . Therefore, the results might not be applicable to onychomycosis caused by non‐dermatophyte moulds and <i>Candida</i>. </p> <p>However, there were major limitations related to the assessment of secondary outcomes. Firstly, none of the studies addressed quality of life as an outcome, which indicates a major gap in the research. Furthermore, the data for adverse events were very heterogenous and not all trials reported adverse events. In addition, we were unable to assess the severity of adverse events, as only data related to the prevalence of adverse events were available. </p> <p>The limited data available suggest that adverse events were more prevalent with griseofulvin treatment. When comparing azoles with terbinafine, there was no statistically significant difference in the occurrence of adverse events. In addition, we were unable to assess the severity of adverse events, as only data related to the prevalence of adverse events were available. </p> <p>Recurrence rate was reported in a limited number of studies only, so the reported differences between treatment arms were underpowered and not statistically significant. </p> </section> <section id="CD010031-sec-0153"> <h3 class="title" id="CD010031-sec-0153">Quality of the evidence</h3> <p>We summarise the quality of evidence for all our comparisons in <a href="./full#CD010031-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD010031-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD010031-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD010031-tbl-0004">summary of findings Table 4</a>; <a href="./full#CD010031-tbl-0005">summary of findings Table 5</a>; and <a href="./full#CD010031-tbl-0006">summary of findings Table 6</a>. Overall, the quality of the evidence varied widely from high to very low depending on the outcome and comparison. The main reason for downgrading evidence was limitations in study design such as lack of blinding. </p> <p>The quality of the evidence for the primary outcomes was high for azole versus placebo (comparison 3) as well as terbinafine versus placebo (comparison 2), and it was moderate for azole versus terbinafine directly (comparison 1). For griseofulvin versus azole (comparison 4), the quality of the evidence was moderate; for griseofulvin versus terbinafine (comparison 5), it was low, and for terbinafine plus azole versus terbinafine monotherapy (comparison 6), quality was very low. </p> <p>For our secondary outcome, adverse events, the quality of the evidence was moderate (comparisons 1, 2, 3, 4) or low (comparisons 5 and 6). The quality of the evidence for recurrence rate was low (comparisons 1, 2, 3) or very low (comparison 4). </p> <section id="CD010031-sec-0154"> <h4 class="title">Limitations in study design or execution</h4> <p>Many of the studies had methodological limitations; often information on allocation concealment and details about randomisation was unclear. Because of this, we downgraded the level of evidence by one level. In the comparisons where in addition to the first problem at least half of the studies were non‐blinded studies, we downgraded a further level. </p> </section> <section id="CD010031-sec-0155"> <h4 class="title">Inconsistency of results</h4> <p>We found many studies (4 to 16, depending on the comparison) reporting on our primary and secondary outcomes, with minimal inconsistency of the results between studies. We have not downgraded the evidence for any of the comparisons for inconsistency. </p> </section> <section id="CD010031-sec-0156"> <h4 class="title">Indirectness of evidence</h4> <p>All included studies report on our primary outcomes, clinical and mycological cure; none of the studies used surrogate or intermediate outcome markers. </p> </section> <section id="CD010031-sec-0157"> <h4 class="title">Imprecision</h4> <p>For our primary outcomes and the secondary outcome adverse events, the sample size was sufficiently large to detect a statistically significant difference between the treatment groups for most comparisons. However, for recurrence rate for comparison one (azole versus terbinafine), we may have failed to detect a meaningful difference due the small sample size. Therefore, we have downgraded the evidence by one level for this outcome. For recurrence rate in comparison four (griseofulvin versus azole), we included only one study with seven participants; therefore, we reduced the evidence by two levels for imprecision. Comparison six (combination terbinafine plus azole versus terbinafine monotherapy) only included one study, which again increased the risk of imprecision, so we downgraded the evidence by one level. </p> </section> <section id="CD010031-sec-0158"> <h4 class="title">Publication bias</h4> <p>We conducted a comprehensive search that would have reduced the risk of publication bias. For the primary outcomes, where we found more than 10 studies, funnel plots (<a href="#CD010031-fig-0003">Figure 3</a>; <a href="#CD010031-fig-0004">Figure 4</a>) confirmed a low risk of publication bias. </p> </section> <section id="CD010031-sec-0159"> <h4 class="title">Large effect</h4> <p>For the comparisons including placebo (comparisons two and three), we upgraded the level of evidence by one or two levels due to the large effect seen for the primary outcomes. </p> </section> </section> <section id="CD010031-sec-0160"> <h3 class="title" id="CD010031-sec-0160">Potential biases in the review process</h3> <p>For this review we searched a wide range of databases with no restrictions based on language. We contacted pharmaceutical companies for additional unpublished trials and searched trials registers. We may have missed other relevant studies, especially ones with a negative result, and the fact that five studies have not yet been incorporated may be a source of potential bias. However, funnel plots for the primary outcomes do not show evidence of publication bias. Even in its presence, we believe that given the large number of studies included in this review, additional negative studies are unlikely to change the overall conclusion. </p> <p>Two authors independently selected studies for inclusion, extracted data, and assessed risk of bias, with a third author acting as arbiter in order to minimise the risk of bias in the review process. In addition, we attempted to contact study authors for additional data. </p> <p>None of the review authors had a conflict of interest regarding any of the medications in this review. </p> </section> <section id="CD010031-sec-0161"> <h3 class="title" id="CD010031-sec-0161">Agreements and disagreements with other studies or reviews</h3> <p>Recent systematic reviews found that both azoles and terbinafine are effective treatments (<a href="./references#CD010031-bbs2-0083" title="DeSaDC , LamasAP , TostiA . Oral therapy for onychomycosis: an evidence‐based review. American Journal of Clinical Dermatology2014;15(1):17‐36. [PUBMED: 24352873] ">De Sa 2014</a>; <a href="./references#CD010031-bbs2-0089" title="FerrariJ . Fungal toenail infections. BMJ Clinical Evidence2011:1715. [PUBMED: 21846413] ">Ferrari 2011</a>; <a href="./references#CD010031-bbs2-0100" title="GuptaAK , DaigleD , PaquetM . Therapies for Onychomycosis A Systematic Review and Network Meta‐analysis of Mycological Cure. Journal of the American Podiatric Medical Association2015;105(4):357‐66. [PUBMED: 25032982] ">Gupta 2015</a>), which is in agreement with our findings. <a href="./references#CD010031-bbs2-0089" title="FerrariJ . Fungal toenail infections. BMJ Clinical Evidence2011:1715. [PUBMED: 21846413] ">Ferrari 2011</a> states that terbinafine is more effective for achieving cure than azoles (itraconazole), which is also consistent with our findings. <a href="./references#CD010031-bbs2-0100" title="GuptaAK , DaigleD , PaquetM . Therapies for Onychomycosis A Systematic Review and Network Meta‐analysis of Mycological Cure. Journal of the American Podiatric Medical Association2015;105(4):357‐66. [PUBMED: 25032982] ">Gupta 2015</a> suggests that a specific dosing of itraconazole was as effective as the terbinafine treatment; however, the number of studies included in this review was considerably lower than in ours, which might have affected the power to detect such a difference. <a href="./references#CD010031-bbs2-0083" title="DeSaDC , LamasAP , TostiA . Oral therapy for onychomycosis: an evidence‐based review. American Journal of Clinical Dermatology2014;15(1):17‐36. [PUBMED: 24352873] ">De Sa 2014</a> suggested that for non‐dermatophyte infections, azoles are the most effective treatment. This advice is partly based on treatment trials that did not include a control group. In our review we did not analyse subgroups based on causative organism. </p> <p>While we set out to assess risks of the treatment, we could only assess the frequency of reported adverse events for the different treatments, not the severity. We found low‐quality evidence that griseofulvin is associated with an increased rate of adverse events compared to azoles, and we are uncertain about adverse events for the comparison of griseofulvin versus terbinafine, as the quality of the evidence was very low. In the literature, case reports have been published on serious adverse events (<a href="./references#CD010031-bbs2-0105" title="KaoWY , SuCW , HuangYS , ChouYC , ChenYC , ChungWH , et al. Risk of oral antifungal agent‐induced liver injury in Taiwanese. British Journal of Clinical Pharmacology2014;77(1):180‐9. [PUBMED: 23750489] ">Kao 2014</a>); however, systematic reviews looking specifically at liver injury caused by azoles and terbinafine found that the absolute numbers of patients affected are low (<a href="./references#CD010031-bbs2-0094" title="GreenblattHK , GreenblattDJ . Liver injury associated with ketoconazole: review of the published evidence. Journal of Clinical Pharmacology2014;54(12):1321‐9. [PUBMED: 25216238] ">Greenblatt 2014</a>; <a href="./references#CD010031-bbs2-0117" title="YanJ , WangX , ChenS . Systematic review of severe acute liver injury caused by terbinafine. International Journal of Clinical Pharmacy2014;36(4):679‐83. [PUBMED: 24986266] ">Yan 2014</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010031-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/urn:x-wiley:14651858:media:CD010031:CD010031-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_t/tCD010031-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD010031-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_n/nCD010031-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/full#CD010031-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_n/nCD010031-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010031-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/urn:x-wiley:14651858:media:CD010031:CD010031-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_t/tCD010031-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010031-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_n/nCD010031-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/full#CD010031-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_n/nCD010031-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010031-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/urn:x-wiley:14651858:media:CD010031:CD010031-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_t/tCD010031-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 3 Azole versus terbinafine, outcome: 3.1 Clinical cure." data-id="CD010031-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_n/nCD010031-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Funnel plot of comparison: 3 Azole versus terbinafine, outcome: 3.1 Clinical cure.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/full#CD010031-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_n/nCD010031-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010031-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/urn:x-wiley:14651858:media:CD010031:CD010031-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_t/tCD010031-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 3 Azole versus terbinafine, outcome: 3.2 Mycological cure." data-id="CD010031-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_n/nCD010031-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot of comparison: 3 Azole versus terbinafine, outcome: 3.2 Mycological cure.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/full#CD010031-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_n/nCD010031-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010031-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/urn:x-wiley:14651858:media:CD010031:CD010031-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_t/tCD010031-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Azole versus terbinafine, Outcome 1 Clinical cure." data-id="CD010031-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_n/nCD010031-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Azole versus terbinafine, Outcome 1 Clinical cure.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/references#CD010031-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_n/nCD010031-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010031-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/urn:x-wiley:14651858:media:CD010031:CD010031-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_t/tCD010031-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Azole versus terbinafine, Outcome 2 Mycological cure." data-id="CD010031-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_n/nCD010031-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Azole versus terbinafine, Outcome 2 Mycological cure.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/references#CD010031-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_n/nCD010031-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010031-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/urn:x-wiley:14651858:media:CD010031:CD010031-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_t/tCD010031-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Azole versus terbinafine, Outcome 3 Adverse events." data-id="CD010031-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_n/nCD010031-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Azole versus terbinafine, Outcome 3 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/references#CD010031-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_n/nCD010031-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010031-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/urn:x-wiley:14651858:media:CD010031:CD010031-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_t/tCD010031-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Azole versus terbinafine, Outcome 4 Recurrence rate." data-id="CD010031-fig-0008" src="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_n/nCD010031-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Azole versus terbinafine, Outcome 4 Recurrence rate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/references#CD010031-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_n/nCD010031-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010031-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/urn:x-wiley:14651858:media:CD010031:CD010031-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_t/tCD010031-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Terbinafine versus placebo, Outcome 1 Clinical cure." data-id="CD010031-fig-0009" src="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_n/nCD010031-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Terbinafine versus placebo, Outcome 1 Clinical cure.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/references#CD010031-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_n/nCD010031-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010031-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/urn:x-wiley:14651858:media:CD010031:CD010031-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_t/tCD010031-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Terbinafine versus placebo, Outcome 2 Mycological cure." data-id="CD010031-fig-0010" src="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_n/nCD010031-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Terbinafine versus placebo, Outcome 2 Mycological cure.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/references#CD010031-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_n/nCD010031-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010031-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/urn:x-wiley:14651858:media:CD010031:CD010031-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_t/tCD010031-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Terbinafine versus placebo, Outcome 3 Adverse events." data-id="CD010031-fig-0011" src="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_n/nCD010031-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Terbinafine versus placebo, Outcome 3 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/references#CD010031-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_n/nCD010031-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010031-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/urn:x-wiley:14651858:media:CD010031:CD010031-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_t/tCD010031-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Terbinafine versus placebo, Outcome 4 Recurrence rate." data-id="CD010031-fig-0012" src="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_n/nCD010031-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Terbinafine versus placebo, Outcome 4 Recurrence rate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/references#CD010031-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_n/nCD010031-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010031-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/urn:x-wiley:14651858:media:CD010031:CD010031-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_t/tCD010031-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Azole versus placebo, Outcome 1 Clinical cure." data-id="CD010031-fig-0013" src="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_n/nCD010031-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Azole versus placebo, Outcome 1 Clinical cure.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/references#CD010031-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_n/nCD010031-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010031-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/urn:x-wiley:14651858:media:CD010031:CD010031-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_t/tCD010031-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Azole versus placebo, Outcome 2 Mycological cure." data-id="CD010031-fig-0014" src="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_n/nCD010031-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Azole versus placebo, Outcome 2 Mycological cure.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/references#CD010031-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_n/nCD010031-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010031-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/urn:x-wiley:14651858:media:CD010031:CD010031-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_t/tCD010031-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Azole versus placebo, Outcome 3 Adverse events." data-id="CD010031-fig-0015" src="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_n/nCD010031-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Azole versus placebo, Outcome 3 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/references#CD010031-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_n/nCD010031-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010031-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/urn:x-wiley:14651858:media:CD010031:CD010031-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_t/tCD010031-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Azole versus placebo, Outcome 4 Recurrence rate." data-id="CD010031-fig-0016" src="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_n/nCD010031-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Azole versus placebo, Outcome 4 Recurrence rate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/references#CD010031-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_n/nCD010031-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010031-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/urn:x-wiley:14651858:media:CD010031:CD010031-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_t/tCD010031-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Griseofulvin versus azole, Outcome 1 Clinical cure." data-id="CD010031-fig-0017" src="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_n/nCD010031-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Griseofulvin versus azole, Outcome 1 Clinical cure.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/references#CD010031-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_n/nCD010031-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010031-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/urn:x-wiley:14651858:media:CD010031:CD010031-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_t/tCD010031-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Griseofulvin versus azole, Outcome 2 Mycological cure." data-id="CD010031-fig-0018" src="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_n/nCD010031-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Griseofulvin versus azole, Outcome 2 Mycological cure.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/references#CD010031-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_n/nCD010031-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010031-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/urn:x-wiley:14651858:media:CD010031:CD010031-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_t/tCD010031-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Griseofulvin versus azole, Outcome 3 Adverse events." data-id="CD010031-fig-0019" src="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_n/nCD010031-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Griseofulvin versus azole, Outcome 3 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/references#CD010031-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_n/nCD010031-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010031-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/urn:x-wiley:14651858:media:CD010031:CD010031-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_t/tCD010031-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Griseofulvin versus azole, Outcome 4 Recurrence rate." data-id="CD010031-fig-0020" src="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_n/nCD010031-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Griseofulvin versus azole, Outcome 4 Recurrence rate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/references#CD010031-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_n/nCD010031-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010031-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/urn:x-wiley:14651858:media:CD010031:CD010031-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_t/tCD010031-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Griseofulvin versus terbinafine, Outcome 1 Clinical cure." data-id="CD010031-fig-0021" src="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_n/nCD010031-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Griseofulvin versus terbinafine, Outcome 1 Clinical cure.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/references#CD010031-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_n/nCD010031-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010031-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/urn:x-wiley:14651858:media:CD010031:CD010031-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_t/tCD010031-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Griseofulvin versus terbinafine, Outcome 2 Mycological cure." data-id="CD010031-fig-0022" src="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_n/nCD010031-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Griseofulvin versus terbinafine, Outcome 2 Mycological cure.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/references#CD010031-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_n/nCD010031-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010031-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/urn:x-wiley:14651858:media:CD010031:CD010031-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_t/tCD010031-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Griseofulvin versus terbinafine, Outcome 3 Adverse events." data-id="CD010031-fig-0023" src="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_n/nCD010031-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 Griseofulvin versus terbinafine, Outcome 3 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/references#CD010031-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_n/nCD010031-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010031-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/urn:x-wiley:14651858:media:CD010031:CD010031-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_t/tCD010031-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Combination terbinafine plus azole versus terbinafine monotherapy, Outcome 1 Clinical cure." data-id="CD010031-fig-0024" src="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_n/nCD010031-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Combination terbinafine plus azole versus terbinafine monotherapy, Outcome 1 Clinical cure. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/references#CD010031-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_n/nCD010031-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010031-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/urn:x-wiley:14651858:media:CD010031:CD010031-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_t/tCD010031-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Combination terbinafine plus azole versus terbinafine monotherapy, Outcome 2 Mycological cure." data-id="CD010031-fig-0025" src="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_n/nCD010031-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Combination terbinafine plus azole versus terbinafine monotherapy, Outcome 2 Mycological cure. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/references#CD010031-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_n/nCD010031-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010031-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/urn:x-wiley:14651858:media:CD010031:CD010031-CMP-006-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_t/tCD010031-CMP-006-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Combination terbinafine plus azole versus terbinafine monotherapy, Outcome 3 Adverse events." data-id="CD010031-fig-0026" src="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_n/nCD010031-CMP-006-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 Combination terbinafine plus azole versus terbinafine monotherapy, Outcome 3 Adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/references#CD010031-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/media/CDSR/CD010031/image_n/nCD010031-CMP-006-03.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD010031-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Azole compared to terbinafine for toenail onychomycosis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Azole compared to terbinafine for toenail onychomycosis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population</b> : participants with confirmed toenail onychomycosis<br/> <b>Setting</b> : outpatients clinics<br/> <b>Intervention</b> : azole<br/> <b>Comparison</b>: terbinafine </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with terbinafine</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with azole</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Clinical cure</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.82<br/> (0.72 to 0.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2168<br/> (15 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>575 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>471 per 1000<br/> (414 to 546) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mycological cure</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.77<br/> (0.68 to 0.88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2544<br/> (17 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>682 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>525 per 1000<br/> (464 to 600) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.00<br/> (0.86 to 1.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1762<br/> (9 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>346 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>346 per 1000<br/> (298 to 405) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence rate</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.11<br/> (0.68 to 1.79) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>282<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>333 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>370 per 1000<br/> (227 to 597) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>None of the studies addressed quality of life.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI</b> : confidence interval; <b>RCT</b> : randomised controlled trial; <b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality</b> : we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality</b> : our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality</b>: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one level for risk of bias because of large number of unblinded studies, lack of description of randomisation process and allocation concealment for most studies.<br/> <sup>b</sup>Downgraded by one level for risk of bias (large number of unblinded studies, lack of description of randomisation process and allocation concealment for most studies).<br/> <sup>c</sup>Downgraded by two levels for risk of bias (large number of unblinded studies, lack of description of randomisation process and allocation concealment for most studies) and imprecision (small numbers of participants in this comparison). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Azole compared to terbinafine for toenail onychomycosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/full#CD010031-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010031-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Terbinafine compared to placebo for toenail onychomycosis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Terbinafine compared to placebo for toenail onychomycosis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population</b> : patients with confirmed toenail onychomycosis<br/> <b>Setting</b> : outpatient clinics<br/> <b>Intervention</b> : terbinafine<br/> <b>Comparison</b>: placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with terbinafine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Clinical cure</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 6.00<br/> (3.96 to 9.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1006<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> High<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>62 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>370 per 1000<br/> (244 to 560) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mycological cure</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 4.53<br/> (2.47 to 8.33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1006<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> High<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>167 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>755 per 1000<br/> (412 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.13<br/> (0.87 to 1.47) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>399<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>429 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>484 per 1000<br/> (373 to 630) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recurrence rate</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>667 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>33 per 1000</p> <p>(7 to 253)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.05</p> <p>(0.01 to 0.38)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not addressed by any of the trials</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI</b> : confidence interval; <b>RCT</b> : randomised controlled trial; <b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality</b> : we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality</b> : our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality</b>: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Large number of unblinded studies and studies with poor description of blinding and randomisation but large effect estimate; therefore, this outcome was not downgraded for risk of bias as the quality of evidence was considered to be high because of the large effect observed.<br/> <sup>b</sup>Downgraded by one level due to risk of bias (randomisation and blinding was poorly described in most studies).<br/> <sup>c</sup>Downgraded by two levels due to poor description of randomisation and blinding as well as due to selective follow‐up and only single study with small number of participants. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Terbinafine compared to placebo for toenail onychomycosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/full#CD010031-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010031-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Azole compared to placebo for toenail onychomycosis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Azole compared to placebo for toenail onychomycosis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population</b> : participants with confirmed toenail onychomycosis<br/> <b>Setting</b> : outpatient clinics<br/> <b>Intervention</b> : azole<br/> <b>Comparison</b>: placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with azole</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Clinical cure</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 22.18</p> <p>(12.63 to 38.95)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3440<br/> (9 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> High<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>14 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>309 per 1000</p> <p>(176 to 543)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mycological cure</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 5.86<br/> (3.23 to 10.62) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3440<br/> (9 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> High<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>74 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>431 per 1000<br/> (237 to 781) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.04<br/> (0.97 to 1.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3441<br/> (9 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>537 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>559 per 1000<br/> (521 to 602) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence rate</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.55</p> <p>(0.29 to 1.07)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>26</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1000 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>550 per 1000</p> <p>(290 to 1000)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>None of the studies addressed quality of life.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI</b> : confidence interval; <b>RCT</b> : randomised controlled trial; <b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality</b> : we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality</b> : our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality</b>: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Large number of unblinded studies and studies with poor description of blinding and randomisation, but large effect estimate; therefore, this outcome was not downgraded for risk of bias as the quality of evidence was considered to be high because of the large effect observed.<br/> <sup>b</sup>Downgraded by one level because of risk of bias (high number of unblinded studies and studies with poor description of blinding and randomisation).<br/> <sup>c</sup>Downgraded by two levels due to poor description of randomisation and blinding as well as selective follow‐up and only single study with small number of participants. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Azole compared to placebo for toenail onychomycosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/full#CD010031-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010031-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Griseofulvin compared to azole for toenail onychomycosis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Griseofulvin compared to azole for toenail onychomycosis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population</b> : participants with confirmed toenail onychomycosis<br/> <b>Setting</b> : outpatient clinics<br/> <b>Intervention</b> : griseofulvin<br/> <b>Comparison</b>: azole </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with azole</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with griseofulvin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Clinical cure</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.94<br/> (0.45 to 1.96) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>222<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>144 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>136 per 1000<br/> (65 to 283) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mycological cure</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.87<br/> (0.50 to 1.51) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>222<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>186 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>161 per 1000<br/> (93 to 280) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.41<br/> (1.56 to 3.73) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>143<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>276 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>665 per 1000<br/> (430 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence rate</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 4.00<br/> (0.26 to 61.76) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>7<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>None of the studies addressed quality of life.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI</b> : confidence interval; <b>RCT</b> : randomised controlled trial; <b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality</b> : we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality</b> : our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality</b>: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one level due to risk of bias (about half of the studies were not blinded).<br/> <sup>b</sup>Downgraded by one level due to risk of bias (two unblinded studies; neither participants nor outcome assessors were blinded).<br/> <sup>c</sup>Downgraded by three levels due to risk of bias (single study; neither participants nor outcome assessors were blinded) and imprecision (two levels due to single study, low number of participants and wide confidence intervals). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Griseofulvin compared to azole for toenail onychomycosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/full#CD010031-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010031-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Griseofulvin compared to terbinafine for toenail onychomycosis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Griseofulvin compared to terbinafine for toenail onychomycosis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population</b> : participants with confirmed toenail onychomycosis<br/> <b>Setting</b> : outpatient clinics<br/> <b>Intervention</b> : griseofulvin<br/> <b>Comparison</b>: terbinafine </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with terbinafine</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Griseofulvin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Clinical cure</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.32<br/> (0.14 to 0.72) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>270<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>561 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>179 per 1000<br/> (78 to 404) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mycological cure</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.64<br/> (0.46 to 0.90) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>465<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>716 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>458 per 1000<br/> (329 to 645) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.09<br/> (1.15 to 3.82) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>100<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>160 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>334 per 1000<br/> (184 to 611) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recurrence rate</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No studies addressed recurrence rate.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No studies addressed quality of life.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI</b> : confidence interval; <b>RCT</b> : randomised controlled trial; <b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality</b> : we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality</b> : our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality</b>: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by two levels due to risk of bias (two studies not blinded; other studies at unclear risk for blinding of participant and outcome assessor).<br/> <sup>b</sup>Downgraded by two levels due to risk of bias (two levels: one unblinded study; one study at unclear risk of bias for blinding or participants and outcome assessor). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Griseofulvin compared to terbinafine for toenail onychomycosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/full#CD010031-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010031-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Combination terbinafine plus azole compared to terbinafine monotherapy for toenail onychomycosis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Combination terbinafine plus azole compared to terbinafine monotherapy for toenail onychomycosis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population</b> : participants with confirmed toenail onychomycosis<br/> <b>Setting</b> : outpatient clinics<br/> <b>Intervention</b> : combination terbinafine plus azole<br/> <b>Comparison</b>: terbinafine monotherapy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with terbinafine monotherapy</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with combination terbinafine plus azole</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Clinical cure</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.41</p> <p>(1.01 to 1.97)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>176<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>368 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>519 per 1000</p> <p>(732 to 726)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mycological cure</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.41</p> <p>(1.08 to 1.83)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>176<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>474 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>668 per 1000<br/> (512 to 867) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.64<br/> (0.34 to 1.21) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>176<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>232 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>148 per 1000<br/> (79 to 280) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recurrence rate</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No studies addressed recurrence rate.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No studies addressed quality of life.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI</b> : confidence interval; <b>RCT</b> : randomised controlled trial; <b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality</b> : we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality</b> : our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality</b>: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by three levels due to risk of bias (two levels: single non‐blinded study) and imprecision (single study).<br/> <sup>b</sup>Downgraded by two levels due to risk of bias (single non‐blinded study) and imprecision (single study) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Combination terbinafine plus azole compared to terbinafine monotherapy for toenail onychomycosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/full#CD010031-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010031-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Azole versus terbinafine</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical cure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.72, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Short‐term follow‐up (≤ 52 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>911</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.77, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Long‐term follow‐up (&gt; 52 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1257</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.63, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mycological cure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2544</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.68, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Short‐term follow‐up (≤ 52 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1287</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.64, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Long‐term follow‐up (&gt; 52 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1257</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.64, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1762</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.86, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Recurrence rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>282</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.68, 1.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Azole versus terbinafine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/references#CD010031-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010031-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Terbinafine versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical cure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.00 [3.96, 9.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Short‐term follow‐up (≤ 52 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>800</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.60 [3.66, 8.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Long‐term follow‐up (&gt; 52 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>26.01 [3.69, 183.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mycological cure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.53 [2.47, 8.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Short‐term follow‐up (≤ 52 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>800</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.60 [2.26, 9.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Long‐term follow‐up (&gt; 52 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.79 [0.42, 144.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>399</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.87, 1.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Recurrence rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [0.01, 0.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Terbinafine versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/references#CD010031-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010031-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Azole versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical cure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3440</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>22.18 [12.63, 38.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Short‐term follow‐up (≤ 52 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2695</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>23.89 [11.99, 47.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Long‐term follow‐up (&gt; 52 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>745</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>19.11 [7.21, 50.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mycological cure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3440</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.86 [3.23, 10.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Short‐term follow‐up (≤ 52 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2695</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.05 [2.91, 17.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Long‐term follow‐up (&gt; 52 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>745</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.22 [2.34, 7.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3441</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.97, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Recurrence rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.29, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Azole versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/references#CD010031-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010031-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Griseofulvin versus azole</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical cure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.45, 1.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Short‐term follow‐up (≤ 52 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.32, 2.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Long‐term follow‐up (&gt; 52 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.34, 2.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mycological cure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.50, 1.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Short‐term follow‐up (≤ 52 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.52, 1.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Long‐term follow‐up (&gt; 52 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.16, 2.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.41 [1.56, 3.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Recurrence rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.0 [0.26, 61.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Griseofulvin versus azole</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/references#CD010031-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010031-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Griseofulvin versus terbinafine</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical cure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.14, 0.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Short‐term follow‐up (≤ 52 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [0.01, 0.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Long‐term follow‐up (&gt; 52 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>181</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.36, 0.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mycological cure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>465</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.46, 0.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Short‐term follow‐up (≤ 52 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>284</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.40, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Long‐term follow‐up (&gt; 52 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>181</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.21, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.09 [1.15, 3.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Griseofulvin versus terbinafine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/references#CD010031-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010031-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Combination terbinafine plus azole versus terbinafine monotherapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical cure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Short‐term follow‐up (≤ 52 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Long‐term follow‐up (&gt; 52 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mycological cure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Short‐term follow‐up (≤ 52 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Long‐term follow‐up (&gt; 52 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Combination terbinafine plus azole versus terbinafine monotherapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010031.pub2/references#CD010031-tbl-0012">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010031.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD010031-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD010031-note-0008">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD010031-note-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD010031-note-0006">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD010031-note-0005">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD010031-note-0004">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD010031-note-0007">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD010031-note-0002">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD010031-note-0003">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD010031-note-0009">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD010031-note-0019">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010031\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010031\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010031\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010031\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010031\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010031\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010031\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010031\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010031\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010031\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010031\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010031\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010031\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010031\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010031\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010031\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010031\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010031\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=4nUWI3Cc&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010031.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010031.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010031.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010031.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010031.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740718085805"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010031.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740718085808"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010031.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dc7bb9973f49c',t:'MTc0MDcxODA4Ni4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 